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Aneurysmal degeneration is the end result of a multi-factorial process leading to the 
destruction of aortic wall connective tissue. Compelling evidence indicates that elastin 
and collagen destruction associated with increased production of enzymes capable of 
degrading these fibrillar extracellular matrix proteins forms the basis of this 
pathological process.
Xanthine Oxidoreductase (XOR) has been attributed roles in diverse pathologies 
primarily because of its capacity to generate reactive oxygen and nitrogen species 
(RONS). Evidence that hypoxia exists in arterial walls and that XOR is transcriptionally 
induced and activated by hypoxia leading to increased RONS, give the enzyme 
importance as a potential inducer of vascular pathology, as both hypoxia and RONS are 
known to activate transcription factors such as hypoxia-inducible factor (HIF-1), 
activator protein (AP-1) and nuclear factor kappa B (NFkB). I hypothesised that local 
hypoxia or RONS generated from XOR could modulate such transcription factors and 
increase the expression of the elastolytic enzymes MMP-2 and MMP-9, or they could 
directly affect MMP function resulting in enhanced elastolytic activity, a feature of 
AAA formation.
The level, localisation characteristics and activity of XOR in aortic tissue were assessed. 
It was found that no significant difference existed in XOR protein levels between AAA 
and non-AAA control tissue.
The effect of hypoxia on the expression and protein levels of MMP-2 and MMP-9 in 
cultured vascular smooth muscle cells (VSMCs) were assessed. In addition the effect of 
hypoxia on elastolytic activity of conditioned media from VSMC cultures was assessed. 
These experiments demonstrated that hypoxia did not influence MMP expression, 
protein levels or elastolytic activity in VSMC cultures.
Finally, aortic tissue was assessed for evidence of increased oxidant stress by measuring 
peroxynitrite levels and superoxide generating capacity. In addition, the effects of 
oxidant stress on MMP activation were assessed in vitro. These studies demonstrated 
that aortic tissue from AAA patients had evidence of increased peroxynitrite formation 
and oxidant stress activated MMPs.
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INTRODUCTION
Chapter 1 Clinical aspects of abdominal aortic aneurysms
1.1 Definition
The term aneuiysm is derived from the Greek word aneurynein, meaning to widen or 
dilate. A consensus definition of aneurysm published by the Society of Vascular 
Surgery and the International Society for Cardiovascular Surgery defined an abdominal 
aortic aneuiysm (AAA) as a permanent localised dilation of an artery having at least a 
50% increase in diameter compared with the expected normal diameter of the artery, or 
of the diameter of the segment proximal to the dilatation (Johnston et al 1991). Based 
on a maximum diameter of 2.1 cm of the infrarenal aorta in healthy individuals, an 
AAA is present when the diameter exceeds 3.0cm.
1.2 Epidemiology
1.2.1 Prevalence
Estimates of the prevalence of AAA obtained from population screening surveys and 
autopsy studies vary between 1.3% and 8.4%, depending on the age group screened and 
criteria used for the definition of AAA (Table 1.1 and Table 1.2).
Aneurysmal disease is predominately a condition of elderly men, being up to six times 
more common in men than women in population screening studies {Scott et al. 1995).
1.2.2 Incidence
The reported incidence of asymptomatic AAA varies between 3.0 and 117.2 per
100.000 person-years {Wilmink et al 1998b) (Table 1.3). The age-adjusted incidence of 
AAA is rising and this increase appears to be real and not just the result of an increasing 
elderly population or improvements in diagnostic techniques. A nationwide study from 
Denmark reported an increase in the incidence of asymptomatic lesions from 7.1 per
100.000 to 25.8 per 100,000 person years from 1977 to 1990 {Eickhoff 1993). This 
increase was constant over all age groups examined.
The incidence of ruptured AAA (RAAA) varies from 1 to 21 per 100,000 person years 
and again appears to be increasing {Wilmink et al 1998a) (Table 1.4). One study found 
a sevenfold increase in RAAA over a 36-year period as well as an increase in the age 
standardised mortality rate from RAAA, indicating that the rise in incidence was not 
caused by changes in age distribution of the population {Drott et al 1992).
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Oxford (<Collin et al 1988) M 65-74 426 5mm >SA 5.4
Oxford {Collin et al. 1988) M 65-74 426 >40 2.3
Gloucestershire (Lucarotti et M 65 4232 >25 8.4
al 1993)
Gloucestershire {Lucarotti et M 65 4232 >40 1.3
al 1993)
Birmingham {Smith et al M 65-75 2669 >29 8.4
1993)
Birmingham {Smith et al M 65-75 2669 >40 3.0
1993)
Chichester {Scott et al 1995) M 65-80 2342 >29 7.6
Chichester {Scott et al. 1995) F 65-80 3052 >29 1.3
Table 1-1 Prevalence of AAA in screened populations
Location No
examined




UK {Turk 1965) 1544 1963-1964 2.3 1.6
USA {McFarlane 1991) 5244 1950-1984 2.6 1.2
Sweden {Bengtsson et 
al 1992)
45838 1958-1986 4.3 2.1





Location Men Women Total
Western Australia (Castleden et 
al 1985)
117.2 33.9 36.5
England and Wales (Fowkes et al. 
1989)
11.3 3.0 -
Scotland {Naylor et al 1988) - - 63.6
Netherlands (Pleumeekers et al 
1994)
37.6 5.5














Swansea {Ingoldby et al 
1986)
1974-1983 7 17 80
Worthing {Mealy et al 
1988)
1979-1988 9 18 89
East London {Thomas et 
al 1988)
1981-1986 13 21 81
Swindon {Budd et al 
1989)
1982-1987 9 17 86
Gotenborg {Drott et al 
1992)
1952-1988 1 7 85
Table 1-4 Trends in the incidence of ruptured abdominal aortic aneurysms
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1.3 Risk factors
Risk factors for AAA formation include; increasing age, male gender, family history, 
previous vascular disease, hypertension, smoking and hypercholesterolaemia (Wilmink 
et al 1998a). Several screening studies have shown that the prevalence of AAA 
increases with age (Bengtsson et al. 1992; Morris et al 1994). Familial clustering of 
AAA was described by Clifton in 1977 (Clifton 1977). Powell and Greenhalgh 
interviewed 60 patients with AAA and identified that one third had at least one first 
degree relative with an AAA. The incidence among the patients' siblings was 7.3% and 
among their parents it was 8.6%. Mathematical analysis of AAA clustering in this study 
suggested that the inheritance pattern was multifactorial {Powell et al 1987).
One study reported a tenfold increased risk of developing the condition in men with a 
first degree relative with an AAA, whereas others have found a lower relative risk 
{Baird et al 1995; Verloes et al 1995). The magnitude of the increased risk in first- 
degree relatives suggests a genetic component, although the influence of a common 
lifestyle cannot be excluded. Wilmink and Quick performed a pooled relative risk 
estimate of several risk factors for AAA from population based screening surveys and 
concluded that the risk factors most strongly associated with AAA were male sex and 
smoking. Patients with peripheral vascular disease and cardiovascular disease were 
twice as likely to have an AAA than those without these diseases, and hypertension was 
associated with a mildly increased risk of AAA. Diabetes and hypercholesterolaemia 
were not associated with increased risk in the population-based studies that considered 
these risk factors {Wilmink et al 1998a).
1.4 Natural History and prognosis
The life expectancy of a patient with an AAA is lower than that compared to age 
matched controls, with the majority of deaths being due to coronary heart disease or 
aneuiysm rupture {Szilagyi et al 1972; Conway et al 2001). The prognosis for non­
operated AAA is poor with up to 40 % of the patients dying from rupture and three 
quarters of these deaths occurring within 2 years of diagnosis {Szilagyi et al 1972). The 
5-year survival of patients with aneurysms greater than 5 cm diameter not treated by 
surgery was 20% {Szilagyi et al 1972). Similar data from Conway documenting the 
outcome of patients with AAAs larger than 5.5 cm in diameter who were turned down 
for elective open repair showed an overall 3-year survival rate of 17%. Patients with 
AAAs larger than 7.0 cm lived a median of 9 months. A ruptured aneuiysm was 
certified as a cause of death in 36% of patients with an AAA of 5.5 cm to 5.9 cm, 50%
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of patients with an AAA 6 cm to 7.0 cm and 55% of patients with an AAA larger than
7.0 cm (Conway et al. 2001).
Ruptured AAA (RAAA) is responsible for 10,000 deaths annually in the UK, 
accounting for 1.36 per cent of deaths in men and 0.45 per cent of deaths in women over 
the age of 65 in England and Wales (Office for National Statistics 1995). Operative 
mortality for RAAA is around 50% but fewer than half of those who rupture reach 
hospital alive (Ingoldby et al. 1986). Overall mortality is approximately 80-90% for all 
RAAA (Ingoldby et al. 1986; Bengtsson et al. 1993; Katz et al. 1994).
1.5 Risk of rupture
The risk of rupture of an AAA depends mainly on the maximum diameter of the AAA, 
however, it is also independently and significantly associated with female gender, 
current smoking and higher mean blood pressure (Powell et al. 2001). The UK Small 
Aneuiysm study and North American Aneurysm detection and Management study 
(ADAM study) revealed than AAAs less than 5.5 cm had a 1 %/year rupture rate (UK 
Small Aneurysm Trial Participants 1998; Lederle et al. 2002) The reported rupture rate 
for 6 cm and 7 cm AAAs have been quoted as 5% and 65% respectively (Szilagyi et al. 
1966; Sterpetti et al. 1991).
Aneuiysm enlargement/expansion, estimated to be exponential with a growth rate of 
approximately 10% per annum has been shown to be related to the risk of rupture 
(Bengtsson et al. 1993). Expansion rates will vary between different patients and within 
the same patient over different time periods, however, AAAs observed to expand 
rapidly, i.e. > 5 mm in 6 months are regarded as being at high risk for rupture 
(Bengtsson et al. 1993).
1.6 Treatment
The aim of prophylactic elective repair of an AAA is to prevent death from AAA 
rupture and is indicated when the risk of death/major morbidity from the operation is 
less than the risk of death from rupture. Setting the intervention criterion too high risks 
losing lives owing to rupture occurring at small size, while setting the intervention 
criterion too low risks losing lives because of the mortality rate associated with elective 
repair in those whose AAA might never rupture.
Mortality rates of between 1% and 5% are published for elective aneurysm repair 
(Hollier et al. 1992; Akkersdijk et al. 1994; Hak et al. 1996). These published series 
undoubtedly contain significant publication and selection bias thus producing a falsely
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low impression of surgical mortality. Others believe that the true mortality is 8% 
(Blankensteijn et al 1998).
Estimation of the risk of rupture for an individual patient is difficult, but in general the 
principle determinant of rupture is AAA diameter. An aortic diameter greater than 5.5-
6.0 cm is believed to be the level when the risk of surgery is less then the potential risk 
of rupture. Smaller AAAs (< 5 cm) rarly rupture, thus given an elective mortality of 5- 
8% expectant management of such AAAs appears to be pragmatic (UK Small Aneurysm 
Trial Participants 1998; Lederle et al. 2002). The UK Small Aneuiysm Study, 
randomised 1090 patients, aged 60-76 years and fit for surgery, with asymptomatic 
aneurysms 4.0-5.5 cm to early surgery or ultrasound surveillance until the aneurysm 
either grew to 5.5 cm or became symptomatic when operation was undertaken. At a 
mean follow up of 4.6 years and analysed on an intension to treat basis, there were no 
statistical differences in mortality between the two groups. Cost analysis indicated that 
surveillance was a cheaper option than early surgery. The conclusion from this study 
was that AAAs less than 5.5 cm should be managed by ultrasound surveillance (UK 
Small Aneurysm Trial Participants 1998). A  similar conclusion was found in the North 
American ADAM study (Lederle et al 2002).
AAA repair is known to prolong life and five and ten year survival rates of 60 % and 40 
% respectively have been reported (Hollier et al 1984; Stonebridge et al 1993; Aune et 
al 1995; Feinglass et al 1995; Batt et al 1999). Survival is better than patients not 
undergoing repair, and several studies have suggested that the survival rate is as good as 
age and sex matched control populations. However, others suggest that it is below that 
of aged-matched controls, due to a higher incidence of coronary artery disease in the 
AAA population (Hollier et al 1984; Reigel et al 1987; Johnston 1994; Aune et al. 
1995; Batt et al 1999; Yasuhara et al 1999). A Norwegian study found that the 10- 
year survival rate for all patients after AAA repair was 38% compared with an expected 
52% (Aune et al 1995). The standardized mortality rate was 1.30 indicating a 30% 
higher mortality rate than in a demographically matched population. A Canadian study 
came to similar conclusions, showing that the late survival rate of patients with AAA is 
significantly less than that of age and sex matched normal populations. Late deaths from 
cardiac and cerebrovascular causes were the most common causes of death (Johnston 
1994).
Several published series have documented that quality of life returns to normal within 3 
months of elective surgery and even improves by 6 months compared to preoperative 
levels (Hennessy et al 1998; Perkins et al 1998; Malina et al. 2000). Indeed
assessment of quality of life in survivors of rupture AAA repair was excellent at 6 
months, a possible argument for aggressive treatment of this condition (Hennessy et al 
1998; Bohmer et al 1999). There are no differences in the quality of life measurements 
after endovascular or open aneurysm repair (Malina et al. 2000; Aquino et al 2001).
1.7 Screening
The difference in mortality rate from ruptured AAA and elective AAA repair, combined 
with the easy detectability of asymptomatic lesions, has led to calls for a national 
screening programme (Harris 1992; Cheatle 1997). A screening programme can be 
justified if two main criteria are met (Wilmink et al 1998a; Lindholt 2001). Firstly, such 
a programme should be effective in reducing death or disability from a disease, and 
secondly, it should be cost effective. The recent Multicentre Aneurysm Screening Study 
(MASS study) has answered these two questions and supports data from previous pilot 
studies (Scott et al 1995; Wilmink et al 1999; Heather et al 2000; Lindholt et al 
2002; Scott 2002).
The Gloucestershire community based screening service targets all males aged over 65 
years (O'Kelly et al 1989; Lucarotti et al 1993). This population based screening 
approach has reported prevalence rates of 5% for aortas > 2.6 cm, 2.5 % for AAA >3.0 
cm and only 1% > 4.0 cm (Crow et al 2001). The important conclusion is that 95% of 
men have a normal scan at age 65 and subsequent work has demonstrated that they can 
be safely excluded from further follow up as they are unlikely to develop a clinically 
significant AAA (Emerton et al 1994; Crow et al 2001).
The prevalence of AAAs and the incidence of rupture AAA is significantly less in 
females (Scott et al 1995; Choksy et al 1999; Scott 2002). In a controlled trial 
assessing the effects of screening in 9342 women aged 65-80 randomized to age- 
matched screen and control groups, the prevalence of AAA was six times lower in 
women than in men, and over 5- and 10-year follow-up intervals, the incidence of 
rupture was the same in the screened and control groups. The conclusion from this study 
was that screening women for AAA is neither clinically indicated nor economically 
viable (Scott 2002)
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Chapter 2 Aortic structure and pathology of abdominal aortic 
aneurysms and formulation of hypothesis
Late onset degenerative aneurysms comprise 95% of all abdominal aortic aneurysms, 
and include the subgroups ' atherosclerotic aneurysm/non-specific aneurysm’ and 
‘inflammatory aortic aneurysms’. The traditional view that atherosclerosis was the 
cause of AAAs was based on the histological association of atherosclerosis and AAA, 
as well as evidence from population epidemiological studies. However, over the last 
decade increasing advances in molecular biology have indicated that AAA is a unique 
and complex biochemical, structural, and physiological change in the constituents of the 
aortic wall. This chapter summarises the evidence from published literature.
2.1 Aortic wall structure and function
2.1.1 Structure
The aorta is a large elastic artery with a well developed tunica media consisting of 
elastin, collagen and vascular smooth muscle cells (VSMC) embedded in the 
extracellular matrix (ECM) connective tissue. The extracellular connective tissue matrix 
consists of proteoglycans, collagen, elastin, as well as smaller amounts of fibronectin, 
laminin and various plasma components. It provides structural support as well as 
serving multiple biological functions, including providing a medium for diffusion of 
nutrients and regulating cell migration and proliferation (Ye et al 1998).
Proteoglycans possess one or more linear glycosaminoglycan chains attached to serine 
residues along a core protein. There are principally four types of proteoglycans (PG) 
present in the ECM, chondroitin sulphate PG, heparan sulphate PG, dermatan sulphate 
PG and keratan sulphate PG, all of which are synthesized by endothelial cells and 
smooth muscle cells. Proteoglycans play a role in extracellular architecture, arterial 
permeability, filtration, ion exchange and the regulation of cellular metabolism (Ye et al 
1998).
The elastin, collagen and VSMC are arranged in multiple concentric elastic lamella 
(Clark et al 1985; Dobrin 1988). The radial sequence is elastin-cells-elastin-collagen 
bundles-elastin-cells-elastin-collagen bundles. The adventitia is organised in alternating 
lamellae of collagen and elastin (Haas et al 1991).
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Figure 2-1 Aortic wall structure
Image l(x65) is a longitudinal section through the entire thickness of the aorta 
demonstrating the tunica intima (TI), tunica media (TM) and tunica adventitia 
(TA). Image 2 shows the tunica intima at higher magnification (x 160) and consists 
of a lining of endothelial cells and connective tissue (collagen, elastin) and vascular 
smooth muscle cells (VSMCs)(arrows). Image 3 (x 65) and the higher 
magnification image 5 (x 160) stained for elastin (Van Gieson’s stain) reveal the 
elastic laminae present in the aortic media (TM) as well as the deep portion of the 
intima (TI). Image 4 (H+E xl60) shows the TM containing VSMCs arranged in a 
closely wound spiral between the elastic membranes. The arrowheads reveal the 
site of some of the lamellae, whose presence is recognized by the apparent absence 
of structure, which in turn is due to the absence of staining of elastic fibres. Image 
6 (x60) demonstrates the outermost layer, the tunica adventitia (TA). The TA 
consists mostly of collagenous fibres that course in longitudinal spirals. There are 
no elastic laminae in the adventitia, but elastic fibres are present. The principle cell 
type is fibroblasts.
Elastin molecules are highly cross linked and assembled with microfibrils to form 
elastic fibres on the cell surface that are highly resistant to proteolytic degradation 
(Mecham et al. 1995). Elastin is a stable protein with a biological half-life of 
approximately 70 years and is produced by VSMC during early childhood, but is not 
synthesized in the adult aorta thus total elastin content is dependent on the degree of 
destruction {Powell et a l 1992).
Fibrillar collagen is composed of three polypeptide chains (a chains) wound around 
each other as a triple helical structure (Ye et al. 1998). Approximately 25 distinct a  
chains have been identified, which constitute about 15 types of collagen molecules. In 
the normal aortic wall the bulk of collagen exists in the form of two interstitial
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collagens, type I and III in a ratio of 3:1 (Menashi et al. 1987). In addition types IV, V, 
VI are also found which account for 0.5-1% of the total arterial collagen content. It is 
synthesised continuously throughout life by VSMC within the media and by fibroblasts 
within the adventitia, and total collagen content reflects the net effect of synthesis and 
degradation within the aortic wall (Ye et al. 1998).
2.1.2 Function
The structural arrangement of the aorta imparts both extensile and tensile strength, 
allowing it to conteract haemodynamic force (Clark et al. 1985; Dobrin 1988). Elastin 
imparts viscoelastic properties to the arteiy. It is able to double its length before rapidly 
returning to its original dimensions, a property related to its structure of alternating 
hydrophilic and basic regions. The hydrophilic contain repetitive amino acid sequences 
that form beta turns that can readily be stretched. The basic regions are rich in lysine, 
which forms covalent cross-links by extracellular oxidation to allysine (Ye et al. 1998). 
Collagen has a tensile strength 20 times greater than that of elastin. It is very difficult to 
stretch, and can only extend a small proportion beyond its original length before 
structural damage occurs (Dobrin 1988).
Under normal physiological conditions elastin is the principle load-bearing element, 
with only 1% of collagen being loaded, resulting in an easily distensible vessel. As the 
load increases and the vessel stretches, collagen fibres uncoil and are progressively 
recruited as load bearing elements, resulting in a less distensible vessel. Collagen 
essentially acts as a strong indispensable' safety net1 (Clark et al. 1985).
2.2 Pathological changes in AAAs
2.2.1 Ageing
Epidemiological evidence suggests that the abdominal aorta gradually dilates with 
advancing age in a significant proportion of the population, but only a small proportion 
are prone to AAA formation (Wilmink et al. 1998a; Wilmink et al. 2001). The 'normal 
aorta' ageing is accompanied by elastin fibre calcification, elastin loss and increasing 
content of polar glycoproteins in the media (Powell et al. 1992). In youth the dry weight 
elastin content of the aortic wall is approximately 35% compared with about 25% at the 
age of 70 years and only 8-10% or less in an AAA wall (Campa et al. 1987;
Sakalihasan et al. 1993). The effect is the recruitment of collagen at lower distending 
pressures and less aortic compliance (Lanne et al. 1992; Sonesson et al. 1993). These 
changes alter the mechanical properties of the aorta, such that the elasticity of the aorta 
in a 70-year-old patient is only a third of that of a 20 year old (MacSweeney et al. 1992).
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2.2.2 Histological changes
Abdominal aortic aneurysms are characterised by extensive extracellular matrix 
remodelling with elastin destruction and tunica media disruption. The elastin volume 
fraction is significantly reduced and severely fragmented (Campa et al. 1987; He et al. 
1994). In addition there is fragmentation of the internal elastic lamina, a reduction in 
VSMC numbers, thickening of the aortic intima and adventitia and a ubiquitous chronic 
inflammatory infiltrate {Koch et al 1990).
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Figure 2-2 H+E stain of non-aneurvsmal aortic wall
Image A (x 50) shows an intact intima (I), a thick well organised media (M) and 
adventitia (Ad). Image B (xlOO) demonstrates an organised media layer with 
concentric lamella units containing VSMCs.
Figure 2-3 H+E stain of AAA wall
All sections show medial disruption and attenuation (M) with a varying degree of 
inflammatory infiltrate (I) situated within the media and at the medial-adventitial 
junction (M-Ad). P represents atherosclerotic plaques at the intima surface (x 50 
magnification).
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Inflammatory cells are seen in all AAA specimens and are usually confined to the media 
and adventitia. The subgroup ‘Inflammatory aortic aneurysms’ first described by 
Walker, which is characterised by an intense peri-aneurysmal inflammatory infiltrate is 
believed to be an extreme variant of the disease rather than a distinct entity (Walker et 
al 1972; Koch et al. 1990).
The VSMC number and density in AAAs is decreased compared to controls. In 
aneurysm patients, the volume fraction of VSMC is only 2.2% compared to 22.6% in 
normals (He et al. 1994; Lopez-Candales et al 1997). In addition VSMC apoptosis 
occurs within AAA tissue that is mediated by activated macrophages and T- 
lymphocytes within the AAA media and adventitia. (Holmes et al 1996; Lopez- 
Candales et al 1997; Thompson et al 1997; Henderson et al 1999; Rowe et al 2000; 
Jacob et al 2001). This is potential important as the VSMC population is the principal 
cell type responsible for the synthesis of all the components of the ECM.
2.2.3 Biochemical changes
Elastin loss is a marked feature of AAA formation. Quantitative analysis of aortic tissue 
reveals that elastin forms 35% of the dry weight of normal aortic wall but only 8% in 
AAA tissue (Campa et al 1987; Sakalihasan et al 1993). Histologically the remaining 
elastin is normal (Tilson 1988). There is no evidence of new elastin synthesis as levels 
of elastin mRNA are no different from normal aortic tissue (Mesh et al 1992).
The elastase activity of AAA tissue has been shown to be raised and reciprocally related 
to elastin content (Campa et al 1987; Cohen et al 1987; Cohen et al 1988). The extent 
of elastin destruction appears to be independent of aneurysm diameter, suggesting that 
elastin destruction occurs in the initial stages of the pathogenic process (White et al
1993).
The total protein content of AAA tissue is 8.4 times greater than normal aortic tissue 
and 4.7 times greater than tissue from atherosclerotic occlusive disease (Baxter et al
1994). He calculated that the volume fraction of collagen and ground substance is 
increased from 55 % to 95% in aneurysmal aortas as compared to controls (He et al
1994). This is due to an increase in both the relative collagen concentration and absolute 
collagen content of AAA tissue (Menashi et al 1987; Rizzo et al 1989). However it is 
unclear whether this increase in collagen production is compensatory or pathogenic in 
abdominal aortic aneurysm formation, as stretch is known to be a stimulus for 
connective tissue formation (White et al 1993). Collagen types I and m  are increased 
but the ratio remains the same as in normal aortic tissue (Menashi et al 1987; Rizzo et 
al 1989). Increased collagenase activity has also been noted in AAA tissue which
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supports the hypothesis that there is an increased turnover of collagen in AAA tissue, 
the increased synthesis being partly balanced by increased proteolysis (Menashi et al 
1987; Vine e ta l 1991).
Interestingly the matrix abnormalities demonstrated in AAAs are not solely confined to 
the aneuiysmal segment, but are also found in aortic tissue proximal to the aneurysmal 
segment. Baxter demonstrated a reduction in the elastin/collagen ratio throughout the 
arterial vasculature of AAA patients and Ward revealed that the mean diameters of all 
peripheral arteries were significantly greater in patients with aortic aneurysms 
suggesting that inffarenal aneurysmal disease may be a localised manifestation of a 
systemic dilating process (Ward 1992; Baxter et al 1994). The increased turnover of 
proteins within the aortic media results in an imbalance of structural proteins and altered 
biophysical properties of the aorta, which explains the finding of decreased compliance 
which is a constant feature in AAAs (MacSweeney et al 1992; Sonesson et al 1993).
2.3 Potential Pathological mechanisms of AAA formation
2.3.1 Infra-renal aorta
Abdominal aortic aneurysms occur with greater frequency in the infrarenal segment of 
the abdominal aorta. The predilection for this site is probably multifactorial.
1. Firstly the number of elastic lamellae and therefore elastin content is markedly 
decreased in this segment compared with the thoracic aorta. As elasticity is directly 
related to the elastin content the aorta becomes stiffer and less compliant as it 
progresses distally (MacSweeney et al 1992).
2. Secondly, the abdominal aorta does not have an abundant blood supply being 
relatively devoid of vasa-vasorum compared to the thoracic aorta (Wolinsky et al 
1967). Intimal atherosclerosis will further impair media nutrition and may predispose 
this site to nutritional insufficiency.
3. Atheroma is known to preferentially form in regions of low sheer stress, possibly 
as a result of prolonged contact between atherogenic factors and the vessel wall, a 
situation that exists in the aorta above the iliac bifurcation (Moore et al 1994).
4. Flow dynamics are altered in the distal aorta above the iliac bifurcation. The pulse 
pressure within the aorta increases as the pressure wave passes distally due to aortic 
tapering, branching and decreased compliance (Dobrin 1989). At the iliac bifurcation 
the pressure wave is reflected, the amplitude of which depends on the ratio of the 
cross sectional area of the aorta and iliac vessels. The optimum ratio producing 
minimum reflection is 1:1.5, and in humans this ratio decreases from the ideal in
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infancy to 0.75 by the age of 50 (Gosling et al 1971; Newman et al 1973). 
Theoretically, this ratio reduction will be accelerated by either atherosclerosis in the 
iliac system or aneurysm formation within the aorta, resulting in an increased 
magnitude of the reflected wave and localised areas of high pressure and a potential 
source of mechanical injury to the vessel wall. However MacSweeney found no 
evidence of localised high pressure zones in a small series in which direct 
measurements of pressure within an AAA showed it to be similar to that in the 
brachial artery (MacSweeney et al 1994).
2.3.2 Genetics
Clifton was the first to report the increased prevalence of AAA in first-degree relatives 
and several other epidemiological studies have suggested a genetic cause or familial 
pattern for AAA formation (Clifton 1977; Johansen et al. 1986; Bengtsson et al 1992; 
Adams et al 1993).Two well-characterized genetic disorders have been associated with 
aortic fragility (Ehlers Danlos type IV syndrome) and aortic rupture (Marfans 
syndrome). These disorders are caused by mutations in the type ID collagen gene 
(Chromosome 2) and the fibrillin gene (chromosome 15), respectively. However these 
congenital diseases represent distinct clinical entities that do not often manifest as true 
AAAs.
Studies investigating variations in the human elastin gene have failed to demonstrate 
any significant relationship to AAA formation (Baxter et al 1992; Gandhi et al 1994). 
A single base mutation of type HI collagen has been described, but direct gene 
sequencing studies and population molecular genetics have failed to demonstrate that 
mutations or genetic variations in this gene are a common cause of AAA (Kontusaari et 
al 1990; Louwrens et al. 1993; Tromp et al 1993; Anderson et al 1996). Powell 
identified a specific polymorphism in the type HI collagen gene that was associated with 
increased aortic diameter and decreased compliance of the aorta and suggested that 
variations in the type III collagen gene may influence the mechanical properties of the 
ageing aorta and hence its susceptibility to disease and dilatation (Powell et al. 1993).
In addition deficiency of a -1-antitrypsin (Cohen et al 1990; Elzouki et al 1994), the 
presence of the serum protein haptoglobin 2-1 phenotype (Norrgard et al 1984; Powell 
et al 1990) and the association between genetic variations of the Cholesterol Ester 
Transfer Protein (CETP) gene and AAA disease have all been investigated, however, 
none have been demonstrated to be responsible for significant numbers of AAAs 
(Powell et al. 1990; Ramsbottom et al 1994; Ramsbottom et al 1997). In conclusion, 
although familial clustering of AAA indicates a hereditary component the precise
genetic basis remains obscure. It seems likely that inheritance of AAA disease is 
multifactorial, involving a complex interaction between environmental influences and a 
genetic susceptibility {Powell et al 1987).
2.3.3 Proteolysis
Elastin loss is critical and probably an initiating factor in the development of an AAA 
{White et al 1993). Elastin is very resistant to both chemical and enzymatic degradation 
and only a few enzymes are known to degrade elastin, including leukocyte elastase (a 
serine protease) and the matrix metalloproteinases. Increased elastolytic activity in 
AAA tissue and plasma was first reported separately by Busuttil and Cannon in 1982 
{Busuttil et al. 1982; Cannon et al 1982). Initially believed to be due to leukocyte 
elastase {Cannon et al 1982), Brown and Campa described an elastase that belonged to 
the matrix metalloproteinase (MMP) family rather than the serine proteinase {Brown et 
al 1985; Campa et al 1987). Subsequent work identified increased levels of elastolytic 
MMP-9 in homogenized AAA tissue compared to non-AAA tissue ( Vine et al 1991; 
Newman et al 1994b; Newman et al 1994c) .
2.3.4 Matrix metalloproteinases
2.3.4.1 Classification
The MMPs constitute a family of zinc-dependent endopeptidases. All MMPs share the 
following common features that allow their classification as a family {Ye et al 1998).
1. They are all secreted as latent zymogens requiring activation for proteolytic 
activity,
2. They degrade extracellular matrix components,
3. They function at neutral pH,
4. They contain zinc at their active site and require calcium for stability, and
5. They are inhibited by specific tissue inhibitors of metalloproteinases (TIMPS).
The MMP family is divided into 4 main subgroups, mainly based on their substrate 
preferences {Ye et al 1998):
1. Interstitial collagenases; that mainly degrade the interstitial collagen types I, II 
and IQ.
2. Gelatinases; which have a high affinity for gelatins (denatured collagen that has 
lost the typical helical structure), collagen type IV and elastin,
3. Stromelysins; that have a broad substrate specificity capable of degrading 
proteoglycans, type IV collagen, elastin and laminin, as well as activating interstitial 
procollagenases, progelatinases and other stromelysins and
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4. Membrane bound MMPs (MT-MMPs); that appear to be able to cleave 
gelatins, type IV collagen and activate gelatinases.





MMP-1 Collagen types I, II, III, 









Gelatinases Gelatinase A (72 
KDa type IV 
collagenase)
MMP-2 Gelatins, collagen types 
IV, V, X, XI, elastin, 
fibronectin, 
proteoglycans
Gelatinase B (92 
KDa type IV 
collagenase
MMP-9 Gelatins, collagen types 
IV, V, elastin, 
proteoglycans
Stromelysins Stromelysin 1 MMP-3 Proteoglycans, 
fibronectin, laminin, 
elastin, gelatin, 
collagen types II, IV, 
V, IX, X
Stromeylysin-2 MMP-10 As above
Stromeylysin-3 MMP-11 Gelatin, fibronectin, 
proteoglycan
Matrilysin MMP-7 As above
Metal loproteinase MMP-12 Elastin
Membrane-type MT-MMP-1 MMP-14 1 Collagen type IV,
MMPs MT-MMP-2 MMP-15 J gelatin
Table 2-1 Classification of matrix metalloproteinases
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2.3.4.2 MMP protein structure
The collagenases and stromelysins consist of five domains, including a signal peptide, a 
propeptide containing a cysteine residue bonded to the active zinc site, which is lost on 
activation, a catalytic domain containing the zinc binding site, a so-called ‘hinge region’ 
that bridges the catalytic domain and the COOH-terminal domain, and a hemopexin or 
vitronectin like COOH-terminal domain that appears to be responsible for conferring 
substrate specificity (Loftus et al. 2002). The two gelatinases also have this five domain 
structure, however within the catalytic domain there are tliree fibronectin type II repeats 
which are believed to facilitate binding of gelatinases to their substrate(Blankensteijn et 
al. 1998). The MT-MMPs possess a unique transmembrane domain which anchors MT- 
MMPS to the cell surface (Cao et al. 1995).
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Figure 2-4 Structure of MMP protein
2.3.4.3 MMP activation
All MMPs are secreted as inactive zymogens that are then activated in the extracellular 
environment. The latency is due to the interaction between the cysteine thiol group 
within the propeptide and the zinc atom at the active site, which displaces the molecule 
necessary for catalysis (Van Wart et al. 1990). MMPs can be activated in vitro by 
physical, chemical (HOCL, mercurials, SDS) and enzymatic (trypsin, plasmin) 
treatments that separate the cysteine residue from the zinc atom (Birkedal-Hansen
1995). This critical step in the activation process, described as opening of the ‘cysteine 
switch’, is followed by a series of autocatalytic cleavages resulting in the complete 
excision of the propeptide and activation of the enzyme (Van Wart et al. 1990;
Woessner 1991; Loftus et al. 2002).
The precise mechanism of in vivo activation is not fully resolved but plasmin and
stromelysins 1 and 2 are believed to play a role (Goldberg et al. 1990; Suzuki et al.
1990; Baricos et al. 1995). Recent research has focused on the role of MT-MMP in the
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activation of MMP-2 on the cell surface through the assembly of a ternary complex 
consisting of progelatinase A, TIMP-2 and activated MT-MMP (Cao et al. 1995; 
Strongin et al. 1995; Sato et al. 1996; Okada et al. 1997).
2.3.4.4 Tissue inhibitors o f matrix metalloproteinases (TIMPs)
The natural activity of the MMPs is counteracted by the tissue inhibitors of matrix 
metalloproteinases, (TIMPs). All TIMPs act effectively against MMPs of the 
collagenase, stromelysin and gelatinase groups by forming inhibited, non-covalent 1:1 
stoichiometric complexes with the MMPs and blocking access to their substrate (Ye et 
al 1998). It is suggested that MMP-2 and MMP-9 (gelatinases) can form complexes 
with TIMPs in their zymogen form as well as active forms, whereas collagenase-type 
and stromelysin-type MMPs only form complexes after exposure of the active site 
(Birkedal-Hansen 1995).
TIMP-1 is synthesized and secreted by most connective tissue cells as well as by 
macrophages, and its expression is regulated by a variety of agents including growth 
factors (IL-1, TNF, and EGF). TIMP-2 frequently co-localised with MMP-2 and its 
expression is largely constitutive (Ye et al. 1998).
2.3.5 Physiological extracellular matrix remodelling
Extracellular matrix remodelling, involving the synthesis and degradation of matrix 
components, is a tightly controlled complex but normal physiological phenomenon 
involving complex cell-cell and cell-matrix interactions, the production of resident 
connective tissues, enzymes, activators, inhibitors and regulatory agents such as growth 
factors and cytokines (Ye et al. 1998). Disruption of these regulatory processes is 
thought to contribute to various pathological states such as aneurysm formation.
The key enzymes contributing to extracellular matrix turnover are endopeptidases from 
three major classes:
1. the metalloproteinases,
2. the serine proteases,
3. the lysosomal proteinases.
Matrix degradation initially takes place extracellularly at neutral pH and is catalysed by 
the metallo- and serine proteinases. Fragments are then phagocytosed and digested 
intracellularly. The metallo- and serine proteinase classes are linked in an activation 
cascade, with the metalloproteinases being downstream of the serine proteinases (Fig 
2.5). In general, the serine enzymes have broader substrate specificity than the
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metalloproteinases that tend to be more specialised. Under normal conditions, the lytic 










PAI-1, PAI-2 a2-antiplasmin 
a 1-antitrypsin Tissue inhibitors of 
matrix metalloproteinase 
TIMP-1, TIMP-2, TIMP-3
Figure 2-5 Extracellular matrix protease cascade
Abbreviations: t-PA: tissue-type plasminogen activator; u-PA: urokinase-type 
plasminogen activator; PAI: Plasminogen activator inhibitor; MMPs: Matrix 
metalloproteinases; MT-MMP: Membrane-type MMP; TIMP: tissue inhibitor of 
metalloproteinases. {Ye et al. 1998)
2.3.6 Pathological extracellular matrix remodelling and aneurysm formation
Several lines of evidence support the role of MMPs derived from both inflammatory 
cells and VSMCs in the initiation and expansion of AAA {Shah 1997). These include;
1. Evidence of an increase in net matrix-degrading activity in AAA tissue
2. Experimental studies showing that the infusion of elastolytic enzymes initiates the 
development of AAAs
3. Evidence of over-expression of MMPs in AAA tissue compared with tissue from 
atherosclerotic occlusive disease (AOD) or normal aortic wall
4. Evidence for reduced or unchanged expression of TIMPs
5. Increased expression of activators of pro-MMPs, such as plasmin and u-PA and t- 
PA in AAA.
6. Demonstration that inhibition of inflammatory cell recruitment or inhibition of 
MMP secretion and/or activity by cyclo-oxygenase (COX) inhibitors or by 
tetracycline derivatives decrease AAA development and expansion.
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2.3.6.1 Evidence o f increased elastolytic and collagenolytic activity in AAA tissue 
Elastolytic and collagenolytic activity has been shown to be increased in AAA tissue 
compared to AOD tissue or normal controls {Busuttil et al 1980; Busuttil et al. 1982; 
Cohen et al 1988; Cohen et al 1989; Vineetal. 1991; Webster et al 1991).
2.3.6.2 Evidence from  Experimental data
Animal experiments have shown that arterial infusion of elastase into animal aorta in 
vivo or human vessels in vitro is sufficient to cause aneurysmal dilatation. Following 
infusion the aortas show extensive elastin degradation. Interestingly such aneurysms do 
not rupture unless collagenase is also introduced. These experiments have given rise to 
the hypothesis that elastolysis leads to aortic dilatation and collagenolysis leads to aortic 
rupture {Dobrin et al. 1984; Anidjar et al. 1990; Halpern et al 1994).
2.3.6.3 Over expression o f  MMPs in AAA tissue
Several MMPs have been identified and shown to be elevated in AAA tissue, including 
MMP(Menashi et al. 1987; Vineetal. 1991; Irizarry et al. 1993; Newman et al. 
1994c), MMP-2 (Freestone et al. 1995; McMillan et al 1995; Patel et al. 1996a; Davis 
et al. 1998), MMP-3 (Newman et al 1994d; Carrell et al. 2002), MMP-9 (Newman et 
al 1994d; Sakalihasan etal. 1996a; Elmore et al. 1998), MMV-\2(Curci et al. 1998; 
Annabi et al. 2002) and MMP-13 (Mao et a l 1999).
2.3.6.3.1 MMP-2
Increased levels of MMP-2 mRNA have been demonstrated in AAA tissue compared to 
AOD or normal controls in several studies (McMillan et al. 1995; Davis et al 1998), 
whereas other studies have shown no difference (Tamarina et al 1997; Elmore et al.
1998). Pro-MMP-2 protein has been demonstrated to be elevated in AAA whole tissue 
homogenates compared to normal aortic tissue samples (Freestone et al. 1995; Davis et 
al. 1998) and VSMC and macrophages have been identified as the sources of MMP-2 in 
AAA tissue (McMillan et al. 1995; Patel et al 1996a; Davis et al. 1998; Crowther et 
al 2000b). In Davies study, MMP-2 was principally produced by mesenchymal cells, 
and its production was prominent when the mesenchymal cells were surrounded by 
inflammatory cells, suggesting paracrine modulation of MMP-2 expression from these 
cells (Davis et al. 1998).
Vascular smooth muscle cells derived from the aortic wall of AAA patients produce 
significantly more MMP-2 in culture than VSMC from normal or AOD patients (Patel 
et al 1996a). Crowther demonstrated that VSMCs derived from AAAs produce 3-fold 
higher levels of MMP-2 than VSMCs derived from age-standardised atherosclerotic
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controls. MMP-2 expression from other mesenchymal origin tissue (dermal fibroblasts) 
from patients with AAAs was similar to controls, suggesting that the increased 
expression of MMP-2 was specific to VSMCs. The increased MMP-2 production was a 
result of increased MMP-2 transcription, with comparable levels of TIMP-2 and MT- 
MMP-1 mRNA, suggesting that the regulation of MMP-2 gene expression was altered 
in aortic VSMCs from patients with AAAs (Crowther et al 2000b). A second study 
from Goodall demonstrated that patients with AAAs have elevated VSMC MMP-2 
levels in the vasculature, including venous tissue remote from the aorta. This again was 
shown to be due to increased MMP-2 expression from VSMCs within that tissue. This 
study supports the concept of widespread proteolysis in the vasculature of patients with 
AAA, suggesting that this may be due to over expression of MMP-2 from VSMCs 
(Goodall et al 2001).
2.3.6.3.2 MMP-9
Increased levels of MMP-9 mRNA and pro- and activated MMP-9 have been shown to 
be raised in AAA tissue (Vine et al 1991; Newman et al 1994c; Newman et al 1994d; 
Freestone et al 1995; McMillan et al 1995; Sakalihasan et al 1996a; McMillan et al 
1997; Tamarina et al 1997; Elmore et al 1998; Petersen et al 2000; Yamashita et al 
2001). Macrophages are believed to be the principal source of MMP-9 (Newman et al 
1994b; McMillan et al 1995; Thompson et al. 1995; Davis et al 1998), however, small 
levels of MMP-9 are detectable in normal aorta in the absence of inflammatory cells 
(McMillan et al 1995) and VSMCs in culture from AAA patients do produce MMP-9 
(Patel et al 1996a), particularly in response to pro-inflammatory cytokines (Galis et al.
1994), which are known to be raised in AAA tissue (Newman et al 1994a; Szekanecz et 
al 1994). Recent evidence has demonstrated that MMP-9 levels are raised in the plasma 
of AAA patients, but the clinical use of this observation remains to be elucidated 
(McMillan et al 1999; Hovsepian et al 2000).
MMP-2 is believed to be the dominant elastolytic enzyme in the wall of small early 
aneurysms, with MMP-9 becoming most prominent as the inflammatory infiltrate 
increased in density (Freestone et al 1995; Thompson et al 1995). Freestone 
demonstrated that MMP-2 was the dominant elastolytic enzyme in smaller AAAs, 
whereas MMP-9 (produced from inflammatory cell) was the principle enzyme in larger 
AAAs (Freestone et al 1995). Similar data from Petersen and McMillian suggests that 
MMP-2 levels correlate with increasing expansion of AAAs, but MMP-9 is required in 
larger AAAs for rupture, suggesting the role of MMP-2 in early AAA formation and 
expansion and MMP-9 in AAA rupture. (McMillan et al 1997; Petersen et al 2000;
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Petersen et al. 2002). This has lead to the hypothesis MMP-2 drives aneurysm 
expansion by breaking down elastin, which via the formation of elastin degradation 
products attracts an inflammatory infiltrate that leads to further ECM degradation 
(Crowther et al. 2000b).
23.6.33 MMP-1
Experimental data suggests that for aneurysm rupture to occur aortic collagen must be 
destroyed (Dobrin et al. 1984). Increased collagenase activity has been described in 
AAA tissue by Busuttil and Manashi (Busuttil et al. 1980; Menashi et al. 1987). In the 
latter study, levels of collagenase activity in AAA tissue collected at elective repair 
were low whereas higher levels were noted in specimens from ruptured AAAs (Menashi 
et al. 1987). Increased levels of MMP-1 mRNA (Tamarina et al. 1997), and MMP-1 
protein and activity have all been demonstrated in AAA tissue compared to normal or 
AOD tissue {Irizarry et al. 1993; Newman et al. 1994c; Annabi et al. 2002). The 
cellular sources of MMP-1 are macrophage and mesenchymal cells {Irizarry et al. 1993; 
Newman et al. 1994b; Newman et al. 1994c). Keen demonstrated that MMP-1 is 
transcriptionally upregulated in mesenchymal cells by inflammatory mediators such as 
platelet derived growth factor (PDGF) and interleukin 1 (3 {Keen et al. 1994)
2.3.63.4 MMP-3
Stromelysin-1 (MMP-3) has a specific proteolytic action towards proteoglycans 
{Palombo et al. 1999). MMP-3 is present in increased levels in abdominal aortic 
aneurysms {Newman et al. 1994d; Yoon et al. 1999). Knox demonstrated that MMP-3 
protein levels were increased in diseased but there was no difference between AAA and 
AOD {Knox et al. 1997). Carrell however, using reverse transcriptase and PCR showed 
that the expression of MMP-3 mRNA is significantly higher in AAA compared to AOD 
{Carrell et al. 2002). MMP-3 has been implemented in the destruction of the aortic 
media, both directly {Woessner 1991) and indirectly via the activation of pro-MMPs, 
namely MMP-1 and MMP-9 {Suzuki et al. 1990).
2.3.63.5 MMP-12
Human macrophage elastase (MMP-12) recovered from AAA tissue is seven fold 
greater than that from normal aorta {Curci et al. 1998; Annabi et al. 2002).
2.3.63.6 MMP-13
Collagenase-3 (MMP-13), a recently described matrix metalloproteinase with a limited 
tissue distribution and a highly regulated pattern of expression, has been shown to be 
elevated in AAA tissue {Mao et al. 1999). Mao demonstrated that MMP-13 mRNA was
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present in AAA and AOD tissue but not in normal aortic control tissue. The expression 
of MMP-13 was 1.8-fold higher in AAA compared to AOD tissue. Immunoreactive 
MMP-13 was localized to medial VSMC which were also shown to express MMP-13 in 
culture {Mao et al. 1999).
2.3.6.4 Evidence o f pro-MMP activators
MMPs are secreted as proenzymes that require activation. Evidence suggests that 
plasmin, MMP-3 and MT-MMP are all capable of activating MMPs in vivo {Ye et al
1998).
2.3.6.4.1 Plasmin and Plasminogen activators
Plasmin is known to activate pro-MMPs {Baricos et al. 1995) and increased levels of 
plasmin have been shown in AAA tissue {Jean-Claude et al. 1994). In addition Reilly 
and Louwrens have shown that tissue plasminogen activators are elevated in AAA 
tissue and VSMC are a source of these activators {Reilly et al. 1994; Louwrens et al. 
1995; Reilly 1996). The later study also demonstrated that there was no increase in the 
plasminogen activator inhibitors, (PAI-1 and PAI-2) in AAA tissue {Louwrens et al.
1995). Animal data suggests that blockage of plasminogen activators prevents the 
formation and rupture of experimental aneurysms in animals {Allaire et al. 1998).
2.3.6.4.2 Membrane type metalloproteinases (MT-MMPs)
Recent evidence suggests that MMP-2 can be activated on the cell surface through the 
assembly of a ternary complex consisting of pro-MMP-2, TIMP-2 and activated MT- 
MMP {Cao et al. 1995; Strongin et al. 1995). Crowther demonstrated that the MMP-2- 
TIMP-2-MT-MMP-1 enzyme system was localised to VSMC within the medial layer of 
the arterial wall, suggesting that this system may play an aetiological role in the 
pathogenesis of AAAs, however further work did not demonstrate an increased 
expression of MT-MMP-1 in AAA tissue compared to AOD tissue {Crowther et al. 
2000b, 2000a), and levels of MT-MMP-1 were not elevated in vascular tissue remote 
from the aorta {Goodall et al. 2001). In contrast Nollendorfs demonstrated that MT- 
MMP-1 m RNA and protein were increased in AAA compared with AOD and normal 
tissue. Immunohistochemical analysis localized MT- MMP-1 to aortic VSMC and 
macrophages. AAA tissue demonstrated a greater capacity to activate exogenous pro- 
MMP-2 compared with atherosclerotic and normal aortic tissue suggesting that it may 
be important in AAA pathogenesis through its ability to activate pro-MMP-2 
{Nollendorfs et al. 2001).
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2.3.6.4.3 Prostaglandin E2 (PGEJ
The arachidonic acid metabolite PGE 2 has also been identified as an important regulator 
of the matrix metalloproteinases and has been shown to be elevated in AAA tissue 
compared to normal controls {Holmes et a l 1997). However, no difference in PGE2 was 
observed between AAA tissue and AOD tissue {Reilly et al 1999). Macrophages within 
the aortic wall inflammatory are the source of PGE2 {Holmes et al 1997; Walton et al
1999). This study also demonstrated that its expression was controlled by the Cox-2 
isoform of cyclo-oxygenase. Experimental data using Indomethacin, an inhibitor of 
cyclo-oxygenase, has demonstrated that decreased production of PGE 2 are associated 
with decreased AAA formation {Holmes et al 1996; Miralles et al 1999; Walton et al
1999).
2.3.6.5 Tissue inhibitors o f MMPs
Another possibility which may explain increased proteolytic activity in AAA would be 
a deficiency of the tissue inhibitors of metalloproteinases (TIMPs). In an animal model 
of AAA formation, local seeding of smooth muscle cells retrovirally transfected with 
TIMP-1 cDNA resulted in TIMP-1 local over expression, decreased MMP-9 and MMP- 
2 activity, elastin preservation and prevention of aneurysmal degeneration and rupture, 
suggesting that lack of TIMP-1 may be a reason for AAA development {Allaire et al 
1998).
Brophy demonstrated that levels of TIMP-1 are decreased in AAA tissue {Brophy et al
1991), whereas other studies have shown no difference between AAA and normal tissue 
{Annabi et al 2002), or any difference in TIMP-1 and TIMP-2 levels between AAAs of 
differing sizes {Petersen et al 2002).
Elmore demonstrated that levels of TIMP-1 mRNA were not significantly different in 
AAA tissue compared to control or AOD tissue, but there was a small but statistically 
significant increase in TIMP-2 mRNA in AAA tissue {Elmore et al 1998). Taminara 
showed that mRNA for both TIMP-1 and TIMP-2 were increased in AAAs, but the ratio 
of MMP to TIMP was significantly higher in AAA patients resulting in net elastolysis 
and matrix degradation {Tamarina et al 1997). McMillian found no difference in 
TIMP-2 mRNA between AAA and AOD or normal aortas, but the level of MMP-2 
mRNA was significantly increased resulting in a significantly higher MMP: TIMP ratio. 
TIMP-2 is constitutively expressed and co-localises with MMP-2 to VSMC and 
macrophages {McMillan et al 1995; Crowther et al 2000b).
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2.3.6.6 Inhibition studies
Additional evidence to support the role of MMPs in the pathogenesis of AAAs is 
obtained from experimental animal data. Doxycline, tetracycline or chemical derivatives 
of these compounds have been shown to decrease AAA development in animal and 
human aortic explant models of aneurysm disease (Petrinec et al 1996a; Petrinec et al 
1996b; Boyle et al 1998; Curci et al 1998). These drugs limit the disruption of medial 
elastin without altering the inflammatory response. They are believed to decrease the 
production of MMP-9 (Petrinec et al 1996b; Boyle et al 1998).
Early in vivo studies have shown that tetracycline penetrates the wall of the aorta in 
humans, decreasing MMP-9 and monocyte chemoattractant protein -1 (MCP-l) in a 
concentration dependent manner {Franklin et al 1999a, 1999b). In addition Curci has 
shown that if Doxycline is administered to AAA patients preoperatively, both 
macrophage expression of MMP-9 and post-translational activation of pro-MMP-2 are 
decreased {Curci et al. 2000). In the only clinical study to-date Doxycline has been 
shown to decrease the expansion of small aneurysms {Mosorin et al 2001). Similar 
results were obtained by synthetic MMP inhibitors in turther animal studies {Bigatel et 
al 1999; Moore et al 1999).
Indomethacin, a cyclo-oxygenase type 2 (Cox-2) inhibitor has also been shown to 
decrease AAA formation in an animal model by decreasing macrophage expression of 
MMP-9 {Holmes et al. 1996; Miralles et al. 1999). Additional evidence shows that 
Indomethacin or mefanamic acid abolishes PGE2 secretion and reduces EL-ip and 
interleukin-6 (IL-6) secretion in explants from AAA patients {Franklin et al 1999c; 
Franklin et a l 1999d; Walton et al 1999). These studies also report that the growth rate 
of AAAs is decreased if patients are treated with non-steroidal anti-inflammatory drugs. 
Experimental data suggests that HMG-CoA reductase inhibitors (Statins) decrease 
MMP-9 secretion and activity in condition media from cultured human and mouse 
macrophages {Bellosta et al 1998). Recent evidence also suggests that this group of 
compounds can decrease MMP-2 expression and activity and interleukin-6 (IL-6) levels 
in human AAA tissue explants(isv<ms et al 2002). It is believed that these drugs work 
by reducing the transcription factor nuclear factor-kappa-B (NF-kB) expression, an 
intracellular oxidant dependent transcription factor that is required for cytokine up- 




Abdominal aortic aneurysms are characterized by a non-specific ubiquitous chronic 
inflammatory infiltrate (Koch et al 1990; Brophy et al 1991). In approximately 10% of 
AAAs the inflammatory response is so intense as to be macroscopically detectable as 
the so-called' inflammatory aneurysm' which is characterized by a dense 
perianeurysmal fibrotic infiltrate, which may extend and involve adjacent organs 
(Walker et al 1972; Sterpetti et al 1989).
Immunohistochemical analysis identifies CD3+ T lymphocytes, macrophages and 
polyclonal B-lymphocytes. The infiltrating lymphocytes were often found in clusters, 
with B-cells surrounded by T cells often located around the adventitial vasa-vasorum, as 
well as associated scattered macrophages (Koch et al 1990). Inflammation is a feature 
of both AAAs and aortic occlusive disease however the infiltrate differs in the following 
ways:
1. The lymphocytes present in aortic occlusive disease are predominately T- cells, 
while both T and B cells have been identified in AAA tissue
2. Adventitial inflammation is seen only in more advanced stages of aortic occlusive 
disease, while it is a consistent feature of AAA
3. The CD4+: CD8+ ratio is 7.6:1 in AAA compared to 2:1 in the peripheral 
circulation and 4.3:1 in aortic occlusive disease
4. Macrophages are distributed throughout the wall in AAA but in aortic occlusive 
disease they are limited to the plaque {Beckman 1986; Koch et al 1990; Brophy et 
al 1991).
Experimental animal data support the role of the inflammatory response in the etiology 
of AAA formation. Gertz and Anidjar induced aneurysm development in rabbit carotid 
and rat aorta by the injection of calcium chloride and elastase respectively and found 
that dilatation corresponded with the inflammatory infiltrate, which suggests that this 
forms a crucial central mechanism in the pathogenesis of AAAs {Gertz et al 1988; 
Anidjar et al 1992). Freestone demonstrated that the density of inflammatory cells 
within the aortic wall was the histological feature most clearly associated with AAA 
expansion and rupture {Freestone et al 1995).
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2.3.7.2 Function o f inflammatory infiltrate
2.3.7.2.1 Cytokine production
Inflammatory cells secrete a variety of cytokines which activate and influence local 
mesenchymal cells (Galis et al 1994). Tumour necrosis factor-alpha (TNF-a) (Pearce 
et al. 1992; Newman et al 1994a), Interleukin 1(3 (IL-lp) (Pearce et al 1992; Newman 
et al 1994a), Interleukin-6 (IL-6) (Szekanecz et al 1994), Interferon gamma (INF-y)
(Szekanecz et al 1994), Monocyte chemoattractant protein (MCP) {Koch et al 1993; 
Szekanecz et al 1994) and Interleukin 8 (IL-8) {Koch et al 1993) have all been shown 
to be increased in diseased aortic tissue. Plasma levels of IL-ip, IL-6, interleukin-6, 
TNF-a and INF-y have been demonstrated to be increased in AAA patients compared to 
both patients with ischaemic heart disease or normal controls {Jitvonen et al 1997). 
Indeed, INF-y concentrations were predictive of increased rates of expansion of AAAs 
{Juvonen et al 1997).
Recent interest has focused on differential expression of cytokines between AAA and 
AOD. Reilly showed that AAA and AOD whole tissue organ culture secreted more IL-6 
compared to normal tissue, however, AOD was associated with a much higher level of 
IL-6 expression than AAA {Reilly et al 1999). Contradicting this observation is work 
from Shteinberg who demonstrated that AAA tissue samples contained significantly 
higher mean TNF-a and IL-6 levels compared to the AOD samples, but there was no 
differences related to IL-lp levels {Shteinberg et al 2000). Davis, who analysed 
cytokine expression in tissue with an ELISA showed that AAA tissue contained higher 
levels of IL-10 compared to AOD tissue, whereas higher levels of the IL-lp, TNF-a and 
IL-6 were found in AOD {Davis et al 2001).
The possible role of cytokines in AAA formation is demonstrated by evidence from 
experimental data. Indomethacin or mefanamic acid have been shown to abolishes PGE2 
secretion and reduces IL-ip and IL-6 secretion in explants from AAA patients as well 
as decrease the expansion of AAAs in a small cohort of patients {Franklin et a l 1999c; 
Franklin et al 1999d; Walton et al 1999). Hingorani showed in an animal model of 
AAA formation that blockage of TNF-a with a binding protein inhibited AAA 
formation {Hingorani et al 1998).
The potential effects of these cytokines maybe to;
1. Increase angiogenesis and neovascularisation. TNFa is known to promote 
neovascularisation {Szekanecz et al 1994) and medial neovascularisation is increased 
in AAA tissue compared to normal or AOD tissue {Holmes et al. 1995).
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2. Attraction and recruitment of further inflammatory cells. TNFa and IL-1 (3 incease 
the expression of intercellular adhesion molecules in cultured human aorta epithelial 
cells which are known to be elevated in AAA (Davis et al. 1993; Szekanecz et al. 
1994). In addition IL-8 and Monocyte chemoattractant protein are known to be 
elevated in AAA tissue (.Koch et al. 1993; Szekanecz et al. 1994).
3. Influence the expression of MMPs. Cytokines influence MMP gene expression at 
transcriptional level (Mauviel 1993). Keen demonstrated that AAA derived VSMC in 
culture increased MMP-1 mRNA expression when stimulated with IL-1 (3 (Keen et al. 
1994). Similar results were obtained by Galis who showed that VSMCs stimulated 
with IL-lp and TNF-a expressed several MMPs, including MMP-1,2, 3 and 9. 
Interestingly mRNA and protein levels of TIMPs 1 and 2 appeared unaffected in the 
latter study, supporting the concept that cytokines alter the balance between matrix 
degradation and synthesis (Galis et al. 1994).
2.3.7.2.2 MMP production
Shapiro showed that as monocytes migrate into tissues and differentiate into 
macrophages, the gene expression for a variety of MMPs particularly, MMP-1, MMP-3 
and MMP-9 dramatically increase (Shapiro et al. 1990). Subsequently the macrophage 
has been identified as a source of several MMPs in AAA tissue (Irizarry et al. 1993; 
Newman et al. 1994b; McMillan et al. 1995; Thompson et al. 1995; Curci et al. 1998; 
Annabi et al. 2002).
2.3.7.2.3 Production of MMP activators
Infiltrating macrophages have been demonstrated to be a source of PGE2 within AAA 
tissue (Holmes et al. 1997; Walton et al. 1999).
2.3.8 Infection and aneurysm formation
As chronic inflammation is a contributing factor in the pathogenesis of abdominal aortic 
aneurysms, antigens such as Chlamydia pneumoniae (C.pneumoniae) have been 
suggested as possible triggers for the inflammatory response.
The association between C.pneumoniae and arterial disease is well recognised, but there 
is no proof that C.pneumoniae plays any clinically significant role (Ong et al. 1996; 
Lindholt et al. 1999). Immunohistochemical evidence and the demonstration of C. 
pneumoniae cDNA in AAA tissue suggests that C.pneumoniae may play a role in the 
pathogenesis of AAA formation (Blasi et al. 1996; Juvonen et al. 1996; Ong et al.
1996; Juvonen et al. 1997; Petersen et al. 1998; Halme et al. 1999; Meijer et al. 1999). 
In one study C. pneumoniae specific DNA was detected at a significantly higher
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frequency in the wall of AAA samples compared to tissue from normal aortas {Petersen 
et al 1998).
Antibodies to C. pneumoniae can be detected in between 40-80% of AAA patients 
(Blasi et al 1996; Lindholt et al 1999; Lindholt 2001). Meijer demonstrated the 
presence of C.pneumoniae antigens in the absence of specific DNA in abdominal aortic 
aneurysms, suggesting persistence of the antigens rather than a persistent infection 
{Meijer et al 1999). High levels of immunoglobulin-A (IgA) and immunoglobulin 
(IgG) C. pneumoniae titres have been shown to correlated with mean annual AAA 
expansion and be significant independent predictors of AAA expansion {Lindholt et al 
1999; Lindholt 2001).
In an experimental animal model of AAA formation, macrophage influx into a rabbit 
abdominal aorta was insufficient to cause experimental aortic dilatation, however C. 
pneumoniae antigen influx induced both a macrophage influx and AAA formation, 
raising the possibility that C.pneumoniae may exert an effect on AAA formation 
through a macrophage mediated pathway {Tambiah et al 2001).
Roxithromycin, a macrolide antibiotic with anti-Chlamydia effects, has been shown to 
decrease the clinical expansion rate of AAAs. The conclusion from this particular study 
was that C.pneumoniae induced and maintained a persistent inflammatory response that 
lead to AAA expansion {Vammen et al 2001). Unfortunately whilst this study shows 
that Roxithromycin decreases AAA formation, the mechanism of its action was 
uncertain. The apparent slowing of AAA expansion could be due to a true antibiotic 
effect of Roxithromycin or the consequence of another property of the drug such as an 
anti-inflammatoiy activity. Indeed the tetracycline group of antibiotics have MMP 
inhibitory properties independent of their antimicrobial activity, and in one study have 
been shown to similarly decrease AAA expansion without having a significant effect on 
C.pneumoniae titres {Petrinec et al 1996b; Boyle et al 1998; Mosorin et al 2001).
2.3,9 Autoimmunity
The fact that the inflammatory response associated with AAAs includes B and T
lymphocytes {Koch et al 1990), large amounts of immunoglobulin {Brophy et al 1991;
Pasquinelli et al. 1993; Gregory et al. 1996) and activated complement {Capella et al
1996) suggests an autoimmune component to AAAs. It has been postulated that the
formation of elastin-derived peptides may be an initiating factor in AAA formation
{Cohen et al 1991; Cohen et al 1992). Indeed there are histological similarities with
temporal arteritis where such elastin-derived peptides are also thought to be involved
{Cid et al 1989). Baydanoff demonstrated that anti-elastin antibodies are raised in AAA
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patients (Baydanoff et al 1987) leading Wills to postulate that elastin could potentially 
degenerate or have its structure altered by the ageing process forming elastin-derived 
peptides that could initiate AAA formation via the inflammatory cascade (Wills et al.
1996).
Tilson and Xia identified a matrix protein which is immunoreactive with Ig G isolated 
from AAA wall (Tilson 1995; Xia et al 1996). Initial characterization of this putative 
autoantigen demonstrated homology to a microfibrillar-associated glycoprotein, which 
is an important component of the microfibrils that provide a structural scaffold for 
tropoelastin deposition during elastogenesis. Shah postulated that exposure of this 
putative autoantigen during elastolysis may incite an immune response and 
inflammatory cascade which ultimately leads to AAA formation (Shah 1997).
Despite the fact that several studies have demonstrated an association between the Class 
II major histocompatibility loci, D2, DR B1 and DR 2(15) and AAA formation 
(Pasquinelli et al 1993; Tilson et al 1996; Rasmussen et al 1997), Walton and Yen, 
showed that in the vast majority of AAAs the B cell infiltrate and T cell receptor V beta 
repertoire were polyclonal and did not represent a restricted autoimmune response to a 
limited repertoire of tissue antigens, suggesting that an autoimmune basis for AAA 
formation was unlikely (Walton et al 1997; Yen et al 1997).
2.3.10 Atherosclerosis
The fact that atherosclerosis results in AAA formation in only a small percentage of 
patients suggest that other factors may be involved in AAA formation. Despite sharing 
common risk factors such as smoking and hypertension and the fact that the two 
diseases may co-exist within the same individual, epidemiological data suggest that 
patients with aneurysmal disease are substantially older, overwhelmingly male, in better 
general health, experience lower post-operative mortality and postoperatively have a life 
expectancy similar to a normal population of the same age (Tilson 1992; Shteinberg et 
al 2000). Additionally the incidence of diabetes and the lipid profile of AAA patients 
are normal whereas they are raised in AOD compared to the general population 
(Norrgard et al 1985; Louwrens et al 1993).
In addition, several histological and biochemical differences exist between aneurysmal 
and atherosclerotic aortic disease (MacSweeney et al 1994; Patel et al 1995;
Shteinberg et al 2000). In AAAs, the tunica media is thinner and its integrity destroyed, 
whilst in AOD tissue it is preserved to some extent. The elastic lamellae within the 
media and inner adventitia are destroyed in AAA disease and the VSMCs between the 
lamellae are deficient or reduced in AAA tissue compared to AOD derived tissue.
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Three possible explanations exist to account for the strong association between 
atherosclerosis and AAAs.
1. Despite sharing common risk factors, AAA formation is unrelated to 
atherosclerosis and occlusive disease and is simply a unique clinical entity, with both 
developing and existing independently in the same individual. Tilson proposed that 
the common risk factors in both atherosclerotic occlusive disease and aneurysmal 
disease may mediate the promotion of either disease through unique disease specific 
mechanisms, depending on the constitutional susceptibilities of the individual (Tilson
1992).
2. A second explanation would be that atherosclerosis is a permissive factor required 
for AAA development. It is argued that AAAs may occur as a result of 
atherosclerotic plaque regression leaving a weakened aortic wall (Zarins et al 1990; 
Zarins et al 1992; Zarins et al 2001). The infra-renal aorta is known to be relatively 
deficient in vasa vasorum and subsequently the tunica media is dependent on 
diffusion from the aortic lumen (Wolinsky et al 1967). This paucity in vasa vasorum 
has been suggested as a factor that may explain the particular propensity of the 
infrarenal segment of the human aorta to develop early and severe atherosclerosis 
{Reed et al. 1992). It is argued that atherosclerotic plaques and superimposed 
thrombus form a mechanical barrier to the diffusion of substances into the media, 
thus weakening the media via nutritional deficiencies {Wills et al. 1996).
3. It has been suggested that atherosclerosis in the aneurysmal segment is a response 
to aortic dilatation rather than its cause, as atheromatous plaques preferentially form 
in regions of turbulence and low sheer stress(ReilIy et al. 1989; Cohen et al 1990; 
Tilson 1992).
The controversy surrounding the association between AAAs and atherosclerosis 
remains to be clarified, in particular to identify precisely if one is a prerequisite for the 
other, or whether indeed they are two distinct clinical entities just sharing common risk 
factors and a predilection for the infra renal aorta.
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2.3.11 Summary o f potential pathogenic mechanisms
In summary, AAA formation depends on the interplay between factors that either 
weaken the wall or increase the load on it together with the time scale over which they 
operate (MacSweeney et al. 1994). Advances in immunohistochemistry, biochemistry 
and molecular biology have demonstrated a complex multifactorial biophysical process 
that leads to an inflammatory response which in turn leads to increased media 
destruction and aortic remodelling. See Fig 2.6 and 2.7 for schematic representation of 









































Figure 2-7 Alternative representation of pathogenesis of AAAs 
{MacSweeney et al. 1994)
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2.4 Formulation of hypothesis
2.4.1 Arterial wall hypoxia
Arterial wall oxygenation has been the subject of several investigations. In 1944,
Heuper suggested that artery wall hypoxia may have a role in the pathogenesis of 
atherosclerosis, and since then arterial-wall hypoxia has been a topic of investigation in 
conditions such as atherosclerosis, intimal hyperplasia and myointimal hyperplasia 
(Hueper 1944; Heughan et al 1973; Zemplenyi et al 1989; Crawford et al 1991; 
Martin et al 1991; Bjornheden et al 1999; Lee et al 2000; Santilli et al 2000). 
Wolinsky and Glagov demonstrated that arteries with the diameter and wall thickness of 
the rabbit aorta do not have a medial vasa vasorum (Wolinsky et al 1967). Niinikoski 
demonstrated that a transarterial wall oxygen gradient is present in normal rabbit aortas 
with oxygen tensions falling from the adventitia and reaching a nadir at the junction of 
the inner one third and outer two thirds of the vessel wall. Oxygen tensions then slowly 
rise towards the lumen side (Niinikoski et al 1973). This lead to the postulation that the 
outer two thirds of the artery wall is supplied with oxygen by the vasa vasorum and the 
inner one third of the artery wall is supplied by luminal diffusion of oxygen.
In atherosclerosis, both diffusion distances and the oxygen consumption of the arterial 
wall increase {Vorp et al 1996; Vorp et a l 1998). Heughan demonstrated that the 
presence of an established atherosclerotic lesion eliminated the normal rise in oxygen 
tension found through the inner one-third of the vessel wall. Oxygen tensions 
progressively fell from the adventitia until the lumen was entered. In the presence of an 
atherosclerotic lesion, the luminal diffusion of oxygen to the inner one-third of the 
artery wall was impaired {Heughan et al 1973). Despite the attractiveness of this theory 
the following question remains: What happens before atherosclerotic lesion formation to 
initiate and maintain the formation of atherosclerotic lesions?
Martin postulated that thrombosis of the vasa-vasorum leading to arterial wall hypoxia, 
is an initial lesion in atherosclerosis {Martin et al 1991). Additional evidence from 
animal studies has shown that destruction of vaso-vasorum alters the trans-mural 
oxygen tension and leads to vessel wall hypoxia {Santilli et al 2000). Crawford 
reported that hypertension causes artery wall hypoxia and could lead to atherosclerosis 
through the generation of oxyradicals {Crawford et al 1991). Santilli has shown that 
risk factors for atherosclerosis including diabetes, hypertension, cigarette smoking, 
ageing, and artery bifurcation lead to artery-wall hypoxia before the formation of an
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atherosclerotic lesion (Santilli et al 1992, 1993; Santilli et al 1995; Santilli et al 
1998).
The oxygen concentration in the arterial wall has been measured directly in animals and 
in vitro and in situ systems and these measurements demonstrate that partial pressure of 
oxygen (pCh) decreases with the distance from the lumen and adventitia, reaching a 
minimum of 20 to 50 mm Hg in the media {Niinikoski et al 1973; Crawford et al 1988; 
Zemplenyi et al 1989). These measurements have all demonstrated that a trans-arterial 
wall oxygen gradient is a normal physiological finding, which is exaggerated in an 
atherosclerotic vessel.
Data from human studies and in particular in vivo measurements are limited.
Bjomheden described a hypoxia marker, 7- (4’-(2-nitroimidazol- 1 -yl)-butyl) 
theophylline (N1TP) with potential to assess hypoxia in vivo. The system is based on a 
hypoxia marker originally developed by Hodgkiss to detect hypoxia in tumours 
(Hodgkiss et al 1991). In this system a nitroimidazole derivative with a theophylline 
ligand is taken up intracellularly and undergoes nitroreduction and oxidation (mainly by 
cytochrome P450 reductase) in a futile cycle provided oxygen is present. In hypoxic 
conditions, the cycle is broken and aggressive radicals form which bind to cellular 
constituents and become trapped. The theophylline residues may then be detected by 
immunological methods. The main advantage with this method is that NITP may be 
administered in vivo, which makes it possible to assess hypoxia in arterial tissue in the 
intact animal.
In animal (rabbit) in vivo experiments, experimental atherosclerosis was induced in 
rabbits by a combination of cholesterol-enriched diet and mechanical injury and NITP 
solution was administered intraperitoneally. In the rabbit aorta, distinct NITP- 
associated immunofluorescence was observed in atherosclerotic lesions that were >400 
to 500 pm thick. The fluorescence was localized intracellularly to foam cells that 
occupied a 200- to 300-pm-wide zone at a distance of 200 to 300 pm from the luminal 
surface and from the adventitial vasa vasorum. In in vitro conditions, both foam cells 
and smooth muscle cells accumulated NITP. Smooth muscle cells bound NITP at a pC>2 
< 2 to 3 mm Hg, whereas foam cells bound the hypoxia marker at a somewhat higher 
p02 (Bjornheden et al 1999). The interpretation of these results was that the arterial 
tissue in the zones of NITP immunofluorescence was hypoxic and the presence of the 
bound marker corresponded to a pC>2 of 30 to 40 KPa (2 to 3 mm Hg) in the periphery 
of these zones. To my knowledge this is the only demonstration that hypoxic zones do 
occur within atherosclerotic plaques in rabbits when the lesions exceed certain
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dimensions and at a depth that is readily reached in humans. It seems likely that the 
hypoxia in these areas reflect an impaired diffusion capacity due to the thickness of the 
plaque, together with an increased demand in the metabolically active foam cells.
The fluid mechanics within AAA wall are conducive to a build up of laminated 
intraluminal thrombus (ILT) (Adolph et al 1997; Vorp et al 1998). The role of ILT in 
AAA pathogenesis and progression is unknown although previous studies have 
suggested a relationship between the presence of ILT and AAA size, enlargement and 
rapture (Inzoli et al 1993; Wolfet al 1994; Satta et al 1996; Vorp et al 1996). 
Previous interest has focussed on the possibility that ILT forms a mechanical protective 
layer although recent interest has looked at the possibility that ILT serves as a 
mechanical barrier to oxygen diffusion and leads to a reduction in aortic wall strength 
and stiffness {Inzoli et al 1993; Vorp et al. 1996).
Vorp hypothesized that ILT serves as a barrier to normal physiological oxygen diffusion 
from the lumen to the inner layers of the aortic wall rendering the intima and inner 
media anoxic (Vorp et al 1996; Vorp et al 1998). Assessment of this hypothesis using 
an order-of-magnitude analysis of the oxygen diffusion through the ILT layer compared 
to the oxygen consumption rate required for normal aorta revealed an oxygen flow rate 
20 times less than that required for normal VSMC function in AAA. This analysis 
suggested that ILT may offer a significant barrier to O2 diffusion through the AAA wall, 
leading to anoxia, necrosis and diminished resistance by the aortic wall to physiologic 
distending pressure {Vorp et al 1996). In further computational analysis of oxygen flow 
to the AAA wall, the effects of the ILT thickness and AAA bulge diameter were 
assessed. In this study ILT thickness was critical in determining the amount of 
attenuation of oxygen flow to the AAA wall, while bulge diameter had little effect 
{Vorpetal 1998).
Preliminary data collected by Vorp support the possibility that ILT-induces AAA wall 
hypoxia. In brief, eight patients with AAA had their pC>2 measured intraoperatively with 
a custom needle type polarographic pC>2 electrode. The pC>2 measurements were 
normalised by the intraluminal pC>2 to account for patient variability. The results 
indicated that the normalised pC>2 within the AAA wall in patients with ILT was 
significantly less than that within the AAA wall in patients without ILT {Vorp et al 
1998; Vorp et al 2001).
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2.4.1.1 Effects o f  hypoxia
2.4.1.1.1 Vascular tissue
Hypoxia is recognised as a specific stimulus for gene expression, and has been shown to 
modulate the expression of transcription factors such as Hypoxia inducible factor -1 
(HIF-l), growth factors and angiogenic factors such as vascular endothelial growth 
factor (VEGF), platelet derived endothelial growth factor (PDEGF), endothelin (ET-1), 
and nitric oxide synthase (NOS) (Sakuda et al 1992; Kourembanas et al 1998; Berse et 
al 1999; Chiarugi et al 1999; Dachs et a l 2000).
Hypoxia has been shown to decrease elastin and collagen synthesis in cultured aortic 
endothelial cells, VSMCs and fibroblasts (Stavenow et al 1987; Durmowicz et al 1991; 
Herrick et al 1996; Steinbrech et al 1999). Furthermore, the collagen that is 
synthesised by hypoxic cells is abnormal because oxygen is needed for the 
hydroxylation of praline {Herrick et al 1996). Therefore the extra-cellular matrix 
synthesis by the hypoxic vascular wall is likely to be impaired or results in abnormal 
matrix which could lead to wall weakening {Vorp et al 2001).
2.4.1.1.2 Hypoxia andMMPs
Macrophages exposed to hypoxia show an increase in elastase production {Campbell et 
al 1983). MMP-9 has been shown to contain consensus hypoxia sensitive AP-1 and 
NFkB sites in its promoter region {Himelstein et al 1998). In mice exposed to hypoxia, 
MMP-2 and MMP-9 protein levels increased by 2 days {Zaidi et al 2002). Similarly, in 
pulmonary interstitial tissue harvested from hypoxic exposed rabbits rabbit and human 
keratinocytes exposed to 2% oxygen, MMP-9 expression and protein levels increased 
{O'Toole et al 1997; Miserocchi et al 2001). However in one study using mouse 
fibroblasts, MMP-9 expression and activity decreased after exposure to hypoxia (Saed 
et al 2000).
Other studies have demonstrated an increase in expression of MMP-2 in rat hepatocytes 
subjected to hypoxia {Chen et al 2000). In one study using human trophoblastic and 
breast cancer cells, hypoxia had no effect on either MMP-2 or MMP-9 expression, but 
their activity was increased due to a decrease in TIMP-1 {Canning et al 2001). These 
findings suggest reduced oxygen conditions may shift the balance between MMPs and 
their inhibitors favouring increased MMP activity.
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2.4.2 Xanthine oxidoreductase (XOR)
2.4.2.1 Background information
Xanthine oxidoreductase is a homodimer of 150kDa subunits existing as two 
interconvertible forms, xanthine dehydrogenase (XDH; EC 1.1.1.204) and xanthine 
oxidase (XO; EC 1.1.3.22). The two enzyme forms and their reactions are often referred 
to as xanthine oxidoreductase (XOR) activity (Pritsos 2000).
XOR is a cytosolic and membrane-bound complex molybdoflavoprotein with each 
150kDa subunit containing the following active redox centres (Bray et al. 1996).
1. 1 molybdenum centre with a pterin co-factor
2. 2 iron sulphur centres (Fe/S I and Fe/s II) and,
3. 1 Flavin adenine dinucleotide (FAD) centre.
The gene for xanthine oxidase is located on chromosome 2 and codes for a sequence of 
1330 amino acids (Xu et al 1994). The enzyme is synthesized as xanthine 
dehydrogenase (XDH), which accounts for 90% of the total activity in healthy tissue 
(McCord 1985). The functional distinction is the preference of each for differing 
terminal electron acceptors. XDH is characterized by high xanthine/NAD+ activity and 
low xanthine/02 activity, whereas XO is characterized by high xanthine/ O2 activity and 
low xanthine/ NAD+ activity (Nishino et al 1997; Pritsos 2000). This difference is due 
to the absence of a NAD binding site as a result of destabilization of the FAD redox site 
in the oxidase form. However, the precise structural difference between the two forms 
of the enzyme remains elusive (Nishino et al 1997). Conversion of xanthine 
dehydrogenase into xanthine occurs by two mechanisms:
1. Thiol oxidation of the protein molecule (reversible), or
2. Proteolysis (irreversible).
This conversion readily takes place during isolation procedures unless thiol reducing 
agents and protease inhibitors are included in isolation buffers (Nishino et al 1997; 
Pritsos 2000).
2.4.2.2 Tissue and cellular distribution o f XOR
The expression of XOR is tissue and cell specific. Small amounts of XOR are present in 
various organs, with the highest levels of catalytically active enzyme being observed in 
the liver, intestine, lung and heart (Terao et al 1997; Pritsos 2000). Substantial 
differences in organ distribution of XOR activity exist between mammalian species 
making it difficult to extrapolate animal study results to human physiological and 
pathological events (Pritsos 2000). Human liver and intestine have the highest XOR
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activity of any tissues and this is largely due to the XOR-rich parenchyma cells of these 
tissues (Pritsos 2000).
XOR has also been shown to be present in microvascular endothelial cells which may 
account for the extremely low tissue activity seen when relatively large pieces of tissue 
are homogenized for enzymatic activity or blotting (Jarasch et al 1986; Moriwaki et al 
1993; Vickers et al 1998). In addition XOR has been shown to be released into the 
systemic circulation from the liver and intestine during reperfusion injury (Yokoyama et 
al 1990; Tan et al 1995). XOR has also been localized to the endothelial cell plasma 
membranes, binding via interaction with surface glycosaminoglycans (Adachi et al
1993).
2.4.2.3 XOR and vascular tissue
Levels of both XOR and anti-XOR antibodies are known to be elevated in plasma of 
atherosclerotic patients and the presence of the enzyme has been demonstrated in vessel 
walls and atherosclerotic plaques (Harrison et al 1990; Swain et al 1995; Mohacsi et 
al 1996; Patetsios et al 1996; Patetsios et al 2001).
Swain investigating the presence of redox active iron in human atherosclerotic material, 
demonstrated that ferroxidase activity attributable to XOR was present in both carotid 
endarterectomy plaques and aneurysm tissue (Swain et al 1995). Patetsios’ 
investigation of uric acid (the end product of XOR activity) and its role in “ response to 
injury theory of atherosclerosis” demonstrated that both AAA tissue and carotid 
endarterectomy plaques contained significantly more uric acid than non-atherosclerotic 
arteries obtained from young cadaveric organ donors. Immunohistochemistry localised 
XOR to the intima and inner media of the artery wall. The conclusion from this study 
was that increased XOR activity within an artery wall may lead to the deposition of uric 
acid and trigger arterial injury (Patetsios et al 1996).
In a subsequent study using carotid endarterectomy plaques and control carotid arteries 
from cadaveric organ harvests, significantly higher concentrations of uric acid were 
seen in atherosclerotic plaques. Control carotid arteries stained positive for XOR, but 
staining was less than that of carotid plaque. The staining was localized to both the 
intima and media, being more positive in the media whereas carotid plaque 
demonstrated greater intimal staining. The carotid plaques were irregularly stained, with 
endothelial cells and smooth muscle cells staining positive for XOR in the intima. Uric 
acid and XOR co-localised within the specimens. The conclusion from this study was 
that injury to the endothelial and smooth muscle cells initiated the conversion of XDH 
to XO. Increased XO activity results in the production of uric acid from purine
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precursors with the resultant generation of free radicals that may injure the artery 
{Patetsios et al 2001).
2.4.2.4 Reactions o f XOR
Xanthine oxidoreductase has long been associated with the mechanism of gaining and 
losing electrons in an apparent electron shuttling capacity. The enzyme has a wide 
specificity for reducing substrates, although its’ physiologically role is in the conversion 
of hypoxanthine to xanthine and xanthine to uric acid. Both forms of the enzyme can 
reduce molecular oxygen, although XDH can reduce NAD+ which is its preferred 
electron acceptor {Pritsos 2000).
Reduction of oxygen leads to superoxide and hydrogen peroxide and it is this potential 
to generate reactive oxygen species that lead to interest in this enzyme in the 
pathogenesis of ischaemia re-perfusion injury {McCord 1985). Recent interest has 
focussed on the ability of XOR to reduce inorganic nitrates and nitrites and produce 
nitric oxide (NO) {Millar et al. 1998). The simultaneous production of superoxide and 
NO by XOR leads to the formation of peroxynitrite, a potent oxidising, nitrating and 
hydroxylating agent {Godber et al. 2000b).
It is to the Molybdenum centre that most reducing substrates donate their electrons 
{Pritsos 2000). The only exception to this is when NADH is the reducing substrate, in 
which case the electrons are transferred at the FAD site {Pritsos 2000). The electrons 
are ultimately transferred to either molecular oxygen (xanthine oxidase) or NAD 
(xanthine dehydrogenase), which serve as terminal electron acceptors.
2.4.2.4.1 Purine metabolism
XOR is involved in the oxidation of hypoxanthine to xanthine and the subsequent 
oxidation of xanthine to uric acid. XDH reduces NAD by a direct two-electron 
reduction while XOR reduces molecular oxygen by a single electron. These reactions 
are inhibited by blocking the molybdenum centre of the enzyme with purine analogues 
such as allopurinol and oxypurinol {Pritsos 2000).
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Figure 2-8 Electron shuttle of XOR
(A) demonstrates a generalised scheme of electron transport utilising the three 
redox centres of the enzyme Mo molybdopterin, flavin centre (FAD) and the iron 
sulphur centres (Fe-S). (B) Details the xanthine to urate reaction by XO using 
molecular oxygen as the electron acceptor and (C) details of xanthine to urate 
reaction by XDH using NAD as the electron acceptor.
2.4.2.4.2 NADH
Human XOR purified from breast milk is characterized with a remarkably low activity 
towards hypoxanthine, xanthine and other conventional reducing substrates which 
donate their electrons directly to the molybdenum site (Sarnesto et al. 1996; Harrison 
1997). NADH is an alternative substrate that donates electrons directly at the FAD site. 
Both forms of the enzyme are able to utilize NADH as a substrate, but it is particularly 
XDH which is able to perform this reaction (Sanders et al. 1997).The oxidation of 
NADH to NAD+ is shown in Figure 2.9 with the electron again being given to oxygen 
to produce the superoxide radical.This reaction is not affected by the molybdenum site 
inhibitors allopurinol and oxypurinol in the presence of oxygen but is inhibited by 











Recent interest has focused on the ability of XOR to generate nitric oxide (NO) from 
nitrates (NO3' ) and nitrites (NO2') {Zhang et al. 1997; Millar et al. 1998; Zhang et al. 
1998; Godber et al. 2000b). In an oxygen rich environment, XOR favours its ability to 
oxidize NADH or xanthine generating superoxide radicals. In oxygen depleted tissue, 
NADH or xanthine can donate electrons which rather than forming superoxide, reduce 
NO3' to NO2’. The terminal electron transfer occurs at the molybdenum centre when 
oxygen is restricted. Activity is completely blocked by oxypurinol at the molybdenum 
site. The donated electron may be competed for by the NO3" at the molybdenum centre 
and residual oxygen in the incubation medium at the FAD centre. Activity in favour of 
NO2' production can be enhanced by blocking the leak of electrons to oxygen using the 
FAD-site inhibitor diphenyleneiodonium (DPI) {Blake et al. 1997; Millar et al. 1997). 
Millar demonstrated that XOR has NO2' reducing activity when exposed to an oxygen 
limited environment. Nitrite reductase activity can utilise either xanthine at the 
molybdenum site or NADH at the FAD site as electron donors and the electron is then 
passed to NO2" at the FeS centre generating nitric oxide (HO){Millar et al. 1998). The 
generation of both nitric oxide and superoxide radicals by XOR can lead to their 
interaction and generation of the potent oxidant, peroxynitrite, which is believed to play 
a pivotal role in the pathogenesis of oxidant stress related conditions such as 
atherosclerosis {Godber et al. 2000b).
2,4.2.5 Hypoxia and XOR
The relationship between XOR and hypoxia involves both transcriptional and post­
translation modulation. Hypoxia has been shown to increase the expression of XOR at a 
transcription level in several studies {Hassoun et al. 1994; Lanzillo et al. 1996; Terada 
et al. 1997; Hassoun et al. 1998). The mechanism by which oxygen tension effects 
XOR expression appears to be complex, however the 5’ flanking region of the XOR 
gene has been shown to contain an AP-1 motif, 3 potential AP-2 sites and a putative 
hypoxia-inducible factor-1-binding site {Hassoun et al. 1998).
In addition, studies also show that hypoxia increases XOR activity without a 
concomitant de novo increase in XOR synthesis or mRNA levels, suggesting a post- 
translational effect of hypoxia {Terada et al. 1992; Cote et al. 1996; Poss et al. 1996; 
Terada et al. 1997; Hassoun et al. 1998).
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2.4.3 Oxidative stress
The term oxidative stress refers to a situation in which cells are exposed to excessive 
levels of either molecular oxygen or chemical derivatives of oxygen such as reactive 
oxygen species (ROS) (Zalba et al 2000).
A free radical is any species capable of independent existence that contains one or more 
unpaired electrons. Examples are the oxygen-cantered radicals superoxide and 
hydroxyl, the glutathione radical and nitric oxide, a radical in which the unpaired 
electron is delocalised between both atoms {Halliwell 1993).
A normal chemical bond consists of a pair of electrons, opposite in spin and sharing a 
single molecular orbital. A free radical is a molecule containing an odd number of 
electrons and thus may be considered to contain an open bond, rendering it chemically 
reactive. Radicals can react with other molecules in a number of ways. Firstly, when 
two radicals meet they can combine their unpaired electrons to form a covalent bond. 
Secondly, they can react with non-radicals by either donating the unpaired electron 
(reduction) or they may take an electron from another molecule (oxidation). Thirdly, a 
radical may attach itself to a non-radical. In general, when any of these reactions take 
place the non-radical species becomes a radical. This usually has a knock on effect 
creating a chain reaction of these events. Superoxide, hydroxy radical (OH -) and nitric 
oxide are examples of free radicals whilst others, such as hydrogen peroxide (H2O2) and 
peroxynitrite (OONO-), are not radicals but are biologically reactive species (Zalba et 
al 2000).
In normal individuals, the generation of ROS appears to be in balance with anti-oxidant 
defences, although there may be a slow cumulative oxidative damage that contributes to 
the ageing process. Humans appear not to have a great reserve of anti-oxidant defences, 
perhaps because ROS play some useful metabolic role. An imbalance between ROS and 
anti oxidant defences in favour of formation of ROS leads to oxidant stress. This can 
happen either if anti-oxidant levels are depleted and/or if ROS formation is increased. 
Most cells can tolerate mild oxidative stress, which often leads to increased synthesis of 
anti-oxidant defence systems. However, severe oxidative stress produces derangements
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of cell metabolism, including DNA strand breakage, increased intra-cellular Ca +, 
damage to membrane ion transporters, peroxidation of lipids, depletion of NAD+ and 
ATP and the activation of proteases. Oxidant stress has been implicated in a vast 
number of diseases including atherosclerosis, haemorrhagic shock, ischaemia- 
reperfusion injury, cancer, rheumatoid arthritis and inflammatory bowel disease 
CHalliwell 1993; Zalba et al 2000).
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Metabolism of ROS is tightly controlled. Dismutation of superoxide by superoxide 
dismutase (SOD) produces the more stable hydrogen peroxide, which in turn is 
converted to water by catalase and glutathione peroxidase. Removal of excess 
superoxide by SOD enzymes is an important physiological antioxidant defence 
mechanism. It appears that one of the most important roles of SOD is the prevention of 
the reaction of superoxide with nitric oxide to form peroxynitrite (Wolin 2000). 
Superoxide reacts with nitric oxide at a rate which is 3 times the rate of reaction with 
SOD {Goldstein et al 1995). When the level of NO increases and approaches the local 
concentrations of SOD, nitric oxide is able to compete with SOD for the scavenging of 
superoxide to form significant amounts of peroxynitrite {Wolin 2000).
The tight regulation of both production and removal of ROS makes fluctuations in their 
levels transient {Griendling et al 2000). On the whole, however, superoxide and 
hydrogen peroxide have limited chemical reactivity and interest has focused on their 
ability to generate more reactive species such as peroxynitrite {Zalba et al 2000). 
Peroxynitrite is much more reactive than NO or superoxide and will cause diverse 
chemical reactions in biological system including nitration of the tyrosine residues of 
proteins, triggering of lipid peroxidation, inhibition of mitochondrial electron transport, 
and oxidation of biological thiol compounds {Maeda et al 1998a).
2.4.3.1 Vascular oxidant stress
In the vascular wall, increases in oxidant stress are thought to alter several important 
physiological functions, including regulation of blood flow, platelet aggregation, 
leukocyte adhesion and cellular growth. These phenomena ultimately modulate vessel 
diameter, remodelling and lesion formation {Zalba et al 2000).
Three enzyme systems produce reactive oxygen and nitrogen species in the vascular 
wall: NADH/NADPH oxidase, xanthine oxidoreductase, and endothelial nitric oxide 
synthase (NOS) {Griendling et al 2000; Zalba et al 2000)
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Figure 2-10 Representation of potential roles of oxidant stress in vascular disease
2.4.3.2 Oxidant stress and possible role in aneurysms 
2.4.3.2.1 Evidence o f oxidant stress in aortic aneurysms
The possibility that oxidant stress may contribute to the pathogenesis of AAA formation 
is supported by studies that have shown the AAA tissue has reduced levels of ascorbic 
acid and antioxidant enzyme activities compared to non-aneurysmal tissue (Dubick et 
al. 1999). Furthermore, plasma levels of vitamin E, another anti-oxidant were found to 
be markedly reduced in patients with AAA but not in patients with coronary artery 
disease in the absence of AAA {Sakalihasan et al. 1996a). These intriguing 
observations would support the hypothesis that oxidant stress is potentially increased in 
AAA tissue.
Since the conduction of our study, one published report has appeared in the literature 
about oxidant stress in AAAs. In this study, segments of AAA tissue were compared to 
adjacent non-aneurysmal tissue within the same patient. The study found that 
superoxide levels (measured by lucigenin-enhanced chemiluminescence) were higher in 
the AAA segments compared with the adjacent non-aneurysmal aortic segments, and 
the source of the superoxide was localised to infiltrating inflammatory cells and to 
VSMCs. Formation of thiobarbituric acid-reactive substances and conjugated dienes, 
two indices of lipid peroxidation, were also increased in AAA compared with non- 
aneurysmal segments. Finally, immunostaining for nitrotyrosine was significantly
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greater in AAA tissue, all suggesting that oxidant stress was associated with AAA 
formation {Miller et al. 2002).
2.4.3.2.2 Potential mechanisms of oxidant stress in AAA formation
The potential mechanisms by which oxidant stress may lead to AAA formation include;
1. Apoptosis. Reactive oxygen species have been reported to induce apoptosis of 
VSMCs which is a well described feature of AAA tissue {Holmes et al 1996; Lopez- 
Candales et al. 1997; Henderson et al. 1999).
2. Increased gene expression. Free radicals and ROS are known to influence the 
expression of a number of genes and signal transduction pathways, as well as acting 
as sub-cellular messengers for certain growth factors. The Mitogen-Activated Protein 
kinases (MAP kinase) and the Nuclear factor kappa-B (NFkB) signal transduction 
pathway and the transcription factors AP-1 are all oxidant sensitive {Allen et al.
2000; Griendling et al. 2000). MMP-1, MMP-3 and MMP-9 genes have AP-1 and 
NFkB binding elements in their promoter regions, and NFkB binding sites are also 
present in aneurysm associated cytokine genes including TNFa, IL-1, IL-6  which 
thus confer oxidant sensitivity to these genes {Huhtala et al. 1991; Sato et al. 1993; 
Vincenti et al. 1998; Allen et al. 2000; Bond et al. 2001).The presence of an NFkB 
site in the MMP-9 promoter and an NFKB-like element in the MMP-1 prompted 
Bond to investigate the effects of IL-1 a  (potent activator of NFkB) on the secretion 
of MMP-1 and MMP-9. This study showed that IL-1 a  potently activated NFkB and 
upregulated the expression of MMP-1 and MMP-9. Over expression of IkB (an 
inhibitor of NFkB) almost completely inhibited the expression of these MMPs {Bond 
et al. 2007).Changes in the cellular redox state have been demonstrated to modulate 
the expression of MMP-1 in human dermal fibroblast cultures {Brenneisen et al. 
1997), MMP-2 in cultured bovine aortic endothelial cells {Inoue et al. 2001) and 
MMP-9 in bovine aortic endothelial cells {Uemura et al. 2001). Galis showed that N- 
acetyl-L-cysteine, an anti-oxidant, decreased MMP-9 expression in 
hypercholesterolaemic rabbits {Galis et al. 1998).
3. Activation of MMPs. MMPs are secreted in a latent zymogen form in which the
prodomain shields the catalytic site. This conformation of zymogens is maintained
due to thiol interactions between cysteine residues in the prodomain and the zinc
atom present in the catalytic site of all MMPs {Ye et al. 1998) .The critical step in the
activation process, described as opening of the ‘cysteine switch’, is followed by a
series of autocatalytic cleavages resulting in the complete excision of the pro-peptide
and activation of the enzyme. Reactive oxygen species are known to react with thiol
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groups such as those involved in preserving MMP latency, so they could modulate 
the activity of MMPs (Rajagopalan et al 1996). Rajagopalan demonstrated that pro- 
MMP-2 and pro-MMP-9 secreted into the media of cultured human smooth muscle 
cells are activated by ROS {Rajagopalan et al 1996). Similar work by Siwik, using 
rat cardiac fibroblast demonstrated identical results using both superoxide and 
hydrogen peroxiden {Siwik et al 2001). Buhimschi using human foetal membranes 
demonstrated that superoxide significantly affected MMP-9 activity. Interestingly the 
glutathione precursor N-acetylcysteine (an anti-oxidant) dramatically inhibited 
MMP-9 activity {Buhimschi et al. 2000). Similar results were seen in bovine aortic 
cells {Uemura et al. 2001), and hypercholesterolaemic rabbits {Galis et al 1998). 
Peroxynitrite has been shown to activate MMPs {Rajagopalan et al 1996; Okamoto 
et al 1997; Maeda et al 1998a). Peroxynitrite seems to interact with a single 
cysteine residue in the propeptide autoinhibitory domain, or so-called cysteine switch 
of pro-MMPs, thus transforming pro-MMPs into their active conformation. However 
in one study peroxynitrite was shown to decrease the activity of MMP-2 {Owens et 
al 1997).
4. Inactivation of MMP inhibitors. In addition to its effects on MMPs, peroxynitrite 
has been shown to inactivate TIMPs and alphal -proteinase inhibitor, a major 
protease (neutrophil elastase) inhibitor in human plasma the net effect being 
accelerated tissue degradation {Frears et al 1996; Maeda et al 1998a)
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2.4.4 Hypothesis
The hypothesis tested was that hypoxia leads to increased elastolysis and potential AAA 













Figure 2-11 Diagrammatic representation of hypothesis
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GENERAL METHODS 
Chapter 3 Materials and Methods
3.1 Ethics and consent
The Medical Research Ethics Committee of The Royal United Hospital Bath, approved 
all tissue-harvesting procedures and subsequent laboratory studies. Informed consent for 
the use of surgical tissue specimens was obtained from each patient. Control aortic 
tissue was obtained from cadaveric organ donors (Southmeads Hospital, Bristol). 
Informed consent for tissue collection was obtained from relatives in all cases.
3.2 Tissue collection
Aortic wall biopsy specimens (2cm2) were excised from the anterior aortic wall at the 
time of aortotomy during operative aneurysm repair or from the aortic cuff of cadaveric 
organ donors (Crowther et al 2000b).
3.3 Histology and immunohistochemistry
3.3.1 Tissue preparation
Specimens were stored in formal saline, 40% volume formaldehyde in 0.9% NaCl for 
seven days. Samples were processed using a Shandon hypercenter II wax-embedding 
station. Each tissue sample was enclosed within a plastic cassette and subjected to 
increasing concentration of ethanol, 70%, 80%, 95% and then absolute ethanol (3x) 
with a residence time of 1 hour at each concentration. This was followed by three one- 
hour washes in xylene before embedding in molten wax at 60°C. Wax blocks were 
stored at room temperature. Sections (5 pm) were cut using a microtome blade cutter 
(Leitz) and placed on a microscope slide and left to diy overnight at 50°C. The 
microscope slides were previously coated with poly-L-lysine to aid adhesion and to 
avoid loss of tissue sections during staining procedures. Sections were dewaxed in 
xylene and rehydrated using a graded series of alcohol solutions through to distilled 
water or lx PBS {Appendix).
3.3.2 Haematoxylin and Eosin staining
Sections were immersed in water for 5 minutes and then placed in Harris' haematoxylin 
for 5 minutes. Sections were transferred to an acid alcohol solution (1%) for 1 minute, 
water for a further 5 minutes, eosin for 30 seconds and then water for 5 minutes. 
Sections were then placed in IMS (2 x 30 seconds) and 100% xylene (2 x 30 seconds) 
and then mounted in DPX {Appendix)
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3.3.3 Immunohistochemistry
3.3.3.1 Localisation o f XOR and in human aortic wall sections
Sections were processed for XOR detection by use of the Vectastain ABC-Alkaline 
Phosphatase Kit for detecting rabbit immunoglobulin G. Sections were washed (PBS, 5 
minutes x 2) and incubated with 200pl of blocking buffer (5 mg bovine serum albumin 
(BSA), 333 pi normal goat serum, lOmls PBS) for 30 minutes. After a wash in PBS, 
200pl of the primary antibody (Polyclonal rabbit anti-bovine XO, Chemicon) (1:50 -  
1:200 in blocking solution) was added and sections incubated overnight at 4°C in a 
humidified atmosphere. The sections were washed (PBS, 5 minutes x 2) and incubated 
with biotinylated goat anti-rabbit IgG (1:200) (Vector Laboratories, Vectastatin® 
(200pl per slide)) for lhr. Following washing, sections were incubated with ABC- 
Alkaline Phosphatase conjugate (AP) complex (1:100) (Vectastain, Vector Lab) for 
30mins, and finally with Fast Red TR/Napthol AS-MX in distilled water (Sigma) at 
room temperature. The reaction was followed until a brown colour appeared and then 
terminated by the addition of copious amounts of Ultra pure water.
Sections were counterstained with Mayer’s Haematoxylin for 1 minute and washed in 
water until the blue nuclear colouration was distinct. The sections were mounted in 
Aquamount (Merck){Appendix).
3.3.3.2 Immunohistochemical detection o f 3 nitrotyrosine (3-NT) in human aortic 
wall sections
Formation of free and protein 3-nitrotyrosine derivatives has been used as a probe for 
peroxynitrite formation. (Ischiropoulos 1998; Tarpey et al 2001; Miller et al 2002). 
An identical technique as used for the immunodetection for XOR was employed. Anti- 
nitrotyrosine (Upstate Biotechnology) was used at a dilution of 1:100. The sections 
were washed and incubated with biotinylated goat anti-rabbit IgG (1:200) (Vector 
Laboratories, Vectastatin® (200pl per slide)) for lhr {Appendix).
3.4 Western blotting for determination of proteins
3.4.1 Sample preparation
Additional aortic samples were placed in Hank's balanced salt solution (HBSS). 
Approximately 100 mg (wet weight) of aortic tissue was added to 1.5 mis of 
Homogenisation buffer (50mM KP04 pH 7.3, ImM EDTA, lmM PMSF, Pepstatin A 
(1 jugml-1), Antipain (1 pgml-1), Leupeptin (1 pgml-1), Aprotinin (1 jigml-1) and the 
mixture homogenised with a mechanical homogenizer. The homogenates were
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centrifuged at 10,000 rpm, for lOmins at + 4°C and the supernatant retained and stored 
at -70 °C (Beckman et al. 1989)(Appendix).
3.4.2 Bradford assay for total protein estimation
Total protein was estimated using the Bio-Rad Protein Assay. This is a dye-binding 
assay based on the differential colour change of a dye (Coomassie Brilliant Blue G-250) 
in response to various concentrations of protein (Bradford 1976). The dye binds to 
primarily basic (especially arginine) and aromatic amino acid residues. Briefly, several 
dilutions of bovine serum albumin (protein standard II) containing 0.625 - 80pg/ml 
were prepared. 80pl of diluted standards were added to 2 0 pl of dye reagent per well of a 
96 well plate. All standards were performed in triplicate. After 5mins the optical 
density at 595nm was measured on a microplate reader. A standard plot was constructed 
using the corresponding OD values and the protein concentrations. The amount of 
protein in the unknown sample is determined by interpolation, reading the concentration 
of protein on the standard curve that corresponds to its absorbance (Appendix).
3.4.3 Polyacrylamide gel electrophoresis SDS-PA GE
To confirm XOR protein within aortic samples, an antibody raised against bovine 
buttermilk XOR was used to detect immobilised proteins by Western blot analysis. 
Typically, proteins are electrophoresed through a SDS polyacrylamide gel under 
reducing conditions before transfer to a nitrocellulose membrane. This membrane is 
then probed for the appearance of XOR protein using the anti-XOR antibody and a 
chemiluminescence detection technique. The appearance of a 150 KDa band is typical 
of XOR protein but some preparations show the typical degradation products of XOR 
(Amaya et al. 1990; Harrison 1997; Nishino et al. 1997).
Proteins in a solution of negatively charged detergent (SDS) are unfolded and 
negatively charged. The addition of a reducing agent such as mercaptoethanol or 
dithiothrietol breaks di-sulphide bonds. Applying a current across the gel causes the 
charged proteins to migrate toward the positive anode according to their molecular 
weight, with the larger proteins being retarded by the gel.
Aciylamide gels (8 %) were prepared according to Laemmli (Laemmli 1970). An equal 
volume of 2x reducing sample buffer was added and the solution boiled at 100°C for 3 
minutes. lOpl of rainbow markers (molecular weights, 250-1 OkD) (Amersham) were 
mixed with an equal volume of 2x reducing loading buffer. The samples were 
centrifuged at 10,000 rpm (Biofuge, Heraeus Instruments) for 5mins. The gel plates 
were placed in the ATTO electrophoresis set up and filled with running buffer
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containing 25mM Tris base, 190mM glycine and 0.1% SDS (w/v) pH 8.3. An equal 
volume (10-30 pL) of each sample containing equal amounts of total protein (10-30pg) 
was carefully loaded into the gel wells. The gel was then subjected to electrophoresis at 
a constant voltage of 1 0 0 V for approximately 2  hours, or until the dye reached the base 
of the gel {Appendix).
3.4.4 Western blotting
Following electrophoresis, the gels were removed and incubated in blotting buffer 
containing 190mM glycine, 25mM Tris base, 0.05% SDS (w/v) and 20% methanol(v/v). 
Nitrocellulose paper and Whatman paper were cut to the size of the gel and incubated in 
the blotting buffer for 10 mins. Using a western blot cassette holder, 4 filter papers were 
placed on top of the sponges, followed by nitrocellulose paper and the gel. All air 
bubbles were carefully removed. The second set of filter papers were placed on top of 
the gel and the cassette closed before transfer to a western blotting tank (Hoeffer 
Scientific) making sure that the nitrocellulose paper was nearest to the positive electrode 
(anode). Blotting buffer was added to the tank and the proteins were blotted at 150mA 
for 2  hours.
After this the cassette was removed from the tank and the gel stained with Coomassie 
Brilliant Blue for analysis of complete transfer of protein to the nitrocellulose paper.
The positions of different molecular weight markers were enhanced on nitrocellulose 
paper with a pencil {Appendix).
3.4.4.1 Blocking buffer
The nitrocellulose was incubated in blocking buffer consisting of 5% (w/v) non-fat 
dried milk in 0.5% Tween 20/1 x PBS {Appendix) for 1 hour at room temperature or 
overnight at + 4°C {Appendix).
3.4.4.2 Probing the blots
After a 5-minute wash with 0.5% Tween 20/1 x PBS, the blot was then transferred to a 
50ml falcon tube containing 5mls of the diluted primary antibody (rabbit anti-bovine 
xanthine oxidase (Chemicon), 1:1000 dilution in 5% non-fat dried milk in 0.5% Tween 
20/ lx PBS). This was incubated on a roller plate for 1Vi hours and thoroughly washed 
in 0.5% Tween 20/lx PBS 6  times (5mins per wash). The blot was then incubated with 
the diluted secondary antibody (conjugated horseradish peroxidase swine-anti rabbit 
(Dako) 1:1000 dilution in 5% non-fat dried milk in 0.5% Tween 20/lx PBS) for 1 Vi 
hours. The blot was again washed in 0.5% Tween 20/ PBS 6  times for 5mins each 
{Appendix).
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3.4.43 Chemiluminescence detection o f reaction products
Equal volumes of solution A and solution B from the ECL Amersham detection kit 
were mixed and added to the membrane making sure the whole of the membrane was 
covered. Only proteins bound by the primary and secondary antibodies were detected by 
the utilisation of the hydrogen peroxide/HRP oxidation of luminol. The oxidised 
luminol emits light at a wavelength of 425nm that is detected by blue light sensitive 
autoradiography film.
The membrane was incubated for 90 secs and the excess reagents drained off and 
covered in SaranWrap™ ensuring that all bubbles were smoothed out and placed in a 
film cassette, protein side up. In a dark room, under safe light conditions, the blots were 
exposed to Kodak autoradiography film for a range of time points (Kodak Film: Kodak 
Scientific Imaging Film X-Omat AR (XAR-5) 18 x 24 cm.- Eastman Kodak Co). The 
films were then processed to reveal the reaction products in an automated processor 
(Fuji RGII X-ray film processor (Fuji photo film company, Ltd, ]apax\))(Appendix).
3.5 Immunoblotting (Dot blots)
3.5.1 Xanthine oxidoreductase
Once SDS-PAGE and Western Blotting established the characteristics of XOR protein, 
an immunoblot technique was also utilized for rapid screening for XOR protein in aortic 
samples. This technique relies on the ability to transfer a known quantity of protein 
(negative charge) to a nitrocellulose membrane (positive charge) using suction alone. 
The proteins are not separated according to weight as with a SDS/PAGE. The 
membrane is then probed with the relevant antibodies and the product detected using an 
identical technique as for Western blotting. Radiographic films can be digitally imaged 
and the density of each sample analysed using imaging software. The optical density of 
each well (sample) can then be measured and compared in a semi-quantitative manner. 
One piece of soaked filter paper, followed by nitrocellulose paper was place in a 
Jencons dot blot tank, and the lid tightly applied. Samples were loaded (20jil of 1 pg/pl) 
into each well, taking care to avoid air bubbles. Suction was applied for approximately 
20-30 seconds, after which the nitrocellulose paper was removed from the tank and 
stained with Amido black to confirm equal and complete transfer of protein to the 
nitrocellulose paper.
An identical procedure as for Western blotting was used to probe the blots to detect the
presence of XOR protein. Purified bovine XOR was used as a positive control. Each
analysis was performed in triplicate. Radiographic films were digitally imaged and
stored as Tagged Image Format File (TIFF files). The mean pixel intensity at each well
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position was measured using The Scion Corporation Imaging program (Version 4.0.2;
a
Web site: www.scioncorp.com). A constant area (23.75mm ) was measured for each 
sample.
All results were obtained as mean pixel intensities measured in a constant area of the 
blot (fixed area equivalent to the area covered by the wells; 23.75 mm ). A blank 
reading was obtained and this value was subtracted from all standard and test sample 
readings. Relative densitometric of control tissue and aneurysm tissue were compared.
3.5.2 Nitrotyrosine immunoblotting (3 NT)
An identical technique as described for XOR immunoblotting was used to quantify the 
relative amounts of 3 NT within aortic tissue. Twenty micrograms of total protein was 
loaded per well. Anti-nitrotyrosine (Upstate Biotechnology) was used at a dilution of 
1:1000. The sections were washed and incubated with a conjugated horseradish 
peroxidase swine-anti rabbit secondary antibody, 1 in 2000 dilution (Dako).
Each analysis was performed in triplicate. Radiographic films were digitally imaged and 
stored as TIFF files. The mean pixel intensity at each well position was measured in an 
identical method as Section 3.5.1 (Appendix)
3.6 Enzyme linked immunosorbent assay (ELISA)
3.6.1 Sample preparation
An Enzyme linked immunosorbent assay (ELISA) technique was used to quantify XOR 
protein in tissue homogenates. A sample of aortic tissue was placed in Hank's balanced 
salt solution (HBSS) and transferred to the laboratory. Samples were prepared by 
homogenising 100 mg wet weight of aortic tissue in 1ml of ELISA buffer solution. 
Specimens were centrifuged at 1000 rpm and stored at - 70 °C. Following rapid 
thawing, specimens were further centrifuged at 5,000 rpm and the supernatant retained 
for subsequent experimentation. Total protein content was determined by the Bradford 
assay (Appendix).
3.6.2 Plate preparation
Immulon IB (Dynatech Lab) microtitre plates were coated with lOOp.12ug/ml anti-XO 
IgM antibody (1:500 dilution, Neomarkers Mab 3) in 0.05 M carbonate buffer, pH 9.6 
and incubated overnight at 4°C.
Following three washes with lx PBS, the plates were coated with 200jil Tween 
0.05%/l% BSA for 2 hours at 37 °C. After an additional three washes with PBS/Tween, 
a sample volume of lOOpl, including positive controls (Bovine XO 2-4pg/ml) and
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blanks in PBS/Tween/0.1% SDS were added. Samples were serially half diluted from 1:
2.5 to 1: 20. All wells were incubated overnight at 4°C.
Following three washes with PBS/Tween, 1 OOjul of biotinylated anti-XOR chicken 
antibody (1:1000) was then added, and incubated for 2 hours at 37 °C. After a further 
three washes with PBS/Tween, a streptavidin-peroxidase conjugate (lpg/ml, 1:500 
dilution, Jackson Labs) was added and incubated for 20 minutes at room temperature 
followed by three washes with PBS/Tween {Appendix).
3.6.3 Detection o f product
One hundred microlitres (lOOpl) of orthophenylenediamine (OPD) in citrate/phosphate 
buffer + H2O2 was added to develop a colour. The colorimetric reaction was stopped 
with 25pi 4M H2SO4. The plates were read at 492 nm and 405nm (Background) in a 
Dynex MRX-II Microplate Reader (Dynex Technologies). XOR concentration was 
adjusted for total protein and expressed as XOR ng/mg total protein. Each sample was 
analysed in triplicate {Appendix).
3.7 Determination of XOR activity
3.7.1 Sample preparation
Samples were prepared as described in Section 3.4.1 and total protein estimated using 
the Bradford assay.
3.7.2 Flurometric measurement o f XOR activity (Pterin oxidation)
Xanthine dehydrogenase has a relatively low specificity for its reducing substrates and 
will oxidise pteridines in addition to many purines. The oxidation of pterin (2-amino-4- 
hydroxypteridine) to the fluorescent product isoxanthopterin provides a sensitive assay 
for XOR.
Xanthine oxidase enzyme activity in aneurysm homogenates was measured using a 
fluorometric assay monitoring the conversion of pterin (a xanthine substitute) to the 
fluorescent reaction product isoxanthopterin {Beckman et al 1989). XO was assayed in 
the presence of pterin only, with molecular oxygen serving as an electron acceptor. 
Combined XO and XD activity was assayed in the presence of methylene blue as the 
electron acceptor. The samples were warmed to 37 °C in a water bath prior to testing. 
An aliquot of homogenisation supernatant (50pl) was diluted in 940pl H2O and placed 
in a quartz cuvette in a fluorimeter. Measurements were performed using 5 nm 
bandwidth slits and excitation/emission wavelengths of 345 and 390 nm, respectively. 
The rate of pterin oxidation was determined after adding 10 pi of lOmM pterin (final 
cone 100 pM). Once a linear rate had been measured, 10 pi of lOmM methylene blue
was added as an electron acceptor to measure the combined activities of XO and XDH 
(Total XOR activity). Methylene blue was used as an electron acceptor in place of 
NAD+ because the fluorescence of NADH, the reaction product overlaps with that of 
isoxanthopterin. The reaction was then inhibited by the addition of lOpl of lOmM 
Allopurinol, and a known final concentration of isoxanthopterin was added (lOpl of 100 
pM; final cone lpM) as an internal standard. The immediate fluorescence increase after 
addition of isoxanthopterin provides an internal standard for calculating enzyme 
activity.
The units of activity may be calculated by the following equation:
Activity (pmoles/min) = (change in fluorescence with pterin/100%lsoxanthopterin) 
xlOOO
Activity was corrected for protein content and expressed as pmoles/min/mg protein.
3.7.3 Lucigenin-enhanced chemiluminescettce
Xanthine oxidase generates superoxide radicals using xanthine or NADH as substrates 
with oxygen as the terminal electron acceptor. The generation of superoxide radical was 
measured using the oxidation of lucigenin. Superoxide radical reacts with lucigenin, to 
yield an unstable dioxetane that spontaneously decomposes to produce acridone, which 
then also decomposes to the ground state. This final decomposition emits light which 
can then be detected using a photomultiplier tube (PMT) {Faulkner et al. 1993). 
Experiments were completed using a 96-well plate-reading chemiluminometer (Anthos, 
Lucy 1). A green glass filter of492nm (GG492nm) was used to remove unwanted non- 
lucigenin-emitted light. (Peak light emission for lucigenin is 500nm). Assays were 
performed in triplicate in a final volume of200pl. Samples were prepared as originally 
described in Section 3.4.1. Samples were centrifuged at 2000 rpm for 10 minutes and 
supernatants retained for experiments. An aliquot of homogenisation supernatant (50pl) 
was placed in a well and lOpl of 2mM Diethylenetriaminepentaacetic acid (DTPA) and 
40pl PBS were added. Lucigenin was made up to a stock concentration of 2mM in PBS 
and Hypoxanthine made up to a stock concentration of ImM in PBS. Each plate was 
allowed to equilibrate to 37°C by placing the plate into the closed reaction chamber of 
the chemiluminometer (Lucy) for 5 min. The reactions were initiated by the automated 
injection of 50pl of Hypoxanthine followed by 50jil of lucigenin into the wells of a 96- 
well plate. Each well was measured sequentially with an integration time of one second 
per well. Eight sets of triplicates could be assayed at a time, and forty measurements 
were made per well. Measurements of the peak height of reaction were made, as this is 




Aortic wall biopsy specimens (2cm ) were excised from the anterior aortic wall at the 
time of aortotomy during operative aneurysm repair or from the aortic cuff of cadaveric 
organ donors. All tissues were placed in Hanks balanced salt solution (HBSS) and 
transferred to the labarotory.
3.8.2 Primary culture o f arterial explants and monolayer culture o f VSMCs 
Vascular smooth muscle cell cultures were prepared as described by Patel (Patel et al. 
1996a). Arterial tissue was placed in a petri dish and washed in fresh HBSS. 
Atheromatous material was removed. The intimal and adventitial layers were aseptically 
dissected from medial tissue, which was subsequently diced using a 15 mm scalpel 
blade into 1mm pieces. Three or four segments were placed per well on a 6  well plate 
and were cultured as explants in Dulbecco's Modified Eagles Medium (DMEM) 
supplemented with 10% (v/v) heat-inactivated foetal calf serum, Penicillin (100 IU/ml), 
Streptomycin (lOOpg/ml) and L-Glutamine (0.2mM) in an atmosphere of 5% CO2,95% 
air at 37° C. Two ml of media were added per well and was replaced every 2-3 days.
3.8.3 Trypsin/EDTA
When the cells reached 75% confluence the cell populations were disaggregated by a lx 
solution of Trypsin/ EDTA {Appendix). An equal volume of 10% (v/v) foetal calf 
serum/DMEM was added and the resulting supernatant with disaggregated cells was
*nmplaced in 50ml Falcon (Farenheit) tube. This solution was then pelleted by 
centrifugation, 1100 rpm (Bench top centrifuge, Denley) for lOmins. The supernatant 
was aspirated, leaving just the pellet of cells. This pellet was re-suspended in 5mls of 
tissue culture medium and transferred to either a T25 (25cm ) filter capped cell culture 
flask (Falcon™) or another six well plate. This was placed in a 37°C humidified 
incubator (5%C(V95% air) overnight to allow cells to adhere to the plastic. The media 
was replaced the next day. This represented population II (P2) of vascular smooth 
muscle cells isolated from aortic media {Appendix).
3.8.4 Cell counting
Cells from passage 2 or 3 were trypsinized and seeded into T25 culture flasks at a known 
density of 2.5 x 105 cells per flask (10,000/cm2) or a 6  well plate at a density of 100,000 
cells per well (14,200/ cm ) for experimentation. Cells were counted using a Bright line 
hemocytometer (Sigma). When the cells reached 75% confluence the cell populations 
were disaggregated by a lx solution of Trypsin/ EDTA. Following re-suspension, a
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small amount of cell suspension was transferred to the chamber of the hemocytometer. 
Each chamber was allowed to fill by capillary action and care was taken not to overfill 
or underfill chambers {Appendix).
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Figure 3-1 Hemocytometer view.
The circle indicates the approximate area covered at lOOx microscope 
magnification. Include cells on top and left touching middle line (o). Do not count 
cells touching middle line at bottom and right (0). Count 4 corner squares and 
middle square in both chambers. Cells within five 1mm2 squares were counted. 
Each square of the hemocytometer, represents a total volume of 0.1 mm3 or 10-4 
cm3. Since 1 cm3 is equivalent to approximately 1 ml, the subsequent cell 
concentration per ml (and total number of cells) were determined using the 
following calculations;
Cells per ml = the average count per square x 104
Total cells = cells per ml x the original volume of fluid from which cell sample was 
removed.
3.8.5 Cell count and viability assay
Trypan blue is a dye that is not taken up by viable cells with an intact plasma 
membrane. Non-viable cells take up the dye and appear blue in colour. 
lOOpl aliquots of cell solution were mixed with equal volumes of 0.4% Trypan blue 
solution (Sigma) and allowed to stand for 5 minutes at room temperature.
A lOpl aliquot of this solution was added to the haemocytometer by capillary action. 
Cells were viewed by low power transmitted light microscopy and cells within the 
central 0.1 mm3 section of the haemocytometer were counted.
Total cell counts were calculated by counting all the cells, blue and clear, in the central 
area of the two counting chambers and dividing by two and then multiplying by lxlO4. 
This figure represents the original cell number before dilution and expressed as cells per 
ml. Viable counts were calculated by repeating the above procedure by counting only 
the unstained cells. The percentage viable count was calculated {Appendix).
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3.8.6 Characterisation o f VSMCs
10,000 cells were plated onto an 8 -well chamber culture slide (Lab-tek II chamber slide, 
Nalge Nunc International). The culture slides were placed in a humidified 37°C; 5% 
CO2; 95% air and incubated for 24hours. The slides were washed three times in cold lx 
PBS (w/o Ca2+ and Mg2+) (Gibco), fixed with ice-cold methanolracetone (1 :l)v/v for 3 
minutes and washed again three times with lx PBS.
The slides were incubated in blocking buffer (5% non-fat dried milk, Marvel in lx 
PBS/0.5% Tween 20 (v/v)) for lhr and further incubated with diluted (1:25) mouse 
monoclonal anti-a smooth muscle actin alkaline phosphatase conjugated antibody 
(Sigma) in blocking buffer for 1 hour at room temperature. Control slides were 
incubated with the blocking buffer alone and an irrelevant alkaline phosphatase 
conjugated antibody (negative control) in parallel. The cells were washed with lx 
PBS/0.5% Tween 20 (v/v) (6 x 5 mins) and then finally developed with Sigma Fast 
Red™ (Fast Red TR/Napthol AS-MX Phosphate (4-chloro-2-methyl- 
benzenediazonium/3-hydroxy-naphthoic acid, 2,4-di-methylanilide phosphate (a napthol 
AS-MX) in Tris Buffer (0.1M) at room temperature. The cells were rinsed in cold tap 
water to stop the reaction, counterstained with Mayer's haematoxylin, rinsed with H2O 
and mounted in Aquamount (Merck, Lutterworth, UK). Slides were photographed 
using a Zeiss photomicroscope mark HI {Appendix).
3.8.7 XOR immunocytochemistry
In addition, cells seeded onto an 8 -well chamber culture slide were probed with an 
antibody to xanthine oxidase. The cells were incubated in blocking buffer (5% non-fat 
dried milk, Marvel® in lx PBS/0.5% Tween 20 (v/v) for lhr and further incubated with 
diluted (1:100) rabbit polyclonal anti-bovine XO antibody (Chemicon, Harrow, UK) in 
blocking buffer overnight at 4°C. Control slides were incubated with the blocking 
buffer alone (negative control) in parallel. The cells were washed with lx PBS/0.5% 
Tween 20 (6 x 5 mins) and then incubated with biotinylated goat anti-rabbit IgG (1:100) 
(Vector Labs, Peterborough, UK.) in blocking buffer for lhr. After rinsing (6x5mins), 
the slides were incubated with a 1 :1 0 0  dilution of an alkaline phosphatase-conjugated 
avidin biotin complex (ABC) (Vectastain, Vector Labs, Peterborough, UK.) for 30mins. 
The cells were washed again with PBS/0.5% Tween 20, and developed in identical 
manner as for a-actin characterisation.
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3.9 RNA extraction, reverse transcription and PCR
3.9.1 RNA and protein extraction
RNA and protein were isolated from cell culture experiments using RNA STAT 60, a 
third generation reagent for the isolation of RNA (AMS Biotechnology). The 
manufacturers’ protocol was followed. All items of equipment used for RNA isolation 
and subsequent experimentation were either pre-treated with Diethyl pyrocarbonate 
(DEPC 0.1% v/v, Sigma) autoclaved and dried overnight at 120°C, or were certified to 
be RNAse and DNAse free (ABgene).
Cells were lysed directly by the addition of 1ml of RNA STAT 60 per T25 flask
9 9(40pl/cm ) or 0.5 ml per well of a 6  well plate (140pl/cm ). Samples were stored at 
room temperature for 5 minutes before the addition of 0.2 ml chloroform per 1ml RNA 
STAT 60 used. Samples were covered and vigorously shaken for 15 seconds then 
allowed to stand at room temperature for 15 minutes before being centrifuged for 15 
minutes at 12,000 g (4°C) (Biofuge fresco). The RNA remains in the aqueous phase and 
DNA/protein remain in the inter-phase and organic phase {Appendix).
3.9.1.1 RNA extraction
The aqueous phase was carefully removed and transferred to a fresh 1.5 ml eppendorf 
tube to which 0.5 ml of isopropanol per 1 ml RNA STAT 60 was added. The inter-phase 
and organic phases were retained for subsequent isolation of protein (Section 3.9.13). 
Samples were stored at room temperature for 10 minutes before centrifugation for 10 
minutes at 12,000 g (4°C). The RNA precipitate was often invisible before 
centrifugation but formed a gel-like pellet on the side and bottom of the tube following 
centrifugation.
The overlying liquid was removed and 1 ml of 75% ethanol was added per 1 ml RNA 
STAT 60 that was initially added. Samples were vortexed and centrifuged at 7,500 g for 
5 minutes (4°C), before the RNA pellet was aired dried for 10 minutes. RNA pellets 
were dissolved in RNAse and DNAse free distilled water (GibcoBRL life technologies) 
by repetitive pipetting and an incubation for 15 minutes at 55-60°C. Samples were 
stored at -70°C. Samples were stored for a maximium of 3 months prior to use 
{Appendix).
3.9.1.2 Protein extraction
To the retained inter-phase and organic phase from Section 3.9.I.I. 0.3 ml of 100% 
ethanol per 1 ml RNA STAT 60 was added. Samples were mixed by inversion, stored at
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room temperature for 5 minutes and centrifuged at 2000 g for 5 minutes. The phenol- 
ethanol supernatant was carefully removed and the DNA pellet discarded.
Proteins were precipitated from the phenol-ethanol supernatant by the addition of 1.5 ml 
of isopropanol. Samples were stored at room temperature for 10 minutes before 
centrifugation for 10 minutes at 12,000 g (4°C). The supernatant was discarded and the 
protein pellets retained.
Protein pellets were washed with 2 ml of 0.3 M guanidine hydrochloride in 95% ethanol 
and then stored at room temperature for 20 minutes before centrifugation at 7500 g for 5 
minutes (4°C). A further 2 ml of 100% ethanol were added, followed by further storage 
at room temperature for 20 minutes before further centrifugation at 7500 g for 5 minutes 
(4°C). This washing process was repeated 3 times.
Finally the protein pellets were vacuum dried for 15 minutes and then dissolved in 1% 
SDS (sodium dodecylsulfate) by repetitive pipetting and incubation at 50°C. The 
solution was further centrifuged at 10,000 g for 10 minutes (4°C), and the supernatant 
transferred to a fresh tube for subsequent experimentation {Appendix).
3.9.2 Quantification o f RNA
The concentration of RNA was determined by measuring absorbance at 260 nm. An 
RNA sample with an A260 of 1 has a concentration of 40pg/ml. In practice, absorbance 
measurements are performed using a 1:100 dilution of the RNA sample prepared in 
RNAse and DNAse free H2O.
All measurements were performed using UV Biotech Photometer (Jencons) which was 
blanked with 200pl of distilled RNAse DNAse free water (Gibco BRL) in a Quartz 
cuvette. Samples were prepared by dissolving 2pi of total RNA in 198pl of distilled 
RNAse DNAse free water (Gibco BRL). Measurements were performed at 260 nm and 
280 nm. The total amount of RNA is given by the formula 
Total RNA = A260 x 40 x dilution factor (100)
A measure of the purity of the RNA sample is obtained by the 260/280 ratio. Ideally the 
ratio should be greater than 1.5.
3.9.3 Reverse transcription
Reverse transcription was performed using ABgene's First Strand Synthesis Kit 
following the manufacturers protocol. Sterile RNAse free plastics were used at all times. 
l-2pg of total RNA was mixed with lpl of anchored oligo dT (0.5 pg/pl) and the total 
volume made up to 13 pi with sterile RNAse DNAse free water in a thin-walled reaction 
tube (ABgene). The tubes were placed in a Thermal cycler (Gene E, Techne) and heated 
at 70°C for 5 minutes to remove any secondary structure and then placed on ice.
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Anchored oligo dT primer is designed to anneal at the mRN A/poly-A junction rather 
than at a random point within the poly-A tail. By eliminating transcription through the 
poly-A tail, use of this primer provides more effective cDNA synthesis.
The following components were added, mixed well and spun gently; 4pi (5x) First 
Strand Synthesis buffer, 2pl dNTP mix (5mM each) and lpl of RTase. Tubes were 
incubated at 47°C for 30 min followed by 75°C for 10 minutes to inactivate the RTase. 
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Figure 3-1 Priming cDNA synthesis with anchored oligo dT
The anchored primer is a mixture of primers that all have the basic structure 5’-p 
(dT)-dV-dN-3’ where dV is either dG, dA or dC and dN is any base. The dT bases 
pair with the 5’ region of the poly-A tail, the dV with the final base at the 3’ coding 
region of the mRNA and the dN pairs with the base adjacent to this one, within the 
mRNA. This anchors the primer to the junction between the poly-A tail and the 
portion of mRNA to be reversed transcribed.
3.9.4 PCR Amplification
PCR in conjunction with reverse transcription (RT-PCR) was used to study mRNA 
expression. ABgene®’s ReddyMix™ PCR Master Mix was used as it contains all the 
components for PCR except template and primers {Appendix).
3.9.4.1 XORPCR
A 288bp fragment of XO cDNA was amplified by PCR using XO specific primers 
designed according to the rat liver XO cDNA nucleotide sequence {Nishino et al. 1997). 
The primer sequences selected were 5’- AGT ATG TAC ACA CTG CTC CGG -  3’ for 
the forward primer, positioned between nucleotide numbers 364 -385. The reverse 
primer sequence was the 21 bp oligomer positioned between nucleotide numbers 631 - 
652, thus: 5’- AAG GGG GGT CTC CAA GAC TTC -3’.
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2pl of cDNA were mixed with 8.5pl of RNAse DNAse free water, 12.5pl of 
ABgene®’s ReddyMix™ PCR Master Mix and ljil each of forward and reverse specific 
primers. The reagents were mixed in the tube and covered with 30pl of liquid paraffin. 
Tubes were heated to 94°C for 5 minutes followed by 35 cycles of PCR amplification. 
Each cycle consisted of 94°C for 45 seconds (denaturing), 58°C for 45 seconds 
(Annealing) and 72°C for 45 seconds (Elongation). After the last cycle, samples were 
incubated for a further 7 minutes at 72°C to complete both strands. Samples were then 
analysed or stored at -20°C {Appendix).
3.9.4.2 GAPDHPCR
GAPDH primer sequences (7.5pmoles/pl) obtained from commercially available source 
(GIBCO BRL)
Forward (5' to 3') AAA GGG TCA TCA TCT CTG CC 
Reverse (5' to 3') TGA CAA AGT GGT CGT TGA GG 
Product size 576 base pairs
Tubes were heated to 94°C for 5 minutes followed by 35 cycles of PCR amplification 
using a thermal cycler. Each cycle consisted of 94°C for 45 seconds (denaturing), 56°C 
for 45 seconds (Annealing) and 72°C for 45 seconds (Elongation). After the last cycle, 
samples were incubated for a further 7 minutes at 72°C. Samples were then analysed or 
stored at -20°C {Appendix).
3.9.4.3 MMP-2 andMMP-9 PCR
MMP-2 and MMP-9 PCR was carried out using commercially available primers (R&D 
Systems, human MMP-2 PCR Primer Pair, RDP-84-025, MMP-9 PCR Primer Pair, 
RDP-96-025). MMP-2 product size was 449 base pairs (provided internal positive 
control 380 bp). MMP-9 product size was 564 base pairs, (provided internal positive 
control 380 bp).
Primer Pairs were reconstituted in 50pl of autoclaved de-ionized water for a find 
concentration of 7.5pM each primer. One microlitre of cDNA was mixed with 12pl of 
RNAse DNAse free water, 15jil of ABgene®’s ReddyMix™ PCR Master Mix and 1 pi 
each of forward and reverse specific primers. The reagents were mixed in the tube and 
covered with 30pl of liquid paraffin to prevent evaporation. Positive Control (Supplied) 
was resuspended in 30pL of autoclaved deionized water. Tubes were placed in the 
thermal cycler and heated to 94 °C for 4 minutes followed by 30 cycles of PCR. Each 
cycle consisted of 94 °C for 45 seconds (denaturing), 55 °C for 45 seconds (annealing) 
and 72 °C for 45 seconds (Elongation). After the last cycle, samples were incubated at 
72 °C for a further 10 minutes {Appendix).
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3.9.5 PCR product analysis
The amplification products were analysed by agarose gel electrophoresis and visualised 
using ethidium bromide staining. Agarose gels were prepared by dissolving 1.2 g of 
Agarose (Promega) in 100 ml of lx Tris base, Borate, Ethylenediamine tetracetic acid 
disodium salt (EDTA) (lx TBE). 2 pi of ethidium bromide (1 mg/ml) were added to give 
a final concentration of 20ng/ml. Gels were cast in Embi Tec Run One™
Electrophoresis casts and allowed to set at room temperature.
Set casts were transferred to Embi Tec Run One™-Electrophoresis cell and lOpl of 
PCR product loaded per well. A 100 bp DNA ladder (Promega) together with marker 
Blue/orange 6 x loading dye (Promega) was loaded so that PCR product sizes could be 
identified. The gel was then subjected to electrophoresis at a constant voltage of 50v 
and run until the orange dye marker within the DNA ladder well reached the distal 
marker. Gels were visualised using UV transillumination (Gene Genius) and digital 
images stored as TIFF files. The mean pixel intensity at each PCR product position was 
measured using The Scion Corporation Imaging program (Version 4.0.2; Web site: 
www.scioncorp.com). A constant area (23.75mm2) was measured for each sample. All 
results were obtained as mean pixel intensities measured in a constant area of the blot 
(fixed area equivalent to the area covered by the wells; 23.75 mm2). A blank reading 
was obtained and this value was subtracted from all standard and test sample readings. 
Results are expressed as product/GAPDH ratio {Appendix).
3.10 MMP ELISA
Pro-MMP-2 and Pro-MMP-9 were quantitated using a sensitive commercial 
immunoassay against MMP-2 (Chemicon ECM492) and MMP-9 (Chemicon ECM494) 
respectively. These immunoassay kits utilize antibodies immobilized on a bead matrix, 
in combination with enzyme-labelled antibodies, directed against different antigenic 
sites on the same MMP molecule. Upon addition of an MMP-2 or MMP-9-containing 
specimen, the result is an MMP-2 or MMP-9 molecule being sandwiched between the 
solid phase and enzyme labelled antibodies. After removing unbound enzyme-labelled 
antibody, the bead containing the sandwich is incubated with enzyme substrate and o- 
phenylenediamine, resulting in the development of colour. The activity of peroxidase 
enzyme is proportional to the amount of antigen, MMP-2 or MMP-9, so that MMP-2 
and MMP-9 concentrations in specimens can be determined from a standard curve. The 
MMP-2 kit only measures free pro-MMP-2 and pro-MMP-2 complexed with TIMP-2. It 
does not recognize active MMP-2. The MMP-9 assay system recognizes free pro-MMP-
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9, intermediate 83 KDa MMP-9, and MMP-9 in complex with TIMP-1 with the same 
efficiency. The assay does not recognize active MMP-9 (67 KDa).
Assays were performed according to manufacturers’ instructions. MMP standard 
solutions were prepared by serially diluting the supplied MMP standard. Fifty 
microlitres of each standard Curve Solution or Specimen were placed in the bottom of a 
test tube and 300 pi of Enzyme Labelled Antibody Solution added. One anti-MMP-2 or 
MMP-9 coated bead was placed into each tube and tubes were incubated at room 
temperature for 1 hour. The reaction was stopped by the addition of 3.0ml of supplied 
washing solution. The solution was aspirated and beads were washed three times. 
Following transfer of each washed bead into a clean fresh tube, 300pL of colouring 
solution was added and tubes were again incubated at room temperature for 1 hour. 
Reactions were stopped by the addition of 1.5 ml of Stop Solution. Absorbance at 490 
nm was measured.
3.11 Elastolytic activity assays
3.11.1 Succinyl trialanyl 4-nitroanilide (SAAANA) assay
Elastolytic activity secreted into media samples during culture of VSMC monolayers 
was assayed by degradation of the synthetic tripeptide substrate succinyl trialanyl 4- 
nitroanilide (SAAANA) by using the release of 4-nitro-anilide chromophore as an index 
of enzymatic activity as described by Bieth and modified by Patel {Bieth et al. 1974; 
Patel et al. 1996a). SAANA is a sensitive tripeptide substrate cleaved by elastase and 
related elastolytic enzymes. It is also specific because other non-elastolytic proteases do 
not degrade it.
Media samples from VSMC cultures (0.1 ml) were added to 50mmol/L Tris- 
hydrochloride buffer containing lOmmol/L Calcium Chloride (0.2 ml) in triplicate wells 
of 96 well flat-bottom microtitre plates. An aliquot of SAAANA (lOmmol/L, 10 pi) in 
dimethyl sulphoxide (DMSO) was added per well to initiate the reaction, and the plate 
was sealed and incubated at 37° C for 48 hours. Porcine pancreatic elastase (PPE) was 
used as a positive control, and serially diluted to obtain a standard curve. A standard 
plot was constructed using the corresponding OD values and the PPE concentrations. 
Absorbance values (A405 nm) were measured by an automatic plate reader (Dynex 
MRX-H Microplate Reader). Elastase activity was expressed as pg/ml of PPE. The 
amount of elastase activity in the unknown samples was determined by interpolation, 
reading the concentration of PPE on the standard curve that corresponds to its 
absorbance. Optimal pH for the degradation of SAAANA by AAA VSMC media 
samples has been previously determined to be 7.2 {Patel et al. 1996a) {Appendix).
3.11.2 MMP Gelatinase activity assay kit
The CHEMICON MMP Gelatinase Activity Assay Kit (Chemicon ECM 701) is a 
commercially available kit to assess gelatinase activity.
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12x8 Strip Well Biotin-Briding Plate
Figure 3-2 Demonstration of the test principle of gelatinase activity assay.
The Activity Assay utilizes a biotinylated gelatinase substrate, which is cleaved by 
active MMP-2 and MMP-9 enzymes. Remaining biotinylated fragments are then 
added to a biotin-binding 96-well plate and detected with streptavidin-Enzyme 
complex. Addition of the enzyme substrate results in a coloured product, 
detectable by its Optical Density at 450nm (OD450).
Experimental studies using purified, APMA-activated MMP-2 have established the 
analytical sensitivity of the kit to be less than 5ng/ml. The activity assay kit measures 
endogenous net MMP activity in solution (it is a product of net elastolysis and inhibitors 
of elastolysis). APMA (p-Aminophenylmercuric Acetate) activated MMP-2 is supplied 
as a qualitative positive control for comparison purposes. Quantitative results can be 
obtained by activating purified human MMP-2 and MMP-9. Endogenous MMP activity 
or APMA activated activity may be measured.
The assay was carried out according to manufactures instructions. Supplied Pre­
activated MMP-2 was used as a positive control. Endogenous MMP activity was 
measured (Samples were not activated with APMA). Ten microlitres of media samples 
and 200pl of diluted biotinylated gelatinase substrate were added per well of a 96 well 
assay plate and allowed to incubate for 2 hours at 37°C. lOOpl of this solution were 
added to a re-hydrated biotin-binding plate and allowed to incubate for 30 minutes at 37 
°C. After five washes with (supplied assay buffer), lOOpl of a 1:3000 dilution of a 
supplied streptavidin-enzyme conjugate was added and plates were incubated for 30
minutes at 37 °C. Following a further five washes, lOOpl of substrate solution was added
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and incubated at room temperature for 20 minutes. Reactions were stopped by the 
addition of lOOpl of stop solution and optical densities were measured at 450 nm in the 
Dynex MRX-II Microplate Reader. Optical Density values obtained were compared 
with other test samples to obtain relative activities. Alternatively the MMP control 
provided with the kit is useful as a positive control for qualitative purposes. Values can 
be calculated as a percentage of the control ((Positive control OD/Sample OD) x 100 = 
percent activity){Appendix).
3.11.3 Succinylated Elastin assay
The rationale behind the assay is the use of succinylated elastin as substrate and the 
detection of exposed primary amines upon enzymatic digestion {Rao et al 1997). 
Treatment with succinic anhydride blocks free primary amine groups on the side chains 
of amino acids on the protein (Hatakeyama et al. 1992). Primary amines are exposed 
due to the hydrolysis of peptide bonds in elastin by elastase, which are detected by 
adding 2,4, 6 -trinitrobenzene sulfonic acid (TNBSA). TNBSA on interaction with 
primaiy amines produces a quantifiable colour reaction, the intensity of which is 
proportional to the number of unblocked amine groups available, which in turn is 
proportional to elastase activity. Therefore, the colour reaction can be used to measure 
elastase activity (Rao et al 1997).
Gelatin was succinylated using the procedure described by Rao(7tao et al 1997). 
Gelatin was dissolved in 50mM sodium borate buffer, pH 8.5, at a concentration of 
20mg/ml. An equal amount of succinic anhydride was then gradually added to the 
solution and the pH of reaction was maintained at 8.0-8.5 by the addition of 1 M NaOH. 
The succinylated gelatin was then dialyzed extensively against 50mM sodium borate 
buffer, pH 8.5. As dialysis will result in dilution of the gelatin, the final concentration 
was determined by Bradford assay.
All assays were performed in a 96 well assay plate. Each reaction contained 200 mg of 
succinylated gelatin, 50pl of sample made up-to a reaction volume of 150pl with 
PBS/CaCl2 (ImM) pH 7.2. Blank reactions without substrate but with appropriate 
buffers and enzyme amounts were performed for each enzyme assay. The reactions 
were carried out at 37°C for 30 min. Fifty microliters of 0.03% solution of TNBSA was 
then added to the reaction mixture and allowed to incubate at room temperature for 
20min. The optical density (OD) of each reaction was determined at 450nm in the 
Dynex MRX-II Microplate Reader {Appendix).
83
EXPERIMENTAL SECTION
Chapter 4 Xanthine Oxidoreductase and aortic aneurysms
4.1 Introduction
Xanthine Oxidoreductase (XOR) has been attributed roles in vascular pathology 
primarily because of its capacity to generate reactive oxygen and nitrogen species 
(RONS) (.McCord 1985; Millar et al 1997; Godber et al. 2000b). The amount and 
activity of XOR is species, tissue and cell specific, but small amounts of XOR can be 
detected in various organs with the highest levels of catalytically active enzyme being 
observed in the liver, intestine, lung and heart (Terao et al. 1997; Pritsos 2000). The 
demonstration of XOR in micro vascular endothelial cells and the fact that XOR has 
been shown to be released into the systemic circulation from the liver and intestine 
during reperfusion injury may account for the extremely low tissue activity seen when 
relatively large pieces of tissue are homogenized for enzymatic activity or blotting 
(Vickers et al. 1998).
Levels of both XOR and anti-XOR antibodies are known to be elevated in plasma of 
atherosclerotic patients and the presence of the enzyme has been demonstrated in vessel 
walls and atherosclerotic plaques (Harrison et al. 1990; Swain et al. 1995; Mohacsi et 
al. 1996; Patetsios et al. 1996; Patetsios et al. 2001). Swain demonstrated that 
ferroxidase activity attributable to XOR was present in both carotid endarterectomy 
plaques and AAA tissue (Swain et al. 1995). Patetsios demonstrated using high 
performance liquid chromatography (HPLC) that both AAA tissue and carotid 
endarterectomy plaques contained significantly more uric acid (the end-product of XOR 
activity) than non-atherosclerotic arteries obtained from young cadaveric organ donors. 
Immunohistochemistry localised XOR to the intima, especially in atherosclerotic 
plaques and inner media of the artery wall (Patetsios et al. 1996; Patetsios et al. 2001). 
The suggestion from this study was that increased XOR expression/activity resulted in 
the production of uric acid with the resultant generation of free radicals that promoted 
vascular injury. There are no published reports suggesting a role of XOR in AAA 
pathology or quantifying either the amount of XOR protein or XOR activity in AAA 
tissue compared to aortic tissue from either AOD or normal controls.
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4.2 Aims
The aims of this study were;
1. To identify and localise XOR protein/enzyme in the aortic wall using 
immunohistochemistry and Western blotting techniques
2. To quantify the amount of XOR protein in aortic tissue using an immunoblot and 
an ELISA assay.
3. To measure XOR activity in tissue homogenates.
AAA tissue was compared to non-AAA derived aortic tissue.
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4.3 Patients and Methods
4.3.1 Identification and localisation o f  XOR in aortic wall
Aortic wall biopsy specimens (2cm ) were excised as described in Section 3.2. 
Specimens were either stored in Hank's balanced salt solution (HBSS) or Formalin 
(immunohistochemistry).
4.3.1.1 Polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting fo r  
the identification o f XOR protein
Samples were prepatred as described in Section 3.4.1. Approximately 100 mg (wet
weight) of aortic tissue was homogenized in 1.5 ml of homogenisation buffer and
centrifuged at 10,000 rpm, for lOmins at + 4°C and the supernatant retained (Beckman
et al 1989). Total protein was estimated using the Bio-Rad Bradford Protein Assay.
XOR protein within aortic samples was detected using SDS-PAGE and an antibody
raised against bovine buttermilk XOR as described in Section 3.4.3 and 3.4.4. Purified
bovine XOR was used as a positive control (Biozyme). Blots were probed a rabbit anti-
bovine xanthine oxidase (Chemicon, 1: 500 dilution) and a conjugated horseradish
peroxidase swine-anti rabbit secondary antibody (Dako, 1:1000 dilution). Proteins
binding the primary and secondary antibody were detected by Chemiluminescence as
described in Section 3.4.43.
4.3.1.2 Localisation o f XOR and in human aortic wall sections 
Sections were processed for XOR protein using the Vectastain ABC-Alkaline 
Phosphatase Kit for detecting rabbit immunoglobulin G (Section 33.3). Sections 
probed with a polyclonal rabbit anti-goat XOR (Chemicon, 1 :50 -1 :200 dilution) and a 
biotinylated goat anti-rabbit IgG secondary antibody (Vector Laboratories, Vectastatin® 
1:200 dilution) as described in Section 3.33.
4.3.2 Quantification o f  XOR protein in aortic tissue
4.3.2.1 Immunoblotting (Dot blots)
Once SDS-PAGE and Western Blotting established the characteristics of XOR protein, 
an Immunoblot technique was also utilized for rapid screening of XOR protein in aortic 
samples (Section 3.5.1). Samples were loaded (20jil of 1 pg/pl) into each well and 
suction was applied for 30 seconds. Staining with Amido black confirmed equal and 
complete transfer of protein to the nitrocellulose paper.
An identical procedure as for Western blotting was used to probe the blots to detect the 
presence of XOR protein. Purified bovine XOR was used as a positive control.
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Each analysis was performed in triplicate. Results were analysed as described in 
Section 3.5.1. The parameters of image analysis were kept constant to avoid inter- 
observer variations. Results are expressed in densitometric units. Each sample was 
analysed in triplicate and the whole assay repeated three times.
4.3.2.2 Enzyme linked immunosorbent assay (ELISA) for the detection o f XOR in 
aortic tissue
An Enzyme linked immunosorbent assay (ELISA) technique was used to quantify XOR 
protein in tissue homogenates as described in Section 3.6. Samples were prepared 
(Section 3.6.1) and total protein content determined by the Bradford assay (Section 
3.4.2).
XOR protein immobilised with an anti-XO IgM antibody (Neomarkers Mab 3 ,1 :500 
dilution) was detected with a biotinylated anti-XOR chicken antibody (1:1000) and a 
streptavidin-peroxidase conjugate (Jackson Labs, lpg/ml, 1: 500 dilution) and 
orthophenylenediamine (OPD). Each sample was analysed in triplicate and the assay 
repeated twice. XOR concentration was adjusted for total protein and expressed as 
XOR ng/mg total protein (Section 3.6).
4.3.3 Determination o f XOR activity
Samples were prepared as described in Section 3.4.1 and total protein estimated using 
the Bio-Rad Bradford Protein Assay (Section 3.4.2).
4.3.3.1 Flurometric measurement o f XOR activity (Pterin oxidation)
Xanthine oxidase enzyme activity in aneurysm homogenates was measured using a 
fluorometric assay monitoring the conversion of pterin (a xanthine substitute) to the 
fluorescent reaction product isoxanthopterin (Beckman et al. 79#P)(Section3.7.1). An 
aliquot of homogenisation supernatant (50pl) was diluted in 940pL H2O and placed in a 
quartz cuvette in a fluorimeter. The rate of pterin oxidation was determined after adding 
10 pi of lOmM pterin (final cone 100 pM). Once a linear rate had been measured, 10 pi 
of lOmM methylene blue was added as an electron acceptor to measure the combined 
activities of XO and XDH (Total XOR activity). The reaction was then inhibited by the 
addition of 10 pi of lOmM Allopurinol, and a known final concentration of 
isoxanthopterin was added (10 pi of 100 pM; final cone 1 pM) as an internal standard. 
Activity was corrected for protein content and expressed as pmoles/min/mg protein. 
Each sample was assayed in triplicate and repeated three times. Bovine XOR (Biozyme) 
was used as a positive control.
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4.33.2 Lucigenin-enhanced chemiluminescence
XOR generates superoxide radicals using xanthine or NADH as substrates with oxygen 
as the terminal electron acceptor. The generation of superoxide radical was measured 
using the oxidation of lucigenin (Section 3.7.3). Assays were performed in triplicate in 
a final volume of 200pl. Samples were prepared as for the Pterin assay. An aliquot of 
homogenisation supernatant (50pl) was placed in a well and lOpl of 2mM 
Diethylenetriaminepentaacetic acid (DTPA) and 40pl PBS were added. Lucigenin was 
made up to a stock concentration of 2mM in PBS and Hypoxanthine made up to a stock 
concentration of ImM in PBS. The reactions were initiated by the automated injection 
of 50 pi of Hypoxanthine followed by 50pl of lucigenin into the wells of a 96-well plate. 
Each sample was analysed in triplicate and repeated three times. The results are 
expressed in arbitrary light units (ALU).
4.3.4 Control group, Power calculation and statistical analysis
4.3.4.1 Controls
AAA  tissue was compared to non-AAA derived aortic tissue (Controls). Ideally aortic 
tissue from age and sex matched patients with AOD and normal non-atherosclerotic 
aorta should have been used for this study. However, this proved to be impossible for 
several reasons (see discussion Section 4.5). In the end, the best alternative for ‘control’ 
aortic tissue was the use of cadaveric organ donors and aortic tissue from the cuff on the 
renal artery. This has been used as control tissue in previous studies (Patel et al 1996a)
4.3.4.2 Power calculations and sample size
No formal power calculation could be undertaken to calculate the number of samples 
required in either the AAA group or control group. In a previous published study, no 
statistical difference in XOR activity (using uric acid formation from Hypoxanthine) 
was seen between endarterectomy and AAA specimens, however, only 8 samples were 
analysed in each group (Swain et al 1995). In another study, uric acid concentrations, 
the product of XOR activity, were significantly increased in both AAA and carotid 
plaques compared to non-athersclerotic controls. No analysis was undertaken between 
AAA and carotid plaques in this study, and the data within the paper is insufficient to 
perform any further analyses (Patetsios et a l 1996).
Previous published studies using tissue homogenates that have shown differences 
between AAA and AOD/normals, particularly with reference to MMPs 
expression/activity have all included small numbers of control samples, ranging
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between 3 and 10 (Vine et al 1991; Thompson et al 1995; Patel et al 1996a). In view 
of this, the aim was to obtain 10 ‘normal’ non-AAA tissue samples.
4.3.4.3 Data presentation and statistical analysis
Statistical analysis was performed using GraphPad Prism version 3.02 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com. Data were 
assessed for deviations from Gaussian distribution using the Kolmogorov-Smimov test. 
Continuous variables were expressed as either means ± standard deviation (SD) or 
Standard error of the mean (SEM) for parametric data. Variables were analysed with 




The demographics of the two groups of patients used in this study are given in Table 
4.1. No difference in gender distribution was noted but a statistically significant 
difference was seen with regard to age (Students t test, p< 0.001)
AAA (n=30) Control (n=18) P
Age, y
Gender, % male
74 (range 57-89) 
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Table 4-1 Demographic data of patients used in the study of XOR in aortic 
tissue
4.4.2 Identification and localisation o f XOR in aortic wall
4.4.2.1 SDS-PA GE and Western blotting
Fig 4.1 shows a representative blot of human aortic aneurysm tissue depicting a band at 
the estimated weight of 150 kDa detected using a rabbit polyclonal XO antibody 
(Chemicon). 30pg of total protein were loaded per lane. Blots were probed with a 
primary rabbit anti-bovine xanthine oxidase antibody (Chemicon, 1:500 dilution) and a 
secondary conjugated horseradish peroxidase swine-anti rabbit antibody (Dako, 1:1000 
dilution). A characteristic 150 kDa band was only present in a few samples, whereas 





Figure 4-1 Western blot of human aortic aneurysm XOR after SDS-PAGE
AAA sam ples
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4.4.2.2 Localisation o f XOR and in human aortic wall sections (Xanthine oxidase 
immunohistochemistry)
Figures 4.2 and 4.3 indicate human aortic tissue isolated from patients undergoing
elective surgery or organ donation showing positive immunoreactivity for XOR. To
visualise all cells, including non-immunostained cells, a haematoxylin counterstain was
applied which depicts a blue nucleus. Antibody staining was performed on 20 AAA
specimens and 8 normal human aortas obtained from young organ donors. Control
slides (primary antibody omitted) were negative for any XOR.
Figure 4-2 Photomicrographs showing the immunolocalisation of XOR (red) in 
human non-AAA tissue
Specimens were probed with a rabbit anti-bovine XOR, (Chemicon, 1:100). Slides 
a and c are negative controls. Slide b (x50) shows diffuse positivity for XOR 
throughout the artery wall. Image d (x 200) and image e (x 400) show both 
extracellular (1) and intracellular (2) positivity for XOR. (L=Lumen, M=Media, 
Ad=Adventitia)
Control non-AAA tissue (Fig 4.2) stained positive for XOR and was localised 
throughout the artery wall with both extracellular and intracellular positivity for XOR. 





Figure 4-3 Representative Photomicrographs showing the immunolocalisation of 
XOR (red) in human AAA tissue
Images a, c and e are negative controls. Images b (x50), d (xlOO) f (x200) and h 
(x400) show diffuse positivity throughout the aortic wall. Extracellular (1) and 
intracellular (2) staining is seen. (L=Lumen, M=Media, Ad=Adventitia, 
I=Inflammatory infiltrate)
4.4.3 Quantification o f XOR protein in aortic tissue 
4.4.3.1 Immunoblotting
The amount of XOR protein in AAA samples was compared to XOR levels in non­
aneurysm control tissue using a semi-quantitative immunoblot technique. A positive 
control using bovine XOR (Biozyme) was used. Blank wells were loaded with lx PBS. 
The mean valve of triplicates for each sample was used for each analysis. The assay was 
repeated twice. These data represent the mean value of two separate analyses (AAA n = 
17, Controls n =14). Results are expressed in relative densitometric units.
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XO
Control non-AAA sam ple
AAA sam ples
Figure 4-4 Immunodot blot of AAA and control aortic tissue
Samples analysed in triplicate (AAA n =17, control n =14). 20pg of total protein 
per well. Bovine XOR enzyme used as positive control (20 pg/well). Blots probed 
with rabbit anti-XOR (Chemicon 1:1000 dilution) and conjugated horseradish 
peroxidase swine-anti rabbit (Dako, 1 :1 0 0 0  dilution).
Immunoblot: Densitom etric 
analysis
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Controls Aneurysms
Figure 4-5 XOR protein levels in aortic tissue
Results expressed as relative densitometry units in AAA (n=17) and control 
samples (n=14) quantified using an immunoblot. Data are mean ± SD of sample 
triplicates analysed twice.
There was no statistical difference in the levels of XOR protein between AAA and 
control aortic tissue using immunoblotting.
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4.4.3.2 Enzyme linked immunosorbent assay (ELISA) for the detection o f XOR in 
aortic tissue
Each sample was analysed in triplicate and the mean of each sample triplicate used in 
statistical analysis. The assay was repeated twice. These data represent the mean value 
of two separate analyses (AAA n = 17, Controls n =12). XOR protein content is 
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Figure 4-6 XOR protein levels (ng/mg total protein) in AAA (n=17) and control 
samples (n=12) quantified using an ELISA.
There was no statistical difference in the amount of XOR per mg total protein between 
AAA tissue and normal controls.
4.4.4 Determination o f XOR activity
4.4.4.1 FIuro metric measurement o f XOR activity (Pterin oxidation)
Due to difficulties in establishing clear differences in the XOR immunoexpression in 
control and AAA tissue, a fluorometric assay was used to determine whether the the 
activity of XOR was different in AAA and non AAA tissue. Ten nanograms (lOng) of 
bovine XOR (Biozyme) was used as a positive control for XOR activity using the 
fluorometric assay. The experimental blank consisted of distilled H2O and 100 pM 
pterin alone. Figure 4.7 shows the typical reaction rate of pterin oxidation with bovine 
XOR (Biozyme). The rate of reaction of the oxidase form of XOR (XO) was established 
by the rate of fluoresence change in the presence of oxygen as the terminal electron
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acceptor. The addition of lOOpM methylene blue measured the combined activities of 
XO and XDH (Total XOR activity).
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Figure 4-7 Pterin oxidation graph
A typical graph, showing the rate of XOR-catalysed conversion of pterin to its 
fluorometric reaction product isoxanthopterin.
Figure 4.8 shows the XOR activity detected in AAA and control tissue determined by 
the fluorometric assay described above. Each sample was analysed in triplicate and the 
assay repeated three times. These data presented represent the mean values of the three 
analyses (AAA n = 12, Controls n =10). No measurable XOR activity could be detected 
in either AAA or control tissue using this assay.
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Figure 4-8 XOR activity in human aortic tissue detected using the pterin assay.
4.4.4.2 Lucigenin-enhanced chemiluminescence
Hypoxanthine was used as the assay substrate and ten micrograms (50 pi of 0.2 mg/ml)
of bovine XOR (Biozyme) was used as a positive control. Reaction blanks contained lx
PBS. Blank recordings were subtracted from sample values. Each sample was analysed
in triplicate and the assay repeated on three occasions. The data represent the mean of
three assays. Results are expressed in arbitrary light units per milligram of total protein
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(ALU/mg total protein). Figure 4.9 shows that AAA and control samples contained no 
measurable activity using hypoxanthine as a substrate.
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Figure 4-9 Chemiluminesence activity detected in aortic tissue using 
hypoxanthine as substrate
AAA (n=20) or control tissue (n=12)
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4.5 Discussion
The data presented in this chapter demonstrate that XOR is detected in aortic tissue and 
localises predominantly within the intima and inner media. There is no difference in the 
level of XOR between AAA and non-AAA control aortic tissue and in addition the 
levels of XOR activity within aortic tissue are below detectable limits.
Ideally aortic tissue from age and sex matched patients with AOD and normal non- 
atherosclerotic aorta should have been used for this study. However, this proved to be 
impossible for several reasons. Firstly, the number of procedures undertaken for aortic 
occlusive disease (AOD) was significantly less than for AAA disease during this study 
period and the availability of tissue was limited. Secondly, it is impossible to obtain 
‘normal aortic tissue’ from age or sex matched controls, as these patients do not usually 
require any aortic procedure. In addition it is worth pointing out that this study was 
undertaken during a period of intense and unfavourable media attention to medicine and 
the use of human material for medical research in particular, thus it was difficult not 
only in obtaining ethical approval but also informed consent. Atherosclerotic material 
from other arteries was not thought to be a valid control as it could not be argued that 
the femoral artery had the same biological behaviour as the abdominal aorta.
In the end, the best alternative for ‘control’ aortic tissue was the use of cadaveric organ 
donors and aortic tissue from the cuff on the renal artery. This has been used as control 
tissue in previous studies (Patel et al 1996a). Whilst this is not perfect it was the best 
option available, however I am aware that conclusions from this work are weakened by 
the fact that age and sex matched controls were not possible.
The use of end-stage whole tissue homogenates in the research of the pathogenesis of 
AAAs has potential weaknesses but has been used in the past (Busuttil et al 1980; 
Cohen et al 1988). However several important points must be highlighted when 
drawing conclusions from these types of studies;
1. These studies are unable to separate primary aetiological events from secondary 
effects, i.e they are unable to distinguish between cause and effect.
2. The presence of an inflammatory infiltrate and altered cytokinetic profile within 
AAA tissue confounds the issue and prevents meaningful conclusions from being 
drawn regarding enzyme status or ECM metabolism in the stages of aneurysm 
formation that precede dilatation
3. The absence of a significant result does not preclude an active involvement of the 
subject enzyme/protein at some time during the pathogenesis of AAAs. In relation to 
AAAs, only the two extremes of the condition are being assessed i.e. the non-disease
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state (control) and end-stage-disease, the dynamic stage of aneurysm formation is not 
assessed, and as such no inference can be made about this stage of AAA 
development.
In this study, SDS-PAGE and Western blotting in combination with 
immunohistochemistry identified and localised XOR to the media and intima which 
confirms previous reports (Swain et al 1995; Patetsios et al 1996; Patetsios et al
2001). The use of a polyclonal rabbit anti-goat XOR antibody is a valid and appropriate 
antibody to investigate human XOR enzyme as the human XOR amino acid sequence 
has been shown to have a significant homology (~ 90%) to that of other mammalian 
species (Amaya et a l 1990; Ichida et al 1993; Sato et al 1995). Immunohistochemical 
analysis demonstrated that XOR staining was prominent along the intimal surface and 
inner media (i.e. the region of plaque formation) and separate from the inflammatory 
infiltrate. Both intracellular and extracellular staining was seen in both control and AAA 
tissue, with endothelial cell and smooth muscle cells staining positive for XOR 
suggesting that these cell populations are a significant source for this enzyme. The 
extra-cellular pattern of XOR staining is supported by evidence that XOR has been 
previously demonstrated to be localised to the outer surface of the endothelial cell 
plasma membrane, and is also known to bind to glycosaminoglycans, a significant 
component of the extracellular matrix (Adachi et al 1993; Radi et al 1997; Vickers et 
al. 1998). Two theoretical explanations exist to explain this extracellular pattern of 
XOR staining.
1. XOR is produced intracellularly and then secreted but binds extracellularly to the 
cell membrane.
2. XOR is released into the circulation from organs rich in XOR such as the liver and 
intestine and is then possibly internalised in tissue such as the arterial wall via 
interactions with glycosaminoglycan (Yokoyama et al 1990; Radi et al 1997).
Previous studies have demonstrated that substantial differences exist in the level of 
XOR in different sources of mammalian tissue (Pritsos 2000). A Post-mortem study 
from Finland using RT-PCR, demonstrated very low levels of the XOR transcript in 
heart, brain, lung and kidney tissues. No XOR activity could be detected in these tissues 
suggesting a very low constitutive expression of XOR. The only exception to this was in 
liver and intestine where both expression and activity was significantly higher (Sarnesto 
et al 1996; Saksela et al 1998). The results from these studies, however, are 
inconsistent with the results of an earlier study in which relatively high XOR activities 
were seen in human post-mortem brain and heart tissues, as well as activities in kidney,
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skeletal muscle, spleen and adrenal tissues suggesting a possible leakage of enzyme 
from disintegrating tissue (Wajner et al 1989). In addition, microvascular endothelial 
cells have been identified as a source as being rich in XOR activity and this may 
provide the explanation as for the detection of XOR in the majority of mammalian 
tissue. These XOR-rich but relatively small sub-populations of cells could account for 
the extremely low levels of enzyme or activity when relatively large pieces of tissue are 
homogenized for enzymatic activity or blotting.
XOR has a molecular mass of 300 KDa and is composed of two identical 150 KDa 
subunits. Purified human XOR from breast milk runs as a single band corresponding to 
approximately 150 KDa on SDS/PAGE (.Harrison 1997; Sanders et al 1997). Human 
XOR principally exists as xanthine dehydrogenase but is converted into xanthine 
oxidase during extraction or purification procedures by either thiol oxidation or 
proteolysis (Nishino et a l 1997). This conversion readily takes place during isolation 
procedures unless thiol reducing agents and protease inhibitors are included in isolation 
buffers. In addition, limited proteolysis of the rat enzyme with trypsin converts the 
enzyme into a xanthine oxidase type with concomitant cleavage into 20,40 and 85 KDa 
fragments (Amaya et al 1990).
In this study, evidence of XOR protein in aortic tissue was difficult to assess as it was 
difficult to obtain good clear Westerns blots with characteristic 150 KDa bands. Several 
observations and difficulties encounted are listed below:
1. The sample total protein loading per well/lane was extremely high. In general 
30jig of total protein was required per lane in order to visualise any staining.
2. The concentration/dilution of primary antibody was high, generally in the region 
of 1:250 to 1: 500. Lower dilutions of primary antibody failed to detect evidence of 
xanthine oxidase. The conclusion from these two observations is that the total 
amount and concentration of XOR in the aortic tissue studied, i.e. both control and 
AAA tissue is extremely small.
3. In all Western blots a significant proportion of samples showed degradation 
fragments rather than the characteristic 150 KDa band. There are two possible 
explanations to account for these results. The first explanation is that XOR protein 
does not exist in the samples and any staining observed was non-specific and a false 
positive result. In response to this possibility samples were also probed with a HRP 
conjugated anti XO IgG (Biodesign), and a non-specific rabbit anti human 
immunoglobulin (Dako). The results from these studies confirmed specificity for 
XOR as the anti-XOR antibody showed an identical pattern of staining for XOR and
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the non-immune immunoglobulin showed no staining for any samples. The second 
explanation of this is that XOR had undergone proteolysis during either the isolation 
or experimental procedure. Proteolysis is known to occur during isolation of XOR 
unless thiol reducing agents and protease inhibitors are included in isolation buffers. 
In these investigations anti-proteases such as Pepstatin A, Antipain, Leupeptin and 
Aprotinin were included in the homogenisation buffer. In addition 
Ethylenediaminetetraacetic acid (EDTA) was added to chelate calcium and other 
heavy metals which are required for the activity of many proteases, and 
Phenylmethanesulfonyl fluoride (PMSF) was added as it inhibits serine proteases 
such as trypsin and chymotrypsin and also cysteine proteases. Dithiothreitol (DTT) 
was added as a thiol reducing agent. Despite the presence of these compounds it was 
difficult to isolate XOR as a characteristic 150 KDa on SDS/PAGE and Western 
blotting. It is possible that XOR proteolysis occurred during the period of sample 
storage in the Hanks buffered saline solution and a suggestion now in retrospect is 
that either these compounds are added to the Hanks solution or alternative forms of 
sample storage/processing are undertaken such as snap freezing in liquid nitrogen 
and then homogenisation.
Xanthine Oxidoreductase activity is known to differ both between mammalian species 
and within each species depending on which tissue is assessed. Despite the 
demonstration of XOR in tissues, human XOR activity is known to be low compared to 
other species (Parks et al 1986; de Jong et al. 1990; Sarnesto et al. 1996). Human 
XOR purified from breast milk runs as a single 150 KDa band on SDS/PAGE, however 
the activity towards most reducing substrates is very low, representing only 2-3 % that 
of purified bovine milk enzyme {Harrison 1997; Sanders et al. 1997). This activity may 
result from an exceptionally low molybdenum content of the human enzyme as this 
redox centre is the site to which most reducing substrates donate their electrons {Godber 
et al 1997; Harrison 1997). The exception to this is liver and intestine, in which a high 
molybdenum centre activity is noted to traditional substrates and the purified enzyme 
shows specific activity very similar to those of bovine milk and rat liver enzyme 
{Sarnesto et a l 1996). These observations lead Harrison to postulate that human XOR 
might be tissue specific, with ‘high-activity’ enzyme in a limited number of tissues (e.g. 
liver and intestine) and ‘low-actmty’ enzyme, similar to that in breast milk in the rest 
{Harrison 1997).
In this study the two assays used were dependent on the activity at the molybdenum 
centre of the enzyme. The data demonstrates that no reproducible XOR activity is
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present in any aortic tissue. Significant background readings were obtained from all 
samples. It was believed that this was due to the heterogeneous nature of samples, 
however despite centrifugation for both longer and at faster speeds no difference was 
noted. Sample processing through a PD-10 column (Saphadex™ G-25M, Amersham 
Parmacia Biotech AB) made no difference. Despite increasing the sample volume to a 
maximum o f2 0 0 pl, or increasing the substrate (pterin) concentration to a final of 
200pM, no activity could be detected.
Possible explanations to account for no XOR activity being present in aortic samples 
include;
1. This is a true result and there is indeed no XOR activity is present in aortic tissue
2. The amount of XOR activity present in aortic tissue is below the detection limit of 
the assays employed, i.e. a problem of sensitivity. It is worth pointing out that we are 
unaware of a more sensitive assay for XOR other than that described by Beckman
(Beckman et al. 1989). Interestingly Patetios using high-performance liquid 
chromatography (HPLC) demonstrated significantly increased levels of uric acid, the 
end-product of XOR function, in the walls of aortic aneurysms compared to non- 
atherosclerotic control arteries, suggesting that functioning XOR is present in vessel 
walls. The data also suggest that there is a functional difference of XOR between 
aneurysm and non-aneurysm normal tissue, however we have been unable to support 
this finding (Patetsios et al. 1996).
3. It is possible that Harrison’s postulation may be correct and the XOR present in 
aortic tissue may be a ‘low-activity’ enzyme with little molybdenum centre activity.
If this is the case then an alternative assay is required to measure activity at the other 
redox active centres {Harrison 1997).
4. The functioning of XOR requires an intact enzyme. Electrons donated at the 
molybdenum centre are passed to the FAD site and a terminal electron acceptor,
NAD in the case of the dehydrogenase enzyme and molecular oxygen in the case of 
the oxidase form. Data from SDS/PAGE and Western blotting suggests that in our 
samples very little XOR was intact and this may explain the lack of activity seen in 
our samples.
This is clearly disappointing but could be the result of the end-stage of aneurysm 
formation, and perhaps might have been different in the earlier stages of aneurysm 
formation.
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Chapter 5 Hypoxia and role in AAAs
5.1 Introduction
5.1.1 Arterial wall hypoxia
Arteries with a diameter and wall thickness of the aorta contain areas of hypoxia at the 
junction of the inner one third and outer two thirds of the vessel wall (Wolinsky et al 
1967; Heughan et al. 1973). Experimental animal data and mathematical computational 
models suggest that this normal physiological hypoxia is exacerbated in conditions such 
as atherosclerosis, diabetes, hypertension, cigarette smoking, ageing and arterial 
bifurcation, all of which are known to be associated with AAA formation (.Heughan et 
al. 1973; Crawford et al. 1991; Santilli et al. 1992, 1993; Santilli et al. 1995; Vorp et 
al. 1996; Santilli et al. 1998; Vorp et al. 1998; Santilli et al. 2000). Data from animal in 
vitro and in situ systems demonstrate that in normal arteries the pC>2 decreases in the 
inner media to 20 to 50 mm Hg (Niinikoski et al. 1973; Crawford et al. 1988;
Zemplenyi et al. 1989). In addition the use of the hypoxic probe NITP in a rabbit model 
of atherosclerosis confirms that hypoxia exists within atheosclerotic plaques and the 
inner media (Bjornheden et al. 1999).
AAA are invariably associated with laminated intraluminal thrombus (ILT) (Adolph et 
al. 1997; Vorp et al. 1998). Vorp hypothesized that ILT forms a mechanical barrier to 
oxygen diffusion rendering the intima and inner media anoxic (Vorp et al. 1996; Vorp et 
al. 1998). Data from intra-operative pC>2 measurements with a needle polarographic pC>2 
electrode indicated that the pC>2 within the AAA wall was significantly less in patients 
with ILT and was associated with localised areas of neovascularisation and local wall 
weakness (Vorp et al. 1998; Vorp et al. 2001).
5.1.2 Effects o f hypoxia
Hypoxia has been shown to alter the expression of growth factors and angiogenic 
factors such as vascular endothelial growth factor (VEGF), platelet derived endothelial 
growth factor (PDEGF), endothelin (ET-1), and vasoactive factors such as nitric oxide 
synthase (NOS) probably via modulation of transcription factors such as Hypoxia 
inducible factor -1 (HIF-1) (Sakuda et al. 1992; Kourembanas et al. 1998; Berse et al. 
1999; Chiarugi et al. 1999; Dachs et al. 2000). In addition hypoxia has been shown to 
decrease and elastin and collagen synthesis in cultured aortic endothial cells, VSMCs 
and fibroblasts (Stavenow et al. 1987; Durmowicz et al. 1991; Herrick et al. 1996; 
Steinbrech et al. 1999). Furthermore, the collagen that is synthesised by hypoxic cells is
102
abnormal because oxygen is needed for the hydroxylation of praline (Herrick et al 
1996).
Hypoxia has been shown to increase elastase production in cultured macrophages 
(Campbell et al 1983). The gene for MMP-9 contains consensus hypoxia sensitive AP- 
1 and NFkB sites in its promoter region and levels of MMP-9 and MMP-2 have been 
shown to be increased in mice exposed to hypoxia (Himelstein et al 1998; Zaidi et al.
2002). Similarly, in pulmonary interstitial tissue from hypoxic exposed rabbits and 
human keratinocytes, MMP-9 expression and protein levels were increased {O'Toole et 
al 1997; Miserocchi et al 2001). However in one study using mouse fibroblasts, MMP- 
9 expression and activity were decreased after exposure to hypoxia (Saed et al. 2000). 
Other studies have demonstrated an increase in expression of MMP-2 in rat hepatocytes 
subjected to hypoxia {Chen et al 2000). In one study using human trophoblastic and 
breast cancer cells, hypoxia had no effect on either MMP-2 or MMP-9 expression, but 
their activity was increased due to a decrease in the levels of TIMP-1 {Canning et al 
2001) These findings suggest that hypoxia may shift in the balance between MMPs and 
their inhibitors favouring increased MMP activity.
The hypothesis as outlined in Section 2.4.4 was that hypoxia within the aortic wall 
leads to increased elastolytic activity via either an XOR and/or oxidant stress pathway. 
Published data suggests that MMP-2 and MMP-9 produced by VSMC are the two 
elastolytic enzymes involved in the pathogenesis of AAAs. There are no previous 
studies assessing the influence of hypoxia on either the expression of MMP-2 or MMP- 
9 or elastolytic activity in human VSMC, which would obviously be relevant in the 
pathogenesis of AAA
5.2 Aims
The aims of this study were;
1. To determine if experimental hypoxia alters the expression or level of XOR in 
VSMC in culture
2. To determine if experimental hypoxia alters the;
a. expression of MMP-2 and MMP-9 in V SMCs in culture
b. level of MMP-2 and MMP-9 in conditioned media from VSMCs
c. elastolytic activity of conditioned media from cultured human VSMCs
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5.3 Materials and methods
5.3.1 Tissues preparation and VSMC culture
Tissue was collected as described in Section 3.81 and VSMCs were cultured from aortic 
explants as described in Section 3.8.2 (Patel et al. 1996a) and passaged as described in 
Section 3.8.3
5.3.2 To determine i f  Hypoxia alters XOR expression or XOR protein in cultured 
human VSMCs
5.3.2.1 Experimental protocol
Cells from passage 3 were seeded into 6  well plates at a density of 100,000 cells per 
well (Section 3.8.4). Cells were incubated in 10 % FCS/DMEM for 24-48 hours before 
experimentation. VSMCs were characterised by immunocytochemistry with a mouse 
monoclonal anti-a smooth muscle actin alkaline phosphatase conjugate antibody 
(Section 3.8.6). In addition cells were seeded onto LabTec slides for 
immunocytochemical analysis for XOR protein (Section 3.8.7)
Control (Time 0 (To)) total RNA, protein and unconditioned media (media blank) were 
retained at the beginning of the experiment. 0.5 ml of standard DMEM was added per 
well and plates were incubated in either 1 % oxygen, balanced nitrogen/ CO2 in a 
hypoxic chamber at 37° C (hypoxia group) or an atmosphere of 5% CO2 , 95% air at 37°
C (normoxia group).
Figure 5-1 Hypoxic cabinet used for all experiments 
5.3.2.2 Experiment end-points
At 2 hrs (T2) and 6  hrs (To), total RNA and protein were isolated by adding 0.5 ml of 
RNA STAT 60 per well. RNA was isolated, quantified and reversed transcribed as 
described in Section 3.9.1-3 and subjected to XOR and GAPDH RT PCR as described 
in Section 3.9.4. Expression of XOR mRNA was quantified as described in Section 
3.9.5. Results are expressed as XOR/GAPDH ratio.
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Total protein was isolated from RNA STAT 60 preparation as described in Section
3.9.1.2 and quantified using the Bradford protein assay (Section 3.4.2). Samples were 
subjected to SDS-PAGE and Western blotting as described in Section 3.4.3 and 3.4.4 
At 24 hrs (T24), 0.5 ml of protein lysing buffer (Section 3.4.1) was added per well and 
cell suspensions made by repetitive pippetting through a 23 G needle. Samples were 
centrifuged at 10,000 rpm for 10 minutes and supernatants retained. Total protein was 
quantified using the Bradford assay (Section 3.4.2). Levels of XOR protein were semi 
quantified using the immunoblot assay as described in Section 3.5.1 
Conditioned media was collected at each time point and was used in the SAAANA 
elastolytic activity assay as described in Section 3.11.1.
53,23  Experimental number
No formal power calculation could be undertaken for this experiment as no previous 
studies have been reported. The experiment was carried out in triplicate for each 
experimental condition and repeated 4 times (N=4)
5 3 3  To determine if  hypoxia alters MMP-2 or MMP-9 expression/levels or 
elastolytic activity in cultured human VSMCs
533.1  Experimental protocol
Only cells derived from aortic tissue from non-AAA patients, ie cadaveric organ donors 
were used for this experiment. Cells from passage 3 were seeded into T25 culture flasks 
at a density of 2.5 x 10 5 cells per flask or a 6  well plate at a density of 100,000 cells per 
well (Section 3.8.4). Cells were incubated in standard 10 % FCS/DMEM for 24-48 
hours and then washed with PBS to remove any residual serum and then further cultured 
in serum-free DMEM containing BSA (0.1 mg/ml), Ascorbate (lOOuM), Insulin- 
Transferin-Selenium A supplement lOOx (GibcoBRL Life Technologies), Penicillin 
(100 IU/ml), Streptomycin (lOOpg/ml) and L-Glutamine (0.2mM). VSMCs were 
characterised by immunocytochemistry with a mouse monoclonal anti-a smooth muscle 
actin alkaline phosphatase conjugate antibody (Sigma) (Section 3.85)
5.33.2 Experimental end-points
53.3.2.1 MMP-2/9 mRNA expression
Cells seeded in 6  well plates at a density of 100,000 cells per well were used for this 
experiment. Control total RNA was retained at the beginning of the experiment (Time 0 
(TO)). 1 ml of either serum-free DMEM or standard 10% v/v FCS/DMEM was added 
per well and cells incubated in either 1% oxygen balanced nitrogen/ CO2 in a hypoxic
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chamber at 37°C (hypoxia group) or an atmosphere of 5% CO2, 95% air at 37°C 
(normoxia control group).
At 2 hr (T2) and 6  hrs (T6), total RNA was isolated from cultured VSMCs cells by the 
addition of 0.5 ml of RNA STAT 60. RNA was isolated, quantified and reversed 
transcribed as described in Section 3.9.1-3 and subjected to MMP-2, MMP-9 and 
GAPDH RT PCR as described in Section 3.9.4. Expression of MMP-2 and MMP-9 
mRNA were quantified as described in Section 3.9.5. Results are expressed as 
product/GAPDH ratio.
5.3.3.2.2 MMP2/9protein and elastolytic activity
Cells seeded in T25 culture flasks at a density of 2.5 x 105 cells per flask were used for 
this experiment. Unconditioned serum-free DMEM was retained at the beginning of the 
experiment (Time 0 (To)). 2 ml of serum-free DMEM were added per T25 flask and cells 
incubated in either 1% oxygen balanced nitrogen/ CO2 in an hypoxic chamber at 37°C 
(hypoxia group) or an atmosphere of 5% CO2, 95% air at 37°C (normoxia group) for 
either 24 hours (T24) or 48 hours (T48). Conditioned media was collected from each time 
point and used for MMP-2 and MMP-9 ELISAs (Section 3.10) as well as in SAAANA 
elastolytic activity assay (Section 3.11.1) and the MMP gelatinase activity assay 
(Section 3.11.2).
S.3.3.3 Experimental number
No formal power calculation could be undertaken for this experiment as no previous 
studies have been reported. The experiment was carried out in triplicate for each 
experimental condition and repeated 4 times (N=4)
5.3.4 Data presentation and statistical analysis
5.3.4.1 Controls
Data were analysed at identical time points, ie hypoxia was compared to normoxia 
controls.
5.3.4.2 Data presentation and statistical analysis
Statistical analysis was performed using GraphPad Prism version 3.02 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com. Data were 
assessed for deviations from Gaussian distribution using the Kolmogorov-Smimov test. 
Continuous variables were expressed as either means ± standard deviation (SD) or 
Standard error of the mean (SEM) for parametric data. Variables were analysed with 
students t-test. Statistical significance was considered for p values less than 0.05.
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5.4 Results
5.4.1 Characterisation o f vascular smooth muscle cells
The identification of VSMCs in culture was confirmed by the typical ‘hill and valley’ 
appearance of VSMCs in culture and immunopositivity for a actin (Figures 5.2 and 
5.3).
■ m m m m
Figure 5-2 Phase contrast micrograph of vascular smooth muscle cells (VSMC) 
(Magnification xlOO)




Figure 5-3 Cultured cells showing immunopositivity for a-actin
Image on left is negative control. The cells were incubated with diluted (1:25) 
mouse monoclonal anti-a smooth muscle actin alkaline phosphatase conjugated 
antibody (Sigma). Control slides were incubated with the blocking buffer alone 
and an irrelevant alkaline phosphatase conjugated antibody. The colour was 
developed with Sigma Fast Red M and counterstained with Mayer’s haematoxylin.
Vascular smooth muscle cells were confirmed as a source for xanthine oxidase by 
immunopositivity for XOR (Fig 5.4).
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Figure 5-4 Cultured cells showing immunopositivity for XOR.
Image on left is negative control. Cells were incubated with diluted rabbit 
polyclonal anti-bovine XOR antibody (Chemicon, 1:100) and a biotinylated goat 
anti-rabbit IgG secondary antibody (Vector Labs, 1:100) followed by a 1:100 
dilution of an alkaline phosphatase-conjugated avidin biotin complex (ABC) 
(Vectastain, Vector Labs). The colour was developed with Sigma Fast Red™1 and 
counterstained with Mayer's haematoxylin
5.4.2 Effect o f hypoxia on xanthine oxidase expression and protein levels
5.4.2.1 XOR mRNA expression
Mouse liver cDNA was utilized as a positive control for XOR PCR. Preliminary data 
confirmed that PCR for GAPDH and XOR worked and the PCR product for GAPDH 
was identified as a band corresponding to 576 base pairs and XOR as a product at 288 
base pairs as predicted from the position of the primers on the sequence.
500 bp
Figure 5-5 PCR for XO and GAPDH using mouse liver c DNA
The PCR product for GAPDH was visualised as a product at 576 base pairs,and 
the product for XOR was visualised as product at 288 base pairs.
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All PCR for GAPDH and XOR were run on separate gels. Individual experiments were 
run on the same gel to minimise inter-gel variation. Results are expressed as 
XOR/GAPDH ratio.
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Figure 5-6 Representative PCR for XO (A) and GAPDH (B) for VSMCs
The experiment was carried out in triplicate for each experimental condition and 
repeated 4 times (N=4).
tte s t
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Figure 5-7 XOR mRNA expression of cultured VSMC exposed to normoxia and 
hypoxia for 6  hours.
Data are mean ± SEM of 4 experiments in triplicate. Data were analysed at 
identical time points, ie hypoxia was compared to normoxia controls at T2 and T6
The data from this experiment indicate no significant difference in XOR mRNA 
expression between VSMCs stimulated with 1% hypoxia or normoxia either at 2 or 6  
hours. The data suggest that 1% hypoxia has no effect on XOR expression in cultured 
human VSMCs at 2 or 6  hours.
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5.4.2.2 XOR protein expression 
RNA STAT 60 protocol
No protein bands corresponding to XOR protein were visible in any experimental 
samples tested. Identical results were obtained when the membrane were probed with an 
anti XO HRP conjugated antibody (Data not shown). No further analysis of these 
samples could be undertaken.
Figure 5-8 Western blot of STAT-60 protein preparations
Commercially available bovine XOR enzyme was used as a positive control. 15pg 
of total protein were loaded per lane. Membranes were probed with a rabbit 
polyclonal XO antibody (Chemicon, 1:500) and a secondary conjugated 
horseradish peroxidase swine-anti rabbit antibody (Dako, 1:1000 dilution). 
Characteristic XOR protein bands were only present in positive controls. 
Experiment samples contained no XOR protein bands.
T24 VSMC protein lysates
Levels of XOR protein in protein lysates from VSMCs exposed to either hypoxia or 
normoxia for 24 hours were semi quantified using the immunoblot assay as described in 
Section 3.5.1. Fifteen (15pg) micrograms of total protein were loaded per well.
Biozyme bovine XOR enzyme used as positive control (15pg/well). Blots probed with 
rabbit anti-XOR (Chemicon 1:1000 dilution) and conjugated horseradish peroxidase 
swine-anti rabbit (Dako, 1:1000 dilution). Data are mean ± SEM of 4 experiments in 
triplicate. No statistical difference was observed between XOR protein levels at 24 
hours in VSMCs either exposed to normoxia or hypoxia.
110
T24 normoxia T24 Hypoxia
Figure 5-9 XOR protein levels (relative densitometry units) in VSMC 
stimulated with hypoxia
Data are mean ± SEM of 4 experiments in triplicate.
S.4.2.3 Elastolytic activity. - Succinyl trialanyl 4-nitroanilide (SAAANA) assay 
The sensitivity of the assay determined from the standard curve using porcine pancreatic 
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Figure 5-10 Standard curve for SAAANA assay
Porcine pancreatic elastase (PPE) diluted in unconditioned experimental media.
The absorbance value for unconditioned media (sample blank, i.e. no elastase) was 
greater than the absorbance value for experimental samples, indicating that samples 
contained no measurable elastolytic activity. There were no differences between 







Figure 5-11 Absorbance values of conditioned media
Absorbance values for unconditioned media were similar as for experimental 
samples indicating no measurable elastolytic activity present. Data are mean ± 
SEM of 4 experiments in triplicate.
Possible reasons to explain as to why no elastolytic activity was demonstrated in VSMC 
cultures using this assay are;
1. The phenol red in the DMEM interfered with the absorbance
2. The Foetal calf serum (FCS) colour interfered with the assay
3. The presence of FCS had an anti-elastase activity thus inhibiting the assay
4. T2 and T6 were not long enough time points for elastase enzymes to be secreted 
into the media
5. Elastolytic enzymes maybe in the latent (non-active) form.
In respect to the first two suggestions, if the standard curve was repeated with the 
porcine pancreatic elastase (PPE) diluted in DMEM/ 10% FCS rather than buffer, a 
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Figure 5-12 Standard curve for porcine pancreatic elastase diluted in either 
assay buffer or 10% FCS/DMEM
This observation would suggest that the colour of the DMEM/FCS interferes with the 
absorbance at 405 nm. This result suggests that DMEM/FCS does not inhibit the assay, 
because for each concentration of PPE, a higher absorbance is seen with DMEM/FCS 
rather than buffer alone
5.4.3 Effect o f hypoxia on MMP-2 and MMP-9 expression , protein levels and 
elastolytic activity in cultured human VSMCs
♦ PPE in DMEM/FCS 
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Figure 5-13 Cultured cells grown in serum free media showing immunopositivity 
for a-actin.
Image on left is negative control. The cells were incubated with diluted (1:25) 
mouse monoclonal anti-a smooth muscle actin alkaline phosphatase conjugated 
antibody (Sigma). Control slides were incubated with the blocking buffer alone 
and an irrelevant alkaline phosphatase conjugated antibody. The colour was 
developed with Sigma Fast Red M and counterstained with Mayer's haematoxylin.
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5.4.3.1 Hypoxia and MMP expression
5.4.3.1.1 MMP-2
A representative PCR for MMP-2 from VSMC in serum free media is shown below. 
The experiment was performed in triplicate and repeated on 3 occasions. Results are 
expressed as MMP-2/GAPDH ratio.
449 bp _
Positive control 380 bp
576 bp
Figure 5-14 Representative MMP-2 PCR in serum free media.
The PCR product was visualised at 449 bp. Corresponding GAPDH PCR products 






T2 p = 0.24
T6 p = 0.59
Figure 5-15 MMP-2 mRNA expression of cultured VSMC in serum free media 
exposed to normoxia and hypoxia for 6  hours
Data are mean ± SEM of 3 experiments in triplicate. Data were analysed at 
identical time points, ie hypoxia was compared to normoxia controls at T2 and T6.
The data from this experiment indicate that MMP-2 expression in cultured VSMCs is 
not influenced by hypoxic conditions. Similar results were obtained in parallel 
experiments performed with VSMCs in 10% FCS/DMEM exposed to normoxia or 
hypoxia for up to 6 hours.
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Figure 5-16 MMP-2 mRNA expression of cultured VSMC in 10% FCS/DMEM 
exposed to normoxia and hypoxia for 6  hours
Data are mean ± SEM of 3 experiments in triplicate. Data were analysed at 
identical time points, ie hypoxia was compared to normoxia controls at T2 and T6.
5.4.3.1.2 MMP-9
No MMP-9 PCR product was detected in any of the samples analysed.
The fact that the PCR for GAPDH revealed PCR products of the expected size, and the 
fact that the positive control for MMP-9 worked, all confirmed that mRNA, reverse 
transcription and PCR were adequate. There were no differences if the experiment was 
performed in serum free or serum containing media. The conclusion from this is that 
VSMC in culture did not express MMP-9.
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Figure 5-17 Representative MMP-9 PCR from VSMCs in serum free media
The PCR product for GAPDH was visualised at 576 bp. No experimental MMP-9 
PCR product was visualised.
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5.4.3.2 Hypoxia and MMP-2/9 protein levels and elastolytic activity
5.4.3.2.1 MMP-2 ELISA and MMP-9 ELISA
Conditioned media from experiment 2 were used in the MMP-2 and MMP-9 ELISAs. 
The manufacturers’ protocol was followed.
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Figure 5-19 MMP-9 ELISA standard curve
3 00-











Figure 5-20 Results of MMP-2 ELISA
Data are mean ± SEM of 4 experiments in triplicate. Data were analysed at identical 
time points, ie hypoxia was compared to normoxia controls at T24 and T48.
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VSMCs in culture both showed increased MMP-2 protein levels over 24-48 hours but 
this increase was the same for hypoxia and normoxia. No difference was detected in 
MMP-2 protein levels at either 24 or 48 hours incubation in hypoxia compared to 
normoxia.
No MMP-9 was detected in any samples analysed. All absorbance values were lower 
than the sensitivity of the assay, i.e. 3.1 ng/ml of MMP-9
5.4.3.2.2 Succinyl trialanyl 4-nitroanilide (SAAANA) assay
Conditioned media samples from experiment 5.3.3.2.2 were used in this assay. Due to 
the problems mentioned in Section 5.4.2.3 with this assay, experiments were conducted 
in DMEM without phenol red and in the absence of foetal calf serum. Assay was carried 
out as described by Patel at pH 7.2 (Patel et al. 1996a).
A typical standard curve obtained from porcine pancreatic elastase (PPE) diluted in 
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Figure 5-21 Standard curve for SAAANA assay.
Porcine pancreatic elastase (PPE) diluted in unconditioned experimental media 
was used
Despite the generation of the standard curve as demonstrated above, a problem was 
found with the use of this assay when experimental samples were assayed.
Multiple wells (> 75%) developed a non-specific ‘cloudiness’. The 405 nm readings 
were suggestive of a positive reaction, however, these assay wells also gave high 
reading with a 595 nm non-specific filter, confirming that the data were false positive 
values and not valid.
Initially I believed that the cloudiness was due to infection within the experimental 
media samples, however despite filtering all reagents used in the assay the cloudiness 
remained and was noted to be due to a precipitate in the bottom of each well.
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In investigating this further I determined whether this was a pH related effect.
According to Patel’s description the best pH for this assay is 7.2, and that was the buffer 
pH that I originally used (Patel et al. 1996a). In order to test this variable, a range of 
TrisHCL buffers (7.2-8.4) were used. In addition the presence/absence of media and the 
presence/absence of CaCl2 were investigated. Porcine pancreatic elastase was used as a 
positive control (lOpg/well). 200pl of buffer were added to lOOpl media/H20/elastase 
and lOpl of SAAANA was added. Experiments were incubated for 4 hours at 37°C.
Media H20 Elastase/Media Elastase/H20
Buffer
405
nm 595 nm 405 nm 595 nm 405 nm 595 nm 405 nm
595
nm
7.2 0.073 0.038 0.061 0.035 1.825 0.049 1.795 0.044
7.2 CaCl2 0.076 0.04 0.056 0.033 1.85 0.05 1.82 0.046
7.4 0.075 0.04 0.058 0.035 2.026 0.05 1.8 0.045
7.4 CaCl2 0.076 0.041 0.058 0.034 1.861 0.05 1.786 0.045
7.6 0.073 0.038 0.059 0.035 1.888 0.048 1.803 0.046
7.6 CaCl2 0.079 0.04 0.058 0.034 1.822 0.05 1.843 0.044
7.8 0.077 0.041 0.056 0.032 1.813 0.048 1.803 0.044
7.8 CaCl2 0.142 0.072 0.06 0.034 1.9 0.074 1.826 0.045
8.0 0.076 0.04 0.059 0.034 1.832 0.048 1.812 0.045
8.0 CaCl2 0.156 0.076 0.059 0.035 1.898 0.077 1.856 0.047
8.2 0.076 0.04 0.058 0.034 1.845 0.047 1.79 0.044
8.2 CaCl2 0.275 0.13 0.058 0.034 1.979 0.101 1.837 0.046
8.4 0.08 0.043 0.061 0.036 1.837 0.046 1.783 0.043
8.4 CaCl2 0.258 0.122 0.064 0.036 1.872 0.106 1.792 0.044
Table 5-1 Effects of TrisHCL buffer (7.2-8.4) on SAAANA assay
The results of this experiment show that the combination of pH > 7.8, media and 
calcium chloride result in non-specific ‘cloudiness’ even in the absence of any elastase. 
In a second experiment, longer incubations were observed to determine if time 
influenced the development of the precipitate. Porcine pancreatic elastase was used as a 
positive control (0.1 pg/well). 200pl of buffer were added to lOOpl sample (media +/- 





405 nm 595 nm 405 nm 595 nm
7.2 CaCl2 0.072 0.037 0.083 0.038
7.4 CaCl2 0.073 0.038 0.084 0.038
7.6 CaCl2 0.077 0.041 0.083 0.038
7.8 CaCl2 0.083 0.042 0.087 0.04
8.0 CaCl2 0.085 0.042 0.088 0.039
8.2 CaCl2 0.218 0.101 0.23 0.099
8.4 CaCl2 0.197 0.093 0.212 0.093
t 24
405 nm 595 nm 405 nm 595 nm
7.2 CaCl2 0.089 0.04 2.297 0.064
7.4 CaCl2 0.099 0.045 2.311 0.05
7.6 CaCl2 0.137 0.08 2.261 0.08
7.8 CaCl2 0.186 0.102 2.29 0.098
8.0 CaCl2 0.197 0.101 2.327 0.099
8.2 CaCl2 0.278 0.129 2.376 0.133
8.4 CaCl2 0.273 0.132 2.394 0.152
T48
405 nm 595 nm 405 nm 595 nm
7.2 CaCl2 0.111 0.08 2.302 0.069
7.4 CaCl2 0.126 0.09 2.301 0.09
7.6 CaCl2 0.165 0.095 2.296 0.093
7.8 CaCl2 0.165 0.099 2.222 0.099
8.0 CaCl2 0.178 0.102 2.27 0.12
8.2 CaCl2 0.22 0.128 2.278 0.132
8.4 CaCl2 0.201 0.129 2.396 0.149
Table 5-2 Effect of time on incubations for SAAANA assay
The data demonstrate that the non-specific ‘cloudiness’ developed in lower pH buffers 
with longer incubation periods.
From these observations we believe that the presence of calcium chloride, which is 
required for MMP activation, causes something in the media (probably the ascorbic 
acid) to precipitate as the pH rises with prolonged incubation times.
In an effort to overcome these non-specific ‘colour’ changes, experimental samples 
were ‘blanked’ by subtracting the 595 nm reading from 405 nm reading as well as 
subtracting the unconditioned media/buffer/SAAANA reading. When this was 
performed the results from this assay would suggest that no elastolytic activity could be 
demonstrated in any samples measured using this technique.
5.43.2.3 Gelatinase activity assay
Due to the problems with the SAAANA assay this commercially available assay was 
used to quantify the elastolytic activity of conditioned media from cultured VSMCs 
exposed to either hypoxic or normoxic experimental conditions.
The results are expressed as a percentage activity of the positive control provided 
((Positive control OD/Sample OD) x 100 = percent activity) and as a quantitative result 
by comparison with the activity of purified MMP-2 (Chemicon CC071) activated by p- 
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Figure 5-23 Quantitative gelatinase activity of conditioned media from VSMCs 
exposed to either hypoxia or normoxia for up to 48 hours




Figure 5-24 Relative gelatinase activity of conditioned media from VSMCs 
exposed to either hypoxia or normoxia for up to 48 hours
Data are mean ± SEM of 4 experiments in triplicate.
Using the Chemicon gelatinase activity assay, no difference in gelatinase activity could 
be detected between VSMCs exposed to either hypoxia or normoxia for up to 48 hours.
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5.5 Discussion
Matrix metalloproteinases, in particular MMP-2 and MMP-9 are believed to play a 
prominent role in the initiation and development of ECM changes that lead to 
aneurysmal dilatation (Chapter 2).
MMP-2 derived from VSMCs is believed to be the dominant elastolytic enzyme in the 
wall of small early aneurysms, with MMP-9 becoming more prominent as the 
inflammatory infiltrate increased in density {Freestone et al 1995; Thompson et al 
1995; McMillan et al 1997; Petersen et al 2000; Petersen et al 2002). The reasons for 
the elevated MMP-2 gene transcription in aortic VSMCs derived from patients with 
AAA are unclear. No mutational abnormalities in the MMP-2 gene itself have been 
reported, and the level of expression of MMP-2 is not readily modulated, because it is 
constitutively expressed and exhibits the characteristics of a housekeeping gene 
{Huhtala et al 1990; Galis et al 1994). The MMP-2 promoter lacks a TATA box and 
AP-1 transcriptional binding motif common to other inducible MMPs, however Davis 
demonstrated that MMP-2 production was most prominent in areas of inflammation in 
AAAs and suggested paracrine modulation of the MMP-2 gene {Gaire et al 1994;
Davis et al 1998). MMP-2 has been shown to be up-regulated in rat glomerular 
mesangial cells due to a cis-acting enhancer element in the rat MMP-2 gene which binds 
the transcription factors AP-2 and YB-1 (Harendza et al 1995; Mertens et al 1998) and 
in response to exogenous cytokinetic stimuli {Marti et al 1994). This has never been 
demonstrated in human MMP-2. An alternative explanation may be that there is 
polymorphism in the MMP-2 gene or promoter region and indeed Price has recently 
identified 6 polymorphisms in the human MMP-2 promoter region, one of which, a C-T 
transition at -1306 was associated with differential promoter activity {Price et al 2001). 
The relationship of MMP-2 polymorphism with AAA remains to be clarified and is the 
subject of ongoing investigations {Goodall et al 2001).
In contrast to MMP-2, the gene for MMP-9 contains TATA and CAAT boxes, AP-1, 
NFKB-binding sites and PEA-3 elements in the 5’-flanking region of the gene {Huhtala 
et al 1991; Ye 2000). MMP-9 is principally produced by inflammatory macrophages, 
but AAA VSMCs do express MMP-9 in culture and expression is increased in response 
to inflammatory cytokines such as IL-ip {Evans et al. 1991; Galis et al 1994). 
Interestingly polymorphisms of MMP-9 have been studied in AAA patients, but no 
association has been detected {Yoon et al 1999; Ye 2000).
Hypoxia has been shown to increase elastase production in cultured macrophages and 
levels of MMP-9 and MMP-2 have been shown to be increased in mice exposed to
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hypoxia (Campbell et al. 1983; Himelstein et al. 1998; Zaidi et al. 2002). In addition, 
pulmonary interstitial tissue from hypoxic exposed rabbits had raised MMP-9 
expression and protein levels (Miserocchi et al. 2001) and MMP-2 expression has been 
shown to be increased in rat hepatocytes subjected to hypoxia (Chen et al. 2000). In one 
study using human trophoblastic and breast cancer cells, hypoxia had no effect on either 
MMP-2 or MMP-9 expression, but their activity was increased due to a decrease in the 
levels of TIMP-1 {Canning et al. 2001). These findings suggest that hypoxia may shift 
in the balance between MMPs and their inhibitors favouring increased MMP activity. 
Based on this previous evidence and the potential link between these factors especially 
hypoxia, MMP expression and elastolytic activity, I decided to simulate hypoxia in 
cultured human VSMCs to determine if this stimulus could account for elevated MMPs 
and elastolytic activity. The principle aim of this study was to investigate a possible 
relationship between hypoxia, MMP expression and elastolytic activity in VSMCs in 
culture.
Cell culture has the advantage of allowing the study of isolated cell lines under 
controlled conditions {Carrell et al. 1999). Vascular smooth muscle cells cultured from 
aneurysms have been shown to be a source of the elevated production of both MMP-2 
and MMP-9 and were thus chosen as the study source {Evans et al. 1991; Galis et al. 
1994; Keen et al. 1994; McMillan et al. 1995; Crowther et al. 1996; Patel et al. 1996b; 
Crowther et al. 2000a). The potential disadvantage of isolated cell culture techniques is 
that the interaction and possible paracrine influence of other cell lines is eliminated and 
thus the model may be criticised as not reflecting in vivo conditions, which is why other 
investigators have developed techniques of aortic tissue ex-vivo explants {Wills et al. 
1996).
A major assumption in this study is that hypoxia exists in the wall of aortic aneurysms. 
Whilst data exist to support this assumption in experimental animal models, particularly 
with atherosclerosis, the data for human vessel hypoxia is limited, probably reflecting 
the difficulty in measuring this parameter. Vorp using an order-of-magnitude analysis 
and computational analysis calculated that the aortic wall in aneurysms is hypoxic {Vorp 
et al. 1996; Vorp et al. 1998). In a further study, reported since the completion of our 
study, Vorp demonstrated that the AAA wall adjacent to a thick layer of intraluminal 
thrombus (ILT) have localised areas of hypoxia. In this study patients with AAA were 
placed in one of two groups: (1) those with an ILT of 4-mm or greater thickness on the 
anterior surface or (2) those with little (< 4 mm) or no ILT at this site. During surgical 
resection but before aortic cross-clamping, a needle-type polarographic partial pressure
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of oxygen (pC>2) electrode was inserted into the wall of the exposed aorta and the pC>2 
was measured. The probe was advanced, and measurements were made midway through 
the thrombus and in the lumen. Mural and mid-ILT pC>2 measurements were normalized 
by the intraluminal pC>2 measurement to account for patient variability. In addition,
AAA wall specimens were obtained and assessed for degree of inflammation, 
neovascularisation and tensile strength. Western blotting and immunohistochemistry for 
qualitative evaluation of expression of the cellular hypoxia marker oxygen-regulated 
protein was also performed. The pC>2 measured within the AAA wall in group I (n = 4) 
and group II (n = 7) patients was 18% +/- 9% luminal value versus 60% +/- 6% (mean 
+/- SEM; P <0.01). The normalized pC>2 within the ILT of group I patients was 39% +/- 
10% (P =0.08 with respect to the group I wall value). Group I tissue specimens showed 
greater inflammation and degree of neovascularisation compared to group 2 and non- 
aneurysmal tissue. Tensile strength was significantly less for group 1 specimens. 
Western blotting and immunohistochemistry suggested that oxygen-regulated protein is 
more abundantly expressed in group I versus group II specimens. The conclusion from 
this study was that localized hypoxia occurs in the AAA wall in regions of thicker ILT. 
This localised hypoxia is associated with increased localized mural neovascularisation 
and inflammation, as well as regional wall weakening (Vorp et al 2001).
Whilst this study demonstrates hypoxia in the wall of human aortic aneurysms it is 
worth pointing out that the numbers in the two groups are small. Points arising from this 
study that are worth highlighting are;
1. The question arises as to whether hypoxia is a primaiy etiological event or 
secondary consequence. Hypoxia was seen in both groups, but was most prominent 
in AAAs with large amounts of thrombus. Is it hypoxia that leads to AAA formation 
or AAA formation and ILT that leads to the confounding factor of hypoxia? The 
question as to whether hypoxia exists in non-aneurysmal vessels or in the early stage 
of aneurysm development remains unanswered.
2. Is the degree of hypoxia sufficient to alter cellular function?
3. The results from this study would suggest that hypoxia is associated with 
inflammation and neovascularisation, and it may be down this pathological pathway 
that hypoxia has a potential role in the development of AAAs. This theme was not 
the subject of this study but is obviously a potential channel for future research.
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The data from this study demonstrates that:
1. VSMCs as a source of XOR in vascular tissue
2. The results from XOR RT PCR and XOR immunoblotting indicate that hypoxia 
had no effect on the expression or protein level of XOR.
Any potential association between hypoxia and elastolytic activity could theoretically be 
due to the function of this enzyme in conditions of hypoxia. It was decided not to 
measure XOR function in VSMCs at this stage because of the large number of cell 
numbers required to measure activity in cell cultures. It was decided that such 
measurements would only be required if there was a positive result in the hypoxia- 
elastolytic activity study.
An important observation from this first experiment was the difficulty with the 
SAAANA assay. The difficulties encountered with this assay and the possible causes 
for this are discussed in Section 5.4.23 and 5.43.2.2. A major concern from the first 
experiment was the possibility that either the foetal calf serum or phenol red within the 
media was interfering with the SAAANA assay. In order to overcome this it was 
decided to perform future experiments in serum free media without the presence of 
phenol red. As a consequence of using serum free media, all cells are synchronised at 
the same stage of the growth cycle (Go). In addition to this, cells were seeded at a 
known and equal density at the beginning of each experiment. Cells were seeded at a 
density as described in previous VSMC experiments (Patel et ah 1996b; Crowther et ah 
2000a). The effect of these two procedures was that both cell density and cell cycle 
stage were eliminated as variables that may account for any observed difference that 
may be found.
The results from our study on MMP2, MMP-9 expression and elastolytic activity in 
cultured VSMCs were:
1. VSMCs derived from aortic tissue only express MMP-2 but not MMP-9 in 
culture. In this particular experiment all VSMCs were derived from non-AAA 
control patients, ie normal cadaveric organ donors. Previous reports of cultured 
VSMCs expressing MMP-9 have been in VSMCs derived from AAA patients . 
VSMCs are known to express MMP-9 in response to cytokinetic influences and it 
may be this reason why VSMCs derived from AAA patients express MMP-9 . In the 
latter study MMP-9 was only detected in human VSMCs from saphenous vein if they 
were stimulated with interleukin-la and either platelet derived growth factor (PDGF) 
or basic fibroblast growth factor (b FGF).
2. Hypoxia is unlikely to be a stimulus for MMP-9 expression in VSMCs.
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3. Hypoxia did not influence the expression of MMP-2, or increase the protein levels 
of MMP-2 in VSMCs under the experimental conditions described.
4. Elastolytic activity in conditioned media from VSMCs can not be measured using 
the SAAANA elastolytic assay
5. Hypoxia did not lead to increased elastolytic activity as assessed by the Chemicon 
gelatinase activity assay.
The results from this study suggest that hypoxia does not influence the expression or 
activity of elastolytic MMPs. As stated earlier a major assumption in this study was that 
arterial wall hypoxia existed in vivo. A second point that may be criticized is that only 
one degree of hypoxia was used in the experiment and this may not actually be 
physiologically or pathologically relevant. It could be argued that perhaps a higher 
oxygen concentration or indeed a range of oxygen concentrations be studied before any 
firm conclusions can be drawn from this study. At the beginning of this study there were 
no published data on intramural oxygen tensions/pressures. I decided to choose our 
particular oxygen concentration because I believed that if there was an effect was to be 
seen with hypoxia and MMP expression/activity then it was most likely to be seen with 
severe oxygen tension, i.e. an all or nothing effect. I believe that as no effect was seen 
on either MMP-2 or MMP-9 expression or activity with such an extreme oxygen 
concentration, it is unlikely to be found with higher oxygen concentrations, however I 
do appreciate that I have not presented data to support this statement.
The hypothesis as discussed in chapter 3 was that hypoxia could lead to increased XOR 
activity which could then lead to increased elastolytic activity. A second assumption in 
this experimental model was that the confirmed presence of XOR expression in VSMCs 
implied functioning XOR enzyme. XOR function in hypoxic VSMCs was not measured 
during these experiments. The fact that the result of hypoxia on elastolytic activity was 
negative made the measurement of the influence of hypoxia on XOR activity in VSMCs 
unnecessary, as the link between hypoxia and increased elastolytic activity in VSMCs 
had not been proved.
The data suggest that the SAAANA assay described by Bieth and modified by Patel is 
not useful in the assessment of elastolytic activity (Bieth et al. 1974; Patel et al. 1996b). 
No elastolytic activity was detected in samples analysed, which either suggests that 
there was no MMP present in the samples, or the sensitivity of the test was too low. 
Another possibility is that the MMPs within the media samples were in the pro-enzyme 
form (latent form), which require activation. The finding that the MMP-2 ELISA 
confirmed the presence of MMP-2 enzyme and the finding that the Chemicon gelatinase
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activity assay showed only low levels of endogenous MMP activity would suggest that 
the majority of MMP is in the latent form and the sensitivity of this assay is insufficient. 
Traditionally MMP expression and activity has been measured using a combination of 
semi-quantitative Western blotting and substrate gel enzymography. In addition to the 
measurement of MMPs, TIMPs analysis is required as net elastolytic activity will be a 
result of the balance between MMPs and their natural inhibitors. It is also worth 
pointing out that for MMPs to have elastolytic activity then they need to be in the active 
form. The disadvantage of most ELISA assays is that they are unable to distinguish 
between active MMPs and inactive zymogens. Substrate gel enzymography is sensitive 
and will detect in gel elastin digestion following gel electrophoresis. However, this 
process of elastase detection is not conducive to high capacity screening because it is 
limited by the number of wells that are available per gel, and it is time-consuming 
because it requires gel electrophoresis and protracted gel washing and in-gel digestion 
periods. In addition at best substrate gel enzymography is semi-quantitative. The 
relationship between the amount of enzyme and band intensity is not always linear and 
is a recognised problem with this technique (Baragi et al. 2000).
The MMP ELISA kits used in this study only detect pro-MMPs. The MMP-2 ELISA kit 
recognises both free pro-MMP-2 and pro-MMP-2 complexed with TIMP-2. It does not 
recognise active MMP-2. Likewise the MMP-9 kit recognises free pro-MMP-9, 
intermediate 83 KDa MMP-9 and MMP-9 complexed with TIMP-1. The assay does not 
recognise active MMP-9 (67 KDa) (Chemicon literature ECM 492/494)(Okada et al. 
1992; Fujimoto et al. 1993; Fujimoto et al. 1994).
The Chemicon MMP Gelatinase Activity Assay Kit is ideal for measurement of net 
gelatinase activity. It only measures active MMPs, but is influenced by the amount of 
TIMPs present. Activity levels represent the net elastolytic activity, the balance between 
MMPs and their natural inhibitors. Note that unlike substrate gel zymography, the MMP 
gelatinase activity assay measures MMP activity in solution. The activity observed in 
natural solutions is often quite different from the apparent activity observed on 
zymographs, where the MMP enzymes are physically separated from their natural 
inhibitors. Analytical sensitivity is less than 5ng/ml of MMP, which is comparable to 
the analytical sensitivity of zymography.
If the MMP gelatinase assay is used in combination with the MMP ELISA assays then 
they provide quantitative data for pro-MMPs (inactive), active MMP and the net 
elastolytic activity and thus they negate the need for Western blotting and substrate gel 
zymography.
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In conclusion, the results demonstrate that VSMCs express XOR and MMP-2 but not 
MMP-9 in culture. Hypoxia has no effect on XOR, MMP-2 or MMP-9 expression or 
protein levels in cultured VSMCs. In addition there is no evidence that hypoxia leads to 
increased production of elastolytic MMPs or increased elastolytic activity in VSMCs. 
These data would suggest that if hypoxia does have a role in the pathogenesis of 
aneurysm formation then it is not by directly increasing MMP expression and elastolytic 
activity in VSMCs.
128
Chapter 6 Oxidant stress and aortic aneurysms
6.1 Introduction
Oxidant stress is thought to be involved in atherosclerosis and particular plaque 
remodelling and is now beginning to be considered in AAA formation {Zalba et al 
2000; Miller et al 2002). Reactive oxygen species have been reported to induce 
apoptosis of VSMCs which is a well described feature of AAA tissue {Holmes et al 
1996; Johnson et al 1996; Lopez-Candales et al 1997; Henderson et al 1999). In 
addition the genes for MMP-1, MMP-3 and MMP-9 and the AAA associated cytokines 
including TNFa, IL-1, IL-6 all have AP-1 and NFkB binding elements in their promoter 
regions and thus are oxidant sensitive {Huhtala et al 1991; Sato et al 1993; Vincenti et 
al 1998; Allen et al 2000; Griendling et al 2000; Bond et al 2001). Indeed the 
expression of MMP-1 in human dermal fibroblast cultures (Brenneisen et a l 1997) and 
MMP-2 in cultured bovine aortic endothelial cells (Inoue et al 2001) and MMP-9 in 
bovine aortic endothelial cells {Uemura et a l 2001) have all been shown to be 
modulated by oxidant stress. In addition, Galis showed that N-acetyl-L-cysteine, an 
anti-oxidant, decreased MMP-9 expression in foam cells from hypercholesterolaemic 
rabbits {Galis et al 1998).
Previous studies have demonstrated that reactive oxygen and nitrogen species, including 
peroxynitrite activate the pro-enzyme forms of both MMP-2 and MMP-9 {Rajagopalan 
et al 1996; Okamoto et al. 1997; Galis et a l 1998; Maeda et al 1998b; Buhimschi et 
al 2000; Siwik et al 2001; Uemura et al 2001). Interestingly the glutathione precursor 
N-acetylcysteine (an anti-oxidant) dramatically inhibited MMP-9 activity {Buhimschi et 
al 2000). In addition to its effects on MMPs, peroxynitrite has been shown to inactivate 
TIMPs and alpha 1-proteinase inhibitor, a major proteinase (neutrophil elastase) 
inhibitor in human plasma the net effect being accelerated tissue degradation {Frears et 
al. 1996; Maeda et al 1998b)
Levels of ascorbic acid and antioxidant enzyme activities have been shown to be 
reduced in AAA tissue compared to non-aneurysmal tissue {Dubick et al 1999). 
Furthermore, plasma levels of vitamin E, another anti-oxidant have been shown to be 
reduced in patients with AAA compared to patients with coronary artery disease without 
aneurysms {Sakalihasan et al 1996b). These intriguing observations would support the 
hypothesis that oxidant stress is potentially increased in AAA tissue.
The hypothesis as outlined in Section 2.4.4 was that increased oxidant stress within the 
aortic wall leads to increased elastolytic activity. There are limited studies investigating
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oxidant stress and the potential role of reactive oxygen and nitrogen species in AAA 
formation other than those outlined above.
6.2 Aims
The aims of this study were to
1. To search for evidence of oxidant stress in AAA tissue.
2. To determine if oxidant stress activates MMPs in an in vitro model.
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6.3 Materials and Methods
6.3.1 To demonstrate evidence o f oxidant stress in aortic tissue
The demographics of the two groups of patients used in this study are given in Table 
6.1. The samples were a sub-group from the previous used specimens (Section 4.4.1). 
No difference in gender distribution was noted but a statistically significant difference 
was seen with regard to age (Students t test, p< 0.001).
AAA (n=18) Control (n=13) P
Age, y
Gender, % male
73 (range 57-89) 
82




Table 6-1 Demographic data of patients
6.3.1.1 Peroxynitrite
Superoxide reacts with nitric oxide to form peroxynitrite. Peroxynitrite will cause 
diverse chemical reactions in biological system including nitration of tyrosine residues 
of proteins and the formation of free and protein 3-nitrotyrosine derivatives has been 
used as a probe for peroxynitrite formation (Ischiropoulos 1998; Tarpey et al. 2001; 
Miller et a l 2002).
6.3.1.1.1 Immunohistochemical detection o f 3 nitrotyrosine (3-NT) in human aortic wall 
sections
Aortic tissue was collected and prepared as described in Sections 3.2 and 3.3. 
Immunohistochemical staining for nitrotyrosine was performed using the Vectastain 
ABC-AP kit (Vector Laboratories). An anti-nitrotyrosine antibody (Upstate 
Biotechnology Inc) (1:100) together with a secondary biotinylated goat anti-rabbit IgG 
(1:200) (Vector Laboratories, Vectastatin®) were used as described in Section 3.3.3.1 
and 3.3.3.2.
6.3.1.1.2 Nitrotyrosine immunoblotting (3 NT)
An identical technique as described for XOR immunoblotting was used to quantify the 
relative amounts of 3 NT within aortic tissue (Section 3.5). Specimens were prepared as 
described in Section 3.4.1 and total protein estimated using the Bradford assay (Section 
3.4.2). Twenty micrograms of total protein was loaded per well. Membranes were 
probed with a rabbit anti-nitrotyrosine (Upstate biotechnology, 1:1000), followed by a 
conjugated horseradish peroxidase swine-anti rabbit secondary antibody used at 1 in 
2000 dilution (Dako, 1:2000). Each sample was analysed in triplicate. Radiographic 
films were digitally imaged and stored as TIFF files. The mean pixel intensity at each
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well position was measured as described in Section 3.5.1. Relative densitometry of 
control tissue and aneurysm tissue were compared.
6.3.1.2 Lucigenin-enhanced chemiluminescence to detect superoxide generation
Superoxide levels were measured by lucigenin-enhanced chemiluminescence as 
previously described in Section 3.7.3
6.3.1.2.1 Sample preparation
Samples were prepared in one of three ways,
1. Samples were homogenised in the standard homogenisation buffer as described in 
Section 3.4.1.
2. Fresh samples were crushed in liquid nitrogen and homogenised in lxPBS. 
Samples were centrifugation at 4000 rpm for 10 minutes and supernatants retained 
for subsequent experiments.
3. Fresh samples were crushed in liquid nitrogen and homogenised in collagenase 
Type II (1 mg/ml) in PBS/1% Tween (lml/100 mg wet weight). Samples were 
centrifuged at 4000 rpm for 10 minutes and supernatants retained for experiments.
6.3.1.2.2 Assay protocol
An aliquot of homogenisation supernatant (50pl) was placed in a well and lOpl of 2mM 
DTPA and 40jil PBS were added. Lucigenin was made up to a stock concentration of 
2mM in PBS and NADH made up to a stock concentration of 2mM in PBS. The 
reactions were initiated by the automated injection of 50pl of substrate NADH followed 
by 50 pi of lucigenin into the wells of a 96-well plate. Measurements were as described 
in Section 3.7.3. Each sample was analysed in triplicate and the assay repeated three 
times. The results are expressed in arbitrary light units (ALU).
6.3.1.3 Controls and sample size
AAA tissue was compared to non-AAA derived aortic tissue (Controls). Control aortic 
tissue was obtained from cadaveric organ donors from the cuff on the renal artery/aorta. 
No formal power calculation could be undertaken to calculate the number of samples 
required in either the AAA group or control group. Previous published studies using 
tissue homogenates that have showed a difference between AAA and AOD/normal 
tissue, have all included small numbers of control samples, ranging between 3 and 10 . 
In view of this, the aim was to obtain 10 ‘normal’ non-AAA tissue samples.
6.3.2 To determine if  oxidant stress increases the activation ofpro-MMPs
To determine if reactive oxygen species activate MMP-2 or MMP-9, commercially 
available purified MMP-2 was incubated with a superoxide generating system.
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Purified Human MMP-2 and MMP-9 (Chemicon) are 90% pro-enzyme and as such only 
give low gelatinase activity.
63.2.1 Standard curve
Solution of 300ng/ml of MMP-2 or MMP-9 were prepared and a standard curve 
generated using a serial dilution of purified MMP-2/9 activated with AMPA as 
described in the literature provided with the Chemicon gelatinase kit {Appendix).
63.2.2 Experimental samples
Eighty microlitres of a 360 ng/ml MMP solution were added per well to a 96 well plate. 
Xanthine oxidoreductase (Biozyme) (Log 10 scale 0.001- lmu) in the presence of 
Hypoxanthine (Final 20 pM) was used to generate superoxide. The total reaction 
volume was 100 pi, and was made up with lx PBS. Samples were incubated for 3 hours 
at 37°C. Each reaction was performed in triplicate and the assay was repeated three 
times. Xanthine oxidoreducatase and hypoxanthine reaction blanks were used. 
Specificity for XOR was confirmed with the addition of lOOmM allopurinol.
63.2.3 Experimental end-points
Gelatinase (elastolytic) activity after incubation was assessed using the Chemicon 
gelatinase assay as described in Section 3.11.2 and the succinylated elastin assay as 
described in Section 3.11.3.
63.2.4 Experimental number
No formal power calculation could be undertaken for this experiment as no previous 
studies have been reported. The experiment was carried out in triplicate for each 
experimental condition and repeated 3 times (N=3)
6.3.3 Statistics
Statistical analysis was performed using GraphPad Prism version 3.02 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com. Data were 
assessed for deviations from Gaussian distribution using the Kolmogorov-Smimov test. 
Continuous variables were expressed as means ± Standard error of the mean (SEM) for 
parametric data. Variables were analysed with students’ t-test or One-way analysis of 
variance (ANOVA) for multiple group comparison. Statistical significance was 
considered for p values less than 0.05.
133
6.4 Results
6.4.1 Demonstration o f oxidant stress in aortic tissue
6.4.1.1 Peroxynitrite
6.4.1.1.1 Nitrotyrosine immunolocalisation (3 NT)
A I L B
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Figure 6-1 Photomicrographs showing the immunolocalisation of nitrotyrosine 
(red) in human non-AAA tissue
Specimens were probed with a anti-nitrotyrosine (Upstate Biotechnology Inc) 
(1:100) and a biotinylated goat anti-rabbit IgG (1:200) (Vector Laboratories, 
Vectastatin®). Slides a and c are negative controls. Slide b (x50) shows diffuse 
immunopositivity for nitrotyrosine throughout the artery wall. Image d (x 200) 
and image e (x 400) show both extracellular (1) and intracellular (2) positivity for 
3NT. (L=Lumen, M=Media, Ad=Adventitia).
Immunopositivity for nitroyrosine was seen throughout the aortic wall (B) with both the 
intima (I) and media showing positivity for 3 NT. Immunopositivity was particularly 
prominent in the intima and inner media. Interestingly the distribution of 
immunopostivity was similar to XOR which is a known potential source of 
peroxynitrite (Godber et al. 2000a).
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Figure 6-2 Photomicrographs showing the immunolocalisation of nitrotyrosine 
(red) in human AAA tissue.
Specimens were probed with a anti-nitrotyrosine (Upstate Biotechnology Inc) 
(1:100) and a biotinylated goat anti-rabbit IgG (1:200) (Vector Laboratories, 
Vectastatin®). Slides a, c and e are negative controls. Slide b (x50) shows diffuse 
immunopositivity for nitrotyrosine throughout the artery wall. Image d (x 200) 
and image f (x 400) show both extracellular and intracellular positivity for 3NT.
(L=Lumen, M=Media, Ad=Adventitia).
The pattern and distribution of immunopositivity for nitrotyrosine was similar in AAA 
tissue as in non-AAA derived aortic tissue.
6.4.1.1.2 Nitrotyrosine immunoblotting (3 NT)
The amount of nitrotyrosine in AAA samples was compared to nitrotyrosine levels in 
non-aneurysm control tissue using a semi-quantitative immunoblot technique. Staining 
with Amido black confirmed equal and complete transfer of protein to the nitrocellulose 
paper. Blank wells were loaded with lx PBS. Each sample was analysed in triplicate 
and the assay repeated twice. These data represent the mean value of two separate 
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Figure 6-3 Nitrotyrosine protein levels in aortic tissue quantified by 
immunoblot
Results expressed in relative densitometry units. AAA (n=18) and control samples 
(n=13). Data are mean ± SD of sample triplicates analysed twice.
The data demonstrate that significantly more 3 -NT is detected in AAA tissue compared 
to aortic tissue from control patients.
The result was confirmed by calculating the nitrotyrosine/protein ratios in order to 
confirm that slight variations in protein transfer did not account for the observed 
statistically significant difference. Each sample protein density was measured by taking 


















Figure 6-4 Nitrotyrosine protein levels quantified with immunoblot (expressed 
as 3NT/total protein)
Correction for total protein content in each sample also showed statistical significance 
confirming the validity of the observation.
6.4.1.2 Lucigenin-enhanced chemiluminescence
6.4.1.2.1 Samples in homogenisation buffer
Frozen samples prepared by homogenisation with standard homogenisation buffer 
(Section 3.4.1) were analysed. Sixteen AAA samples were compared to 8 non-AAA 
control samples. Ten micrograms of bovine XOR (Biozyme) was used as a positive 
control. Reaction blanks contained lx PBS. Blank recordings were subtracted from 
sample values. Each sample was analysed in triplicate and the assay repeated three 
times. The data represent the mean of three assays. Results are expressed in arbitrary 
light units per milligram of total protein (ALU/mg total protein). Figure 6.5 shows that 
AAA and control samples contained no measurable activity using NADH as a substrate.
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Figure 6-5 Chemiluminesence activity detected in aortic tissue using NADH as 
substrate
AAA (n=16), control tissue (n=8)
6.4.1.2.2 Samples prepared in liquid nitrogen/PBS
5 AAA samples and 4 control samples were analysed. Ten micrograms of bovine XOR 
(Biozyme) was used as a positive control. Reaction blanks contained lx PBS. Blank 
recordings were subtracted from sample values. Each sample was analysed in triplicate 
and the assay repeated three times. The data represent the mean of three assays. Figure
6.6 shows that AAA and control samples contained no measurable activity using NADH 
as a substrate.
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Figure 6-6 Chemiluminesence activity detected in aortic tissue using NADH as 
substrate.
AAA (n=5), control tissue (n=4). Samples prepared in liquid nitrogen/PBS
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6.4.1.2.3 Samples prepared in liquid nitrogen/co/lagenase type II 
7 AAA samples and 4 control samples were analysed. Ten micrograms of bovine XOR 
(Biozyme) was used as a positive control. Reaction blanks contained lx PBS. Blank 
recordings were subtracted from sample values. Each sample was analysed in triplicate 
and the assay repeated three times. The data represent the mean of three assays. Figure
6.7 shows that AAA and control samples contained no measurable activity using NADH 
as a substrate.
Figure 6-7 Chemiluminesence activity detected in aortic tissue using NADH as 
substrate.
AAA (n=7) or control tissue (n=4). Samples prepared in liquid 
nitrogen/collagenase
6.4.2 Oxidant stress and MMP activation
6.4.2.1 MMP-2
A standard curve was generated using purified MMP-2 activated with AMPA as 
described in the protocol provided with the Chemicon gelatinase kit. Samples were 
incubated for 3 hours at 37°C. Each sample was analysed in triplicate and the assay 
repeated three times.
The results show that the combination of XOR and hypoxanthine (20pM) resulted in 
increasing activation of purified MMP-2 as detected by the Chemicon gelatinase 
activity assay. The reduction in activation seen by lOOpM Allopurinol (an XOR 
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Figure 6-9 MMP-2 activation with hypoxanthine (20pm) and /XOR (0.001 mu-1 
mu XOR)
Activity was measured with the gelatinase activity assay (Chemicon). Data are 
mean ± SEM of sample triplicates analysed three times
The experimental samples were also analysed using the succinylated elastin assay as 
described in Section 3.11.3. A standard curve was generated using AMPA activation of 
serial dilutions of purified MMP-2 as described previously. Adequate succinylation of 
gelatin was confirmed by incubating succinylated gelatin with 50pl of 0.03% TBNSA 
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Figure 6-10 Standard curve for AMPA activated MMP-2 determined using the 
succinylated gelatin assay
Each reaction contained 15 pi of substrate, 40pl of experimental sample and 95pi of 
buffer (PBS/CaCb (ImM)). Specificity of the assay for gelatinase (MMPs) was 
confirmed with the addition of lOmM EDTA to the assay buffer. Reactions were 
incubated for 30 mins at 37°C. Fifty micolitres of 0.03% TBNSA solution was added to 
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Figure 6-11 MMP-2 activation with hypoxanthine (20pm) and /XOR (0.001 mu-1 
mu XOR) Activity was measured with the succinylated gelatin assay.
Data are mean ± SEM of sample triplicates analysed three times
The results from the succinylated gelatin assay confirm the activation of purified MMP- 
2 with XOR/hypoxanthine. The reduction in activated MMP-2 seen with the addition of 
allopurinol (lOOpM) confirms that XOR activity is responsible for MMP-2 activation. 
The reduction in activated MMP-2 seen with EDTA (lOmM) in the assay buffer 
confirms the specificty of this assay for gelatinases (MMPs).
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6.4.2.2 MMP-9
A standard curve was generated using purified MMP-9 activated with AMPA as 
described previously.
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Figure 6-12 Standard curve for AMPA activated MMP-9 determined using the 
succinylated gelatin assay
Samples were incubated for 3 hours at 37°C. Each sample was analysed in triplicate and 
the assay repeated three times. Experimental samples were only analysed with the 
succinylated gelatin assay. The results show that the combination of XOR and 
hypoxanthine (20pM) resulted in increasing activation of purified MMP-9. The 
reduction in activation seen by 100pM Allopurinol (an XOR inhibitor), confirms that 





Figure 6-13 MMP-9 activation with hypoxanthine and XOR
Activity was measured with the succinylated gelatin assay. Data are mean ± SEM 
of sample triplicates analysed three times
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6.5 Discussion
Oxidant stress could promote aneurysm formation through increased expression and 
activation of the MMP cascade. It is known that reactive oxygen and nitrogen species 
are produced by the 3 major types of cells resident in the aortic wall, namely VSMCs, 
fibroblasts and endothelial cells as well as by infiltrating macrophages and in addition 
oxidant stress has been reported to activate MMPs under in vivo conditions 
(Rajagopalan et al 1996; Siwik et al 2001; Miller et al 2002).
Since the conduction of our study, one published report has appeared in the literature 
concerning oxidant stress in AAAs. In this study, segments of AAA tissue were 
compared to adjacent non-aneurysmal tissue within the same patient. This study found 
that superoxide levels (measured by lucigenin-enhanced chemiluminescence) were 
higher in the AAA segments compared with the adjacent non-aneurysmal aortic 
segments. The increased superoxide was associated with the inflammatory infiltrate and 
Dihydroethidium staining indicated that that the increased superoxide was localised to 
inflammatory cells and VSMCs. Further immunostaining for p47phorx and p22phorx, two 
of the subunits of NAD(P)H oxidase and the fact that lucigenin enhanced 
chemiluminescence could be attenuated by treatment with DPI (diphenylene iodonium) 
a flavin inhibitor suggested that an NAD(P)H oxidase was an important source of this 
superoxide. Formation of thiobarbituric acid-reactive substances and conjugated dienes, 
two indices of lipid peroxidation, were also increased in AAA compared with non- 
aneurysmal segments. In addition enhanced nitrotyrosine immunostainning, a marker 
for amino acid oxidation induced by several oxidant species, including peroxynitrite, the 
highly reactive product of superoxide and nitric oxide, was enhanced in AAA tissue 
compared with non-AAA segments (Miller et al 2002). The results from this study all 
suggest that oxidant stress was associated with AAA formation (Miller et al 2002). An 
important point made by Miller, which is relevant to any conclusions drawn from these 
data as well as from this study, is that the investigations were performed on AAA at an 
advanced stage (end-staged disease), and the importance of such oxidant stress in the 
development of smaller sub-clinical aneurysms is unknown.
This study using aortic tissue derived from AAA patients and control tissue from non- 
AAA aortas, which unfortunately were not age matched, demonstrates increased 
nitrotyrosine in AAA tissue. Immunoblotting showed statistically significantly more 
peroxynitrite present in AAA tissue compared to normal controls. Adjusting for total 
protein to eliminate small variations in protein transfer made no difference to this result. 
Despite the statistical difference between the two groups using a semi-quantitative
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technique, the clinical significance of this small difference between the two groups is 
uncertain. As far as I am aware there is no quantitative technique to measure 
peroxynitrite in tissue (Tarpey et al 2001). These data for peroxynitrite support the 
observation of Miller (Miller et al 2002).
Attempts to measure superoxide production from aortic tissue using Lucigenin 
enhanced chemiluminescence were difficult and frustrating. Despite several alternative 
techniques of sample preparation, no activity could be detected. This either means that 
no activity is present or it is below the detection limit of this assay. These results, 
together with the problems encounted with XOR activity measurement suggest that 
sample storage/preparation may have been a problem. In Miller’s recent paper on 
oxidant stress, published after the conclusion of my time in the laboratory, superoxide 
levels measured by lucigenin-enhanced chemiluminescence were detectable. In this 
paper, aortic segments were placed in 0.9% saline (4°C) and transported to the 
laboratory. Aortic segments were placed in PBS and lucigenin (5pmol/L), and after 2 
minutes of dark adaptation, relative light units (RLU) emitted were measured for 5 
minutes after NADH (O.lmmol/L) or NADPH (O.lmmol/L) was added to the PBS- 
lucigenin containing the vessel segment. Some segments were pre-incubated with 
polyethyleneglycolated superoxide dismutase (SOD, 250 U/mL) or the flavin inhibitor 
diphenylene iodonium (DPI, 0.1 mmol/L). Surface areas were measured for each 
segment to allow normalization for tissue size (Miller et al 2002). Our technique 
differed in the following respects;
1. Samples were stored in Hanks balanced salt solution
2. Samples were homogenised and supernatants used for experiments
3. The concentration of Lucigenin was lOOx greater in our technique
4. The concentration of NADH was 5x greater in our technique
MMPs are secreted in a latent zymogen form in which the prodomain shields the 
catalytic site. This conformation of zymogens is maintained due to thiol interactions 
between cysteine residues in the prodomain and the zinc atom present in the catalytic 
site (Ye et al 1998). Reactive oxygen species are known to react with thiol groups such 
as those involved in preserving MMP latency, and several previous reports have 
demonstrated that exogenous generated reactive oxygen and nitrogen species activate 
MMP-2 and MMP-9 in isolated animal cell culture experiments (Rajagopalan et al 
1996; Belkhiri et al 1997; Inoue et al 2001; Siwik et al 2001).
I decided to investigate the possible role of oxidant stress on the activation of purified 
MMP-2 and MMP-9 in cell free experiments to determine if oxidant stress activated
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human MMP. The results from these experiments demonstrate that purified human 
MMP-2 and MMP-9 could be activated by superoxide generated from 
hypoxanthine/xanthine oxidase.
The limitations that I have about extrapolating these data are;
1. Whether this degree of oxidant stress exists in in vivo. There is only one report of 
oxidant stress in AAA tissue (.Miller et al 2002). Whilst data from our study show 
evidence of peroxynitrite, we were unable to measure superoxide in aortic tissue.
2. We have only measured superoxide on MMP-2 and MMP-9 activation. The 
effects of other reactive species on MMP-2 and indeed the effects of reactive species 
on other MMPs are unknown.
Tissue derived from patients with AAAs have been shown to have reduced levels of 
ascorbic acid, vitamin E and other anti-oxidant enzyme activities (Sakalihasan et al. 
1996b; Dubick et al 1999). These observations combined with our data and that 
reported by Miller would add evidence to a hypothesis that oxidant stress within the 
wall of the aorta could have a potential role in the pathogenesis of AAA.
Interestingly recent research, which has focussed on potential mechanisms to decrease 
AAA formation and expansion can all be potentially explained via oxidant stress related 
mechanisms. Simvastatin, an HMG-CoA reductase inhibitor has been shown to decrease 
MMP secretion and decrease active MMP-2 in aortic wall explants {Bellosta et al 1998; 
Marz et al 2000; Evans et al 2002). One such mechanism by which it may act is by 
inhibition the redox sensitive transcription factor NFkB that increases MMP expression 
{Bond et al 2001).
Angiotension n, a pro-inflammatory mediator has been shown to induce AAA 
formation in hypercholesterolaemic mice {Daugherty et al 2000). It is believed that 
angiotensin II stimulates the production of reactive oxygen species via NAD(P)H 
oxidase in VSMCs {Griendling et al 1994). Recent evidence has indicated that 
treatment with Angiotensin converting enzyme inhibitors (ACE inhibitors) suppresses 
the formation of angiotensin II and the subsequent development of elastase-induced 
AAAs in rats {Liao et al 2001). It could be postulated that such effects on AAA 
development are due to the decrease in angiotensin II and subsequent decreased in 
oxidant stress.
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D I S C U S S I O N  
C h a p te r 7 G eneral discussion
7.1 Summary













Figure 7-1 Diagrammatic representation of hypothesis.
7.1.1 Xanthine oxidoreductase
In order to determine if XOR had a role in the pathogenesis of AAAs, end-stage AAA 
tissue was compared to non-AAA control tissue obtained from cadaveric organ donors. 
Unfortunately the controls and AAA tissue were not from age-matched patients, control 
tissue was from a statistically younger population. Whilst XOR protein could be 
demonstrated in aortic tissue, localised to the media and intima, there was no difference 
in XOR protein levels between AAA patients and controls using both an ELISA and 
immunoblotting technique. In addition no XOR activity could be detected in aortic 
tissue (AAA and controls). The conclusion from this work is that there is no difference
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in either the expression or activity of XOR between AAA and control tissue, and thus it 
is unlikely that XOR has a role in AAA formation
The limitation of this study that particularly needs to be pointed out is that it relies on 
the use of end-stage tissue, and thus no conclusions can be drawn as to whether XOR 
has a role in early AAA formation.
7.1.2 Hypoxia and elastolytic activity
The central theme that hypoxia leads to increased elastolytic activity was tested in 
VSMCs culture experiments. Vascular smooth muscle cells (VSMCs) were chosen as 
the most appropriate cell type as these cells have been shown previously to be a source 
of elastolytic MMPs. VSMCS were isolated from aortic explants and exposed to 
hypoxic. These experiments did not demonstrate any increase in MMP-2 or MMP-9 
expression, MMP-2 and MMP-9 protein level, or elastolytic activity in cells exposed to 
hypoxia. In addition hypoxia had no effect on XOR expression or protein levels in 
VSMCs exposed to hypoxia. These studies effectively proved that the hypothesis was 
incorrect and no relationship between hypoxia and elastolytic activity could be 
established.
The limitations of these particular studies were as follows;
1. No measurement of hypoxia was undertaken in in vivo conditions to establish the 
degree of hypoxia present.
2. Only one degree of hypoxia was used in the experiments. As to whether this is the 
level that exists in either physiological situations or pathological conditions such as 
in the wall of the AAA is not known. The effect of hypoxia was used in a situation in 
which it could be argued does not represent in vivo conditions.
3. The use of isolated cell culture for experiments is open to criticism.
4. No MMP-9 mRNA or MMP-9 protein was detectable in the experiments.
7.1.3 Oxidant stress and elastolytic activity
This work was an adjunct to the original hypothesis but seemed to be logical 
continuation. I postulated that increased oxidant stress (increased reactive oxygen and 
nitrogen species) was involved in AAA formation. Despite the demonstration of 
increased levels of peroxynitrite in AAA tissue compared to control tissue, I was unable 
to demonstrate any differences in the ability to generate superoxide which could be 
viewed as an index of raised oxidant stress in tissue.
In-vitro experiments with commercially available MMP-2 and MMP-9 confirmed that 
superoxide activated these elastolytic enzymes. The conclusion from these studies was
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that there was some evidence of raised oxidant stress within AAA tissue and that such 
reactive species can activate pro-MMPs leading to increased elastolytic activity.
The limitation of this study is the obvious concern that I was unable to measure 
superoxide generating activity within the samples. In addition it is not known whether 




I do not feel that any further work analysing XOR protein in aortic tissue is likely to be 
beneficial. However, previous reports of increased uric acid in tissue from AAAs 
suggests that the activity of XOR in AAAs may be increased, although I have been 
unable to prove that in this study {Patetsios et al 1996; Patetsios et al 2001). Perhaps 
alternative techniques of measuring XOR activity, including high performance 
chromatography could be utilised to determine if XOR activity is increased in AAA 
tissue {Patetsios et al 1996).
7.2.2 Hypoxia
The paper published by Vorp suggests that localised areas of hypoxia exist in AAA 
tissue {Vorp et al. 2001). The data from my work would suggest that if hypoxia does 
have a role in the pathogenesis of aneurysm formation then it is not by directly 
increasing MMP expression and elastolytic activity in resident VSMCs.
Vorp demonstrated that the AAA wall adjacent to a thick layer of BLT has localised 
areas of hypoxia.and these areas were associated with increased localized mural 
neovascularisation and inflammation and regional wall weakening {Vorp et al 2001). 
Whilst this study demonstrates hypoxia in the wall of human aortic aneurysms it does 
not answer the question as to whether hypoxia is a primary aetiological event or a 
secondary consequence. The question as to whether hypoxia exists in non-aneurysmal 
vessels or in the early stage of aneurysm development remains unanswered.
In view of the findings in this study and the work by Vorp, I believe the following 
maybe useful areas of further research
1. The development and use of a non-invasive assessment of intra-mural hypoxia 
would greatly aid this area of research. This would then allow the oxygen tension 
areas to be measured in the aorta of non-AAA patients and in patients with small 
AAAs without the ethical concerns associated with invasive assessment
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2. Vorp’s data suggest that hypoxia is associated with inflammation and 
neovascularisation, and it may be down this pathological pathway that hypoxia has a 
role in the development of AAAs. This probably merits further research.
3. The effect of differing oxygen tensions on collagenolytic MMPs, which are 
believed to be important in AAA rupture could be investigated. Laminated intra­
luminal thrombus is found in increasing amounts as AAA expand and has been 
demonstrated to be associated with localised areas of hypoxia (.Adolph et al 1997; 
Vorp et al 2001). Perhaps the build up of thrombus as AAAs expand leads to 
hypoxia which activates the collagenolytic MMPs that lead to AAA rupture?
4. The effect of hypoxia on elastolytic MMPs could be assessed in an alternative 
model of AAA formation such as the aortic tissue ex-vivo explants (Wills et al 
1996). The potential advantage of this model over isolated cell culture experiments is 
that it does not eliminate the paracrine influence of other cell types and is thus a 
better model of in vivo conditions.
7.2.3 Oxidant stress
I believe that this area of research is probably going to be the most productive. The 
initial data from this study in combination with previous reports suggest that oxidant 
stress is increased in AAA tissue (Sakalihasan et al 1996b; Dubick et al 1999; Miller 
et al 2002). In addition, evidence exists to suggest that increases in oxidant stress are 
associated with alterations in MMP expression, MMP protein levels and MMP 
activation that lead to increased elastolysis and collagenolysis (Rajagopalan et al 1996; 
Galis et al 1998; Maeda et al 1998b; Buhimschi et al 2000; Siwik et al 2001;
Uemura et al 2001).
Future areas of research would be as follows
1. Measurement of oxidant stress in tissue obtained from AAA could futher be 
compared to tissue obtained from non-AAA controls. Alternative techniques to 
measure oxidant stress such as formation of thiobarbituric acid-reactive substances 
and conjugated dienes could be used.
2. Measurement of the degree of oxidant stress in plasma of patients with AAAs 
could be compared to age and gender matched controls. The ideal population for this 
study would be a screening cohort of patients, such as in the Gloucestershire 
screening programme. In addition, rates of expansion of AAAs could be correlated 
with the degree of oxidant stress to determine if oxidant stress could explain 
variations in expansion commonly seen in AAA progression.
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3. The effect of experimental oxidant stress on MMP expression, MMP protein or 
elastolytic or collagenolytic activity could be assessed in a model of AAA. The 
alternative models that could be used for this study would be either isolated tissue 
culture or whole tissue aortic explants from either AAA or control non-AAA 
patients. End-points would be MMP mRNA levels, MMP protein levels measured by 
commercially available ELISA and net elastolytic activity that colud be measured by 
either commercially available assays or the succinylated gelatin assay.
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APPENDIX
Shandon Hypercenter II tissue processing apparatus
The procedure for processing tissue samples into wax blocks
Temp (°C) Immersion time
Formalin (10%) RT 1 Omins
Alcohol (70%) RT 30mins
Alcohol (80%) RT lhr
Alcohol (95%) RT lhr
Alcohol (absolute) RT lhr
Alcohol (absolute) RT Hu­






Alcohol = Industrial methylated spirits.
Slides
Poly-l-lysine (Sigma Cat. No. P1524). 0.05-0.1% Poly-l-lysine MW>35000 in DDW 
Microscope slides (BDH. Cat. No. 406/0184/02)
Histological procedures
Dewaxing slides in xylene and IMS
1. Deparaffinize tissue, 2x 30 seconds in Xylene (BDH, Cat. No. 30578564)
2. Fix in IMS, 2 x 30 seconds (BDH, Cat. No. 30244)
3. Rehydrate in lx PBS for 5mins.
Haematoxylin and eosin staining technique
1. Tap water; 5 minutes
2. Harris' haematoxylin; 5 minutes
3. Acid alcohol; 1 minute
4. Tap water; 5 minutes
5. Eosin; 30 seconds
6. Water; 5 minutes
7. IMS; 30 seconds
8. IMS; 30 seconds
9. Xylene; 30 seconds (100%)




Xanthine oxidase (Paraffin-Embedded sections)
1. Dewax slides and rehydrate in lx PBS
2. Blocking solution. Incubate in wet box with 200pl per slide blocking 
solution for 30 minutes.
5 mg bovine serum albumin (BSA),
333|il normal goat serum (Sigma No G9023)
10 ml PBS
3. Wash. PBS, 1x5  minutes
4. Primary antibody. Incubate with 200jil per slide primary antibody overnight 
at 4°C.
1:50 -  1:200 dilution of antibody in blocking solution 
Polyclonal rabbit anti-XOR. (Chemicon AB 1242)
5. Wash. PBS, 2 x 5  minutes
6. Secondary antibody. Incubate with 200pl per slide secondary antibody for 30 
minutes
1:200 dilution of antibody in blocking solution
1 drop of blue bottle in 10 ml (lx) PBS (Biotinylated goat anti-rabbit 
immunoglobulin (Vector Laboratories, Vectastatin® ABC-AP reagent, 
No AK -5001, Peterborough UK))
7. Wash. PBS, 2 x 5  minutes
8. Application of the avidin-bound enzyme probe to link to the biotinylated 
secondary antibody
2 drops of A (Avidin) bottle and 2 drops of B (biotinylated alkaline 
phosphatase) bottle to 10 ml lx PBS (Vector Laboratories, Vectastatin® 
ABC-AP reagent, No AK -5001, Peterborough UK),200pl per slide 
Incubate for 30 minutes
9. Wash. PBS 2 x 5  minutes
10. Application of chromogenic enzyme substrate. Nanhthol AS -MX 
phosphate/Fast red TR Fast™ (Sigma. Cat. No. F-4523).
10 ml distilled water 
Ultra-filtration 
200pl per slide
11. Stop reaction with cold water
12. Conterstain with Mayer’s Haematoxylin for 1 minute
13. Rinse in running tap water for 5 minutes
14. Mount with 4 drops of Aquamount per slide.
Primary antibody for detection of 3 nitrotyrosine
Identical to the technique for XOR immunohistochemistry except primary antibody was 
rabbit anti-nitrotyrosine (Upstate Biotech, cat no: 06-284)
183
Tissue experiments
Hanks balanced salt solution (HBSS)
^  I ^  I
This contained Ca and Mg , sodium bicarbonate and phenol red and was sterile. 
(Gibco, Cat. No 2402 091)
Homogenisation buffer
50mM KP04 pH 7.4 (Sigma. Cat. No. P0662) 
lmM EDTA (Promega, UK. Cat. No. H503a)
ImM PMSF (Sigma. Cat. No. P-7626)
Pepstatin A (lpg/ml) (Sigma. Cat. No. P4265)
Antipain (lpg/ml) (Sigma. Cat. No. A-6191)
Leupeptin (lpg/ml) (Sigma. Cat. No. L-2023)
Protein assay
Bio-Rad Protein Assay Kit II (Bio-Rad, UK. Cat. No. 500-002) 
Western blotting 
2x loading buffer
50mM Tris-HCL pH 6.8 (Sigma Cat. No. T3253) 
lOOmM DTT (Promega Cat. No. V3151)
2% SDS (Sigma Cat. No. L-3771)
20% Glycerol (Sigma Cat. No. G7893)
Added to this is 0.01% bromophenol blue (Promega Cat. No. H5011)
Rainbow markers
High molecular weight range (14300-220000). (Amersham, UK. Cat. No. RPN 756) 
Resolving gel (8%) (lOmls)
Acrylamide 40% (Anachem Cat. No. 20-2400-05) 2 ml 
1.5M Tris/base pH 8.8 (Promega Cat. No. H5131) 2.51 ml 
SDS 20% w/v (Sigma Cat. No. L-3771) 50pl
Ammonium persulphate (AMPS) 10% w/v 
(Sigma Cat. No. A9164) 1 OOpl
Temed (Promega Cat. No. V3161) 7.5pl
Made up with H2O. 5.33 ml
Stacking gel (4%) (3.3mls)
Acrylamide 40% (Anachem Cat. No. 20-2400-05) 0.33 ml 
1.0M Tris/base pH 6.8 (Promega Cat. No. H5131) 0.42 ml 
SDS 20% w/v (Sigma Cat. No. L-3771) 6.7pl
AMPS 10% w/v (Sigma Cat. No. A9164) 33pi
Temed (Promega Cat. No. V3161) 4pi
Made up with H2O 2.49 ml
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Running Buffer pH 8.3
25mM Tris/base (Promega Cat. No. H5131) 3.06 g
190mM Glycine (Sigma Cat. No. G4392) 14.4.g
0.001% SDS (Sigma Cat. No. L-3771) lg
Made up to lOOOmL H2O
Blotting/transfer buffer
25mM Tris/base (Promega Cat. No. H5131) 3.06 g
190mM Glycine (Sigma Cat. No. G4392). 14.4 g
20% Methanol (BDH/Merck Cat. No.l01586B) 200 ml
Made up to lOOOmL H2O
Washing buffer
lx PBS (Oxoid Cat. No. BR14a)/ 0.5% Tween 20 (Sigma Cat No. P1379)
Blocking buffer
5% Non fat dried milk-“Marvel®” in lx PBS/0.5% Tween 20 
Nitrocellulose paper
Nitrocellulose paper-hybond-C super (Amersham Life Sciences RPN 203G) 
Whatman paper
Whatman International Ltd, Maidstone, UK (Cat. No. 3017915)
Secondary antibody
Swine Anti rabbit HRP conjugated (Dako)
Amersham ECL detection kit
(Amersham, UK. Cat. No. RPN 2106)
The principle is based on enhanced chemiluminescence, which is achieved by 
performing the oxidation of luminol by the HRP/hydrogen peroxide system in the 
presence of chemical enhancers such as phenols. This increases the output of light by 
approximately 1000 fold.
185
The detection is summarised in the diagram shown.
Oxidised product 7\ 3 Kodak filmLight
Peracid
Oxidised form o f  acid 








Coomassie blue staining of gels
Stain [45% (v/v) methanol, 10% (v/v) acetic acid and 0.1% Coomassie Brilliant blue] 
(lhr)
De-stain [5% (v/v) methanol and 7.5% (v/v) acetic acid] 3hrs, x 3 changes.
Coomassie Brilliant Blue (Sigma Cat. No. B-0149)
Radiographic film
Kodak X-OMAT AR auto rad film (Amersham Life Sciences, UK Cat. No. V8532665)
XO activity (pterin) assay
Isoxanthopterin
(Sigma. Cat. No. I 7388)
lOmM = 9 mg dissolved in lOOpl of 1M NaOH in 4900 ml DDW 
IOOjiM = lOpl of lOmM stock added to 990 ml DDW
(Sigma Cat. No. (P 1132)
lOmM = 8.2 mg dissolved in lOOpl of 1M NaOH in 4900pl of DDW
Methylene blue
(Sigma Cat. No. MB-1)
lOmM = 18.7 mg dissolved in 5 ml DDW
Allopurinol
(Sigma Cat. No. A 8003)




(Bovine buttermilk) (Biozyme Cat. No. X02) 1.0-1.5 U/mg protein.
Lucigenin-enhanced chemiluminescence
2mM NADH solution (PBS)
ImM Hypoxanthine (PBS)
2mM Lucigenin solution (PBS)







ImM PMSF (Sigma. Cat. No. P-7626).
Pepstatin A (lpg/ml) (Sigma. Cat. No. P4265)
Antipain (lpg/ml) (Sigma. Cat. No. A-6191)
Leupeptin (lpg/ml) (Sigma. Cat. No. L-2023)




Made up to 1 litre with DDW
Phosphate buffered saline (PBS)
8.00g NaCl 
0.20g KH2P04 
2.89g Na2HP04.12H20  
0.20g KCL
Made up to 1 litre with distilled water
Washing buffer (PBS/Tween)
As above + 0.05% Tween (v/v)
Phosphate/citrate buffer
Stock solution A 0.1M citric acid- store at 4°C
Stock solution B 0.2M Na2HP04- store at room temperature
Immediately before use, add 24.3ml A and 25.7ml B to 50ml distilled water in dark
bottle.
Peroxidase substrate
Add 57mg OPD (orthophenylenediamine)/100ml phosphate/citrate buffer incorporating 





Anti-XO IgM antibody (Neomarkers Mab 3)
Biotinylated anti-XO chicken antibody 
Streptavidin-peroxidase conjugate (lpg/ml, Jackson Labs)
Plates
Immulon IB microtitre plates (Dynatech Lab)
Tissue culture
Hanks balanced salt solution (HBSS)
This contained Ca2+and Mg2+, sodium bicarbonate and phenol red and was sterile. 
(GibcoBRL, Cat No. 2402 091)
Dulbecco’s Modified Eagle Media (DMEM)
With Sodium Pyuruvate, with 1000 mg/ml Glucose, with Pyridoxime 
(GibcoBRL, Cat No. 31885-023)
L-Glutamine 200 mm (lQOx)
(GibcoBRL, Cat No. 25030-024)
Penicillin-Streptomycin (10000 IU/ml- lOOOOpg/ml)
(GibcoBRL, Cat No. 15140- 122)
Foetal bovine serum (FCS)
Heat inactivated, sterile filtered 
(Sigma cell culture, F-9665)
10% FCS/DMEM
450 ml DMEM 
50 ml FCS 
5 ml L -  Glutamine 
5 ml Penicillin-streptomycin
All FCS, L- glutamine and penicillin-streptomycin was filtered sterilised through a
0.2pm filter (Triple Red Laboratory technology; Part No. 1520012)
Serum free media
DMEM without phenol red (with Sodium Pyuruvate, with 1000 mg/ml Glucose, with 
Pyridoxime) (GibcoBRL, Cat No 11880-028)





(Sigma cell culture Cat No. T-4174)
5 ml stock added to 45 ml Dulbecco’s Phosphate buffered saline (D-PBS). Filtered 
sterilised through a 0.2pm filter (Triple Red Laboratory technology; Part No. 1520012)
Dulbecco’s Phosphate Buffered Saline (D-PBS)
W/o Ca2+ & Mg2 (Gibco Cat. No.14190-080)
Lab-tek II chamber slide w/cover
8 well (Nalge Nunc International)
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Tissue culture equipment (Orange scientific)
Tissue culture test plates
Tissue culture flasks (screw cap with filters)







5% Non fat dried milk-“Marvel®” in lx PBS/0.5% Tween 20
Antibodies- XOR
Polyclonal rabbit anti-XOR (Chemicon AB 1242)
Biotinylated goat anti-rabbit immunoglobulin (Vector Laboratories, Vectastatin® ABC-
AP reagent, No AK -5001, Peterborough UK)
Anti-a-actin antibody
Monoclonal anti-a- smooth muscle actin alkaline phosphatase conjugate clone 1A4.
IgG fraction of Mouse ascites fluid (Sigma, product no A5691)
Alkaline phosphatase-conjugated avidin biotin complex (ABC) (Vector Laboratories,
Vectastatin® ABC-AP reagent, No AK -5001, Peterborough UK)
Naphthol AS -MX phosphate/Fast red TR Fast™ (Sigma. Cat. No. F-4523)
Cell counting
Bright line hemocytometer (Z35, 962-9) (Sigma)
Cell count and viability assay
1. lOOpl aliquots of cell solutions were mixed with equal volumes of 0.4% 
Trypan blue solution (SIGMA, UK) and allowed to stand for 5 minutes at 
room temperature.
2. A 10pl aliquot of this solution was added to haemocytometer by capillary 
action. Cells were viewed by low power transmitted light microscopy and 
cells within the central 0.1mm3 section of the haemocytometer were counted.
3. Total cell counts were calculated by counting all the cells, blue and clear, in 
the central area of the two counting chambers and dividing by two and then 
multiplying by lxlO4. This figure represents the original cell number before 
dilution and expressed as cells per ml.
4. Viable counts were calculated by repeating the above procedure by counting 
only the unstained cells.
5. The percentage viable count was calculated by dividing the clear cell count 
by the total cell count and multiplying by 100.
RNA/protein extraction
RNA STAT 60™
Total RNA/mRNA isolation reagent (ams Biotechnolgy (Europe) Ltd CS-110
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Equipment/reagents
0.2 ml Micro-tube (Certified DNAse, RNAse free) (ABgene Cat no 0620)
DPEC (diethyl pyrocarbonate) (Sigma D5758)




Distilled water RNAse, DNAse free (0.1 micron filtered)(GibcoBRL Life technologies 
Cat no; 1094595)
Guanidine hydrochloride (Promega H5381)
SDS (sodium dodecylsulfate) (Sigma L-3771)
RNA quantification
Quartz cuvette 200pl 
UV Biotech photometer (Jencons)
260nm and 280 nm filters
Reverse transcription- Reverse-iT™ First Strand Synthesis Kit (ABgene 0789)
Components used;
Anchored oligo-dT (500ng/pl)
5x first strand synthesis buffer 
d NTP mix (5mM each)
Reverse-iT Blend (RTase blend and RNase inhibitor)
PCR Amplification- 2x ReddyMix™ PCR Master Mix (3.0 mM MgCE) (ABgene 
0627-DC-LD)
25pi reaction volume contains 12.5pl of ReddyMix
1.25 units Taq DNA Polymerase 
75 mM Tris-HCL (pH 8.8 at 25°C)
20 mM (NH4)2S0 4
3.0 mM MgCb
0.01% (v/v) Tween 20
0.2 mM each ofdATP, dCTP, dGTP, dTTP.
Precipitant and red dye for electrophoresis
XOR primer sequences (10 pmoles/pl)
GibcoBRL Life Technologies
Forward (5' to 3') AGT ATG TAC ACA CTG CTC CGG 
Reverse (5' to 3') GCC TCA GCA ACT CTG GGG GAA 
Product size 288 base pairs
GAPDH primer sequences (7.5 pmoles/pl)
R+D Systems, Human GAPDH PCR primer pair (RDP-39) 
Forward (5' to 3') AAA GGG TCA TCA TCT CTG CC 
Reverse (5' to 3') TGA CAA AGT GGT CGT TGA GG 
Product size 576 base pairs
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MMP-2 PCR Primer pair (7.5 pmoles/pl)
R+D Systems, Human MMP-2 primer pair (RDP-84-025)
Product size 449 base pairs
MMP-9 PCR Primer pair (7.5 pmoles/pl)
R+D Systems, Human MMP-9 primer pair (RDP-96-025)




100 bp DNA ladder 
Blue/orange 6x loading dye
Tris base/borate/EDTA
5 x stock solution 
Tris base 54g (Promega H5131)
Boric acid 27.5g (Promega H5001)
0.5MEDTA 20 ml (Promega V4231)
Ethidium Bromide
ICN biomedical Inc (Cat no; 806808)
Electrophoresis apparatus
Run One™-Electrophoresis cell and cast (Embi Tec)
Image capture and analysis
Scion Corporation Imaging program (version 4.0.2; Web site: www.scioncorp.com)
MMP ELISA
Human MMP-2 Immunoassay Kit (Chemicon International (ECM 492)
Human MMP-9 Immunoassay Kit (Chemicon International (ECM 494)
1. Pipette 50pl of each Standard Curve Solution or Specimen into the bottom of 
a test tube.
2. Pipette 300pi Enzyme Labelled Antibody Solution into each specimen or 
standard-containing tube.
3. Place one anti-MMP-2/MMP-9 coated bead into each tube.
4. Incubate the tubes at 17-27 °  C for 1 hour.
5. Stop the reaction by adding 3.0ml Washing Solution to each tube
6. Aspirate the solution and dispense 3.0ml washing Solution to each tube.
7. Repeat this washing step 3 times.
8. Transfer each washed bead into a clean fresh tube.
9. Pipette 300pl Colouring Solution into each tube.
(Promega Cat no; V3121)
(Promega Cat no; G210A) 




10. Incubate the tubes at 17-27 0 C for 1 hour.
11. Stop the enzyme reaction by adding 1.5ml of Stop Solution to each tube.
12. Using deionized water as a blank, read the absorbance at 492 nm for the 
Standard Curve Solutions and Specimens.
13. Plot the net absorbance value for each MMP-2/MMP-9 concentration versus 
the MMP-2 concentration (from 6.3 to 400ng/ml) or MMP-9 concentration 
(from 3.1 to lOOng/ml), and using the net absorbance value for a specimen, 
determine the respective MMP-2/MMP-9 concentration from the standard 
curve.
Activity assays
Succinyl trialanyl 4-nitroanilide (SAAANA) assay
96 well plate (Orange scientific)
Succinyl trialanyl 4-nitroanilide (SAAANA) (Sigma)
Dimethyl sulphoxide (DMSO) (Sigma)
Porcine pancreatic elastase (PPE) (Sigma)
50mmol/L Tris-hydrochloride buffer containing lOmmol/L Calcium Chloride ph 7.2
Gelatinase Activity Assay Kit (Chemicon international (ECM701)
1. Rehydrate MMP Positive Control.
2. In a 96-well plate (not provided), add lOpl MMP sample/Positive Control or 
test sample
3. Add 200pl of Biotinylated Gelatinase Substrate.
4. Cover plate and incubate at 37°C for 30 minutes.
5. Rehydrate Biotin-Binding Plate by adding 200 pL of diluted Assay Buffer to 
each well and let stand at room temperature for 1 minute.
6. Aspirate Assay Buffer from Biotin-Binding Plate and add 100 pL of the 
MMP/Substrate mixture from step 3 to the Biotin-Binding plate.
7. Incubate at 37°C for 2 hours.
8. Wash each well 5 times with 200 pL of diluted assay buffer.
9. Prepare a 1:3,000 dilution of Streptavidin-Enzyme Conjugate in Assay 
Buffer (add 4 pL of conjugate to 12 ml of Assay Buffer).
10. Add 100 pL of diluted conjugate to each well.
11. Incubate at 37°C for 30 minutes.
12. Wash each well 5 x with 200 pL of diluted Assay Buffer.
13. Add 100 pL of substrate solution.
14. Incubate at room temperature for 20 minutes.
15. Positive control wells should develop a faint colour.
16. Stop reaction by adding 100 pL of Stop Solution to each well.
17. Read O.D. at 450 nm.
Succinylated Elastin assay
Succinic anhydride (Sigma S7626)
Gelatin (Sigma G2500)
Purified human MMP-2 (Gelatinase A) (Chemicon CC071)
Purified human MMP-9 (Gelatinase B) (Chemicon CC079) 
p-Aminophenylmercuric acetate (APMA) (Sigma A9563)
2,4,6-trinitrobenzene sulfonic acid (TNBSA) (Sigma)
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